Document:

<Page>

WHENEVER CONFIDENTIAL INFORMATION IS OMITTED HEREIN (SUCH OMISSIONS ARE DENOTED
BY AN ASTERISK*), SUCH CONFIDENTIAL INFORMATION HAS BEEN SUBMITTED SEPARATELY TO
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT.

                          COMMERCIAL ALLIANCE AGREEMENT

     This Commercial Alliance Agreement (the "Agreement") dated as of July 12,
2006 (the "Effective Date") is entered into by and among ADM Polymer
Corporation, a corporation duly incorporated and validly existing under the laws
of the State of Delaware, with headquarters located at 4666 Faries Parkway,
Decatur, IL 62526 ("ADM Sub"), Metabolix, Inc., a corporation duly incorporated
and validly existing under the laws of the State of Delaware, with headquarters
located at 21 Erie Street, Cambridge, MA 02139-4260 ("MBX") and ADM / Metabolix
Sales Company, LLC, a limited liability company duly formed and validly existing
under the laws of the State of Delaware, with headquarters located at 21 Erie
Street, Cambridge MA 02139-4260 (the "Joint Sales Company") (MBX, ADM Sub, and
the Joint Sales Company are each a "Party" and are collectively, the "Parties").

                                    RECITALS

     WHEREAS, ADM Sub is a wholly owned subsidiary of Archer-Daniels-Midland
Company ("ADM");

     WHEREAS, MBX and ADM Sub are parties to that certain Technology Alliance
and Option Agreement dated November 3, 2004 (the "Technology Alliance and Option
Agreement") pursuant to which the Parties conducted a mutual assessment of the
technical and commercial feasibility of commercializing PHA Material (as defined
below);

     WHEREAS, MBX granted to ADM Sub the option (the "Commercial Alliance
Option"), on the terms and conditions set forth in the Technology Alliance and
Option Agreement, to enter into a broader commercial alliance as set forth
herein and in the Commercial Alliance Agreements (as defined below) regarding
the manufacture, use and sale of PHA Material;

     WHEREAS, the conditions to ADM Sub's exercise of the Commercial Alliance
Option have been satisfied and ADM Sub has exercised the Commercial Alliance
Option in accordance with the Technology Alliance and Option Agreement; and

     WHEREAS, as a result of ADM Sub's exercise of the Commercial Alliance
Option, MBX and ADM Sub are, as of the date hereof, forming the Joint Sales
Company to assist in the commercialization of the PHA Material and PHA
Formulations, enter into this Agreement and the remaining Commercial Alliance
Agreements in order to establish and begin operation of the broader commercial
alliance, all on the terms and conditions set forth herein and in the remaining
Commercial Alliance Agreements.

     NOW, THEREFORE, in consideration of the recitals and the mutual covenants
and promises contained herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties hereto
do hereby agree as follows.

                                    ARTICLE 1
                                   DEFINITIONS

*    CONFIDENTIAL TREATMENT REQUESTED

<Page>

     "ADM SUB ALLIANCE TECHNOLOGY" means any Technology developed, conceived or
reduced to practice during the course of performance of the Commercial Alliance,
solely by employees of, or consultants to, ADM Sub or its Affiliates, including
without limitation, employees of ADM Sub or its Affiliates who are providing
services to the Joint Sales Company under any of the Commercial Alliance
Agreements (alone or jointly with a Third Party), with or without the material
use of any MBX Technology or Joint Alliance Technology. Technology that is
within the meaning of the term "ADM Program Technology" (as that term is defined
in the Technology Alliance and Option Agreement) is hereby deemed to be included
within the term "ADM Sub Alliance Technology." For the purposes of this
definition, employees of or consultants to the Joint Sales Company (other than
employees of ADM Sub or its Affiliates who are providing services to the Joint
Sales Company under any of the Commercial Alliance Agreements) will be deemed to
be employees of both ADM Sub and MBX. Notwithstanding the foregoing, Unfunded
Technology shall not be included as part of the ADM Sub Alliance Technology.

     "ADM SUB BACKGROUND TECHNOLOGY" means any Technology that is Controlled by
ADM Sub: (i) as of the Effective Date or (ii) developed, conceived or reduced to
practice solely by employees of, or consultants to, ADM Sub or its Affiliates in
the conduct of activities outside of the Commercial Alliance, without the
material use of any MBX Technology or Alliance Technology. Technology that is
within the meaning of the term "ADM Program Technology" (as that term is defined
in the Technology Alliance and Option Agreement) is hereby deemed not to be
included within the term "ADM Sub Background Technology."

     "ADM SUB CONSTRUCTION MASTER PLAN AND BUDGET" shall have the meaning set
forth in the Technology Alliance and Option Agreement.

     "ADM SUB FORMULATION ENGINEER" shall have the meaning set forth in Section
4.3.3.

     "ADM SUB MANUFACTURING AGREEMENT" shall have the meaning set forth in
Section 2.1.1.

     "ADM SUB MANUFACTURING FACILITY" shall have the meaning set forth in
Section 4.1.

     "ADM SUB PATENT RIGHTS" means any Patent Rights Controlled by ADM Sub and
claiming or covering the ADM Technology.

     "ADM SUB PROPRIETARY MATERIALS" means any Proprietary Materials Controlled
by ADM Sub and used by ADM Sub, provided by ADM Sub for use, or necessary or
useful in the Commercial Alliance.

     "ADM SUB SERVICES AGREEMENT" shall have the meaning set forth in Section
2.1.1.

     "ADM TECHNOLOGY" means, collectively, ADM Sub Proprietary Materials, ADM
Sub Background Technology and ADM Sub Alliance Technology.

     "AFFILIATE" of a Person means any other Person that directly, or indirectly
through one or more intermediaries, controls, is controlled by or is under
common control with such Person. "Control" and, with correlative meanings, the
terms "controlled by" and "under common control with" shall mean the power to
direct or cause the direction of the management or policies of a

*    CONFIDENTIAL TREATMENT REQUESTED

                                       2

<Page>

Person, whether through the ownership of voting securities, by contract,
resolution, regulation or otherwise. The Joint Sales Company is hereby deemed
not to be an Affiliate of ADM, ADM Sub or MBX. Tepha, Inc. is hereby deemed not
to be an Affiliate of MBX.

     "ALLIANCE TECHNOLOGY" means ADM Sub Alliance Technology, Joint Alliance
Technology and MBX Alliance Technology

     "BUSINESS DAY" means a day of the year on which banks are not required to
be closed in New York, New York.

     "CALENDAR QUARTER" shall mean each of the following periods in each year:
(i) January 1 through March 31, (ii) April 1 through June 30, (iii) July 1
through September 30 and (iv) October 1 through December 31.

     "CAPITAL CONTRIBUTION" shall have the meaning set forth in the Operating
Agreement.

     "COMMERCIAL ALLIANCE" means the research, development and commercial
activities to be conducted by the Parties as set forth herein, including without
limitation, the Pilot Activities, the manufacturing, formulation, marketing,
distribution and sale of PHA Material and PHA Formulations, the planning,
construction and maintenance of the ADM Sub Manufacturing Facility and the MBX
Formulation Facility, the establishment and operation of the Joint Sales Company
and the evaluation of the Expansion Proposal and potential exercise of the Joint
Venture Option.

     "COMMERCIAL ALLIANCE AGREEMENTS" means this Agreement and the ADM Sub
Manufacturing Agreement, the MBX Formulation Agreement, the Operating Agreement,
the ADM Sub Services Agreement, the MBX Services Agreement, the Consolidated
Confidentiality Agreement and the Loan and Security Agreement.

     "COMMERCIAL ALLIANCE OPTION" shall have the meaning set forth in the above
recitals.

     "COMMERCIAL PHASE" shall mean the period commencing upon the date of the
First Commercial Sale of a PHA Material, produced in the ADM Sub Manufacturing
Facility, to a Third Party by the Joint Sales Company, and expiring upon the
expiration or termination of this Agreement.

     "COMMERCIALLY REASONABLE EFFORTS" shall mean, with respect to the efforts
to be applied by a Party in performing a referenced obligation hereunder, the
amount and quality of effort and resources that would be applied by a reasonable
manager or management team at a corporation having comparable expertise and
assets as such Party, to accomplish a task or to perform an obligation having
comparable relative importance to the success or failure of a commercial
enterprise that is comparable to the Commercial Alliance. For purposes of this
definition, a commercial enterprise would be comparable to the Commercial
Alliance if it poses similar anticipated technical and business risks or
challenges and similar anticipated financial return to the Parties as measured
at the time of the expenditure of the effort. When ADM Sub has an obligation to
use "Commercially Reasonable Efforts" herein, the following shall apply: (i) the
term "Commercially Reasonable Efforts" shall be defined as it is in this
definition but by

*    CONFIDENTIAL TREATMENT REQUESTED

                                       3
<Page>

reference to ADM Sub and ADM as if they were a single entity, and (ii) in
determining whether ADM Sub have satisfied its obligations, the efforts applied
by and ADM Sub and ADM shall both be taken fully into account.

     "CONFIDENTIAL INFORMATION" means: (a) all tangible embodiments of
Technology produced or discovered by either Party or jointly by one or more
Parties under the Commercial Alliance Program, and all information concerning
the terms of this Agreement, and (b) with respect to a Party (the "Receiving
Party"), all information, Technology and Proprietary Materials which are
disclosed by any other Party (the "Disclosing Party") to the Receiving Party
hereunder or to any of its employees, consultants, or Affiliates; except to the
extent that the information, (i) as of the date of disclosure is demonstrably
known to the Receiving Party or its Affiliates, as shown by written
documentation, other than by virtue of a prior confidential disclosure to such
Party or its Affiliates; (ii) as of the date of disclosure is in, or
subsequently enters, the public domain, through no fault or omission of the
Receiving Party, or any of its Affiliates; (iii) is obtained from a Third Party
having a lawful right to make such disclosure free from any obligation of
confidentiality to the Disclosing Party; or (iv) is independently developed by
or for the Receiving Party without reference to or reliance upon any
Confidential Information of the Disclosing Party as demonstrated by competent
written records.

     "CONSTRUCTION" AND "CONSTRUCT" shall mean, in respect to a building, the
activities, and their performance, that are usual and appropriate to create a
completed facility that: (i) is in all material respects in compliance with all
material safety, health, zoning, environmental and other regulations and laws
applicable to it whether such applicability is based on its location, physical
dimensions and attributes, its intended uses or otherwise and (ii) is designed
to enable and support state-of-the-art operations pertaining to its intended
purpose. The terms "Construction" and "Construct" shall include the following
activities and their performance with respect to a facility: planning,
designing, engineering, construction, procurement, equipping and acquiring the
necessary permits.

     "CONSTRUCTION COSTS" are those reasonable costs and expenses that are
actually incurred by either ADM or ADM Sub in connection with the Construction
of the ADM Sub Manufacturing Facility, or MBX in connection with the
Construction or acquisition of the MBX Formulation Facility, in either case, as
and to the extent such costs and expenses were: (i) reasonably incurred in
Construction consistent with the plans, designs, engineering and budget in the
ADM Sub Construction Master Plan and Budget as approved by the TAC as provided
in the Technology Alliance and Option Agreement (or as approved by the Steering
Committee pursuant to Section 4.2.2), or the MBX Facility Master Plan and Budget
(as applicable), (ii) reasonably incurred in Construction consistent with the
plans, designs, engineering and budget in any amended ADM Sub Construction
Master Plan and Budget or the MBX Facility Master Plan and Budget (as
applicable), which amendments were approved by the Steering Committee to the
extent required herein; or (iii) were otherwise designated by the Steering
Committee as Construction Costs. Without limiting the foregoing, the Steering
Committee shall not approve as Construction Costs costs and expenses which it
determines are excessive in amount, or costs and expenses that relate to
improvements of existing facilities, or features of new facilities, to the
extent such improvements or features are not for the benefit for the Commercial
Alliance.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       4

<Page>

     "CONSTRUCTION PHASE" means the period commencing upon the Effective Date
and expiring upon the first to occur of: (i) the date of the First Commercial
Sale of a PHA Material (including, without limitation, PHA Material that is
contained within PHA Formulations) produced in the ADM Sub Manufacturing
Facility, to a Third Party by the Joint Sales Company and (ii) the termination
of this Agreement.

     "CONTROL" OR "CONTROLLED" means (a) with respect to Technology (other than
Proprietary Materials) or Patent Rights, the possession by a Party of the
ability to grant a license or sublicense to such Technology or Patent Rights as
provided herein without violating the terms of any agreement or arrangement
between such Party and any Third Party, and (b) with respect to Proprietary
Materials, the possession by a Party of the ability to supply such Proprietary
Materials to the other Party for use as provided herein without violating the
terms of any agreement or arrangement between the supplying Party and any Third
Party. A Party shall be deemed not to "Control" any Technology, Patent Rights or
Proprietary Materials of any other Party solely by virtue of rights therein, or
possession thereof, that was granted or acquired solely in accordance with this
Agreement or any other Commercial Alliance Agreement.

     "DEFENDING PARTY" shall have the meaning set forth in Section 11.3.1.

     "EFFECTIVE DATE" means the date first above written.

     "EXCLUSIVE PERIOD" shall mean that period of time commencing upon the
Effective Date and continuing until the first to occur of: (i) the JV Option
expiring without having been exercised by ADM Sub and (ii) the end of the Term.

     "EXPANSION PROPOSAL" shall have the meaning set forth in Section 9.1.1.

     "FERMENTATION AND RECOVERY PROCESS" means the process used to produce
fermentation broth containing PHA Material, to produce PHA Cell Paste from
fermentation broth, and to recover PHA Material from such PHA Cell Paste using
solvent and aqueous recovery processes.

     "FIELD" means the research, development, manufacture, use, sale and
importation of PHA Material and PHA Formulations; provided that the Field shall
not include any uses that are within the "Field of Use" as that term is defined
in the License Agreement by and between MBX and Tepha, Inc. dated October 1,
1999, as amended on December 17, 2002.

     "FIRST COMMERCIAL SALE" means the sale of not less than 1,000,000 pounds of
PHA Material (including, without limitation, PHA Material that is contained
within PHA Formulations) manufactured in the ADM Sub Manufacturing Facility,
that meets the then-current specifications for PHA Material, to Third Parties,
who are satisfied with the quality, and who purchased the PHA Material in
greater than sample quantities for commercial use.

     "FUNDED TECHNOLOGY" shall have the meaning set forth in Section 4.4.1.

     "INFRINGEMENT" shall have the meaning set forth in Section 11.3.1.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       5

<Page>

     "JOINT ALLIANCE TECHNOLOGY" means Technology developed, conceived or
reduced to practice jointly by employees of, or consultants to, ADM Sub on the
one hand, and MBX on the other, (in either case, with or without a Third Party)
during the course of performance of the Commercial Alliance. Technology that is
within the meaning of the term "Joint Program Technology" (as that term is
defined in the Technology Alliance and Option Agreement) is hereby deemed to be
included within the term "Joint Alliance Technology." For the purposes of this
definition, employees of the Joint Sales Company, excluding employees of ADM,
ADM Sub or MBX who are providing services to the Joint Sales Company under the
ADM Sub Services Agreement or the MBX Services Agreement, will be deemed to be
employees of both ADM Sub and MBX. Notwithstanding the foregoing, Unfunded
Technology shall not be included as part of Joint Alliance Technology.

     "JOINT VENTURE" shall have the meaning set forth in Section 9.1.1.

     "JOINT VENTURE ENTITY" shall have the meaning set forth in Section 9.1.1.

     "JV OPTION" shall have the meaning set forth in Section 9.1.

     "KNOWLEDGE means, with respect to MBX, the actual knowledge and awareness,
without the requirement of investigation, of any of the following four (4)
members of MBX management: President and CEO, Chief Scientific Officer, Chief
Financial Officer and Director of Manufacturing and Development, without the
requirement of investigation, and, with respect to ADM Sub, the actual knowledge
and awareness, without the requirement of investigation, of any of the following
nine (9) members of ADM management: Senior Vice President (Corn Processing and
Food Specialties), President of Natural Health & Nutrition Division, Assistant
Controller, Corporate Counsel - Intellectual Property, Senior Attorney, Senior
Vice President Venture Research, Vice President Technology Assessment, President
of ADM Research Division, and Vice President of Research, Molecular Biology -
Fermentation.

     "LEDGER ACCOUNT" shall have the meaning set forth in the Operating
Agreement.

     "LICENSE FEE" shall have the meaning set forth in Section 7.2.3.

     "LIMITED SUBLICENSE RIGHT" means that with respect to a particular license
of rights that the licensee shall have no right to sublicense or otherwise
enable a Third Party to perform or participate in the performance of the
Fermentation and Recovery Process, or any part thereof, but that the licensee
shall have the right otherwise to grant sublicenses of such licensed rights, and
further that the Joint Sales Company shall have the right to contract with Third
Parties to conduct Pilot Sourcing as per Section 4.4.2, and the licensee shall
have the right to contract with Third Parties to troubleshoot, consult, or
further develop aspects of the Fermentation and Recovery Process, provided that
the licensee shall pursuant to a written agreement with such third party own all
Technology arising from such contracted activity. Notwithstanding the foregoing,
the licensee shall not transfer or convey any cell line constituting part of the
MBX Proprietary Materials to any Third Party.

     "LOAN AND SECURITY AGREEMENT" shall have the meaning set forth in Section
2.1.1.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       6

<Page>

     "MANUFACTURING COST" shall have the meaning set forth in the ADM Sub
Manufacturing Agreement.

     "MBX ALLIANCE TECHNOLOGY" means any Technology developed, conceived or
reduced to practice during the course of performance of the Commercial Alliance,
solely by employees of, or consultants to, MBX or its Affiliates, including
without limitation, employees of MBX or its Affiliates who are providing
services to the Joint Sales Company under any of the Commercial Alliance
Agreements (alone or jointly with a Third Party), with or without the material
use of any ADM Technology or Joint Alliance Technology. Technology that is
within the meaning of the term "MBX Program Technology" (as that term is defined
in the Technology Alliance and Option Agreement) is hereby deemed to be included
within the term "MBX Alliance Technology." For the purposes of this definition,
employees of or consultants to the Joint Sales Company (other than employees of
MBX or its Affiliates who are providing services to the Joint Sales Company
under any of the Commercial Alliance Agreements) will be deemed to be employees
of both ADM Sub and MBX. Notwithstanding the foregoing, Unfunded Technology
shall not be included as part of MBX Alliance Technology.

     "MBX APPLICATIONS PATENT RIGHTS" means and Patent Rights Controlled by MBX
that claim or cover specific uses, within the Field, of PHA Materials or PHA
Formulations.

     "MBX BACKGROUND TECHNOLOGY" means any Technology that is Controlled by MBX:
(i) as of the Effective Date or (ii) developed, conceived or reduced to practice
solely by employees, of, or consultants to, MBX or its Affiliates in the conduct
of activities outside of the Commercial Alliance, without the material use of
any ADM Technology or Alliance Technology. Technology that is within the meaning
of the term "MBX Program Technology" (as that term is defined in the Technology
Alliance and Option Agreement) is hereby deemed not to be included within the
term "MBX Background Technology."

     "MBX FACILITY MASTER PLAN AND BUDGET" shall have the meaning set forth in
Section 4.3.2.

     "MBX FORMULATION AGREEMENT" shall have the meaning set forth in Section
2.1.1.

     "MBX FORMULATION FACILITY" shall have the meaning set forth in Section 4.1.

     "MBX PATENT RIGHTS" means any Patent Rights Controlled by MBX and claiming
or covering the MBX Technology, including without limitation, the MBX
Applications Patent Rights.

     "MBX PROPRIETARY MATERIALS" means any Proprietary Materials Controlled by
MBX and used by MBX, provided by MBX for use, or necessary or useful in the
Commercial Alliance. MBX Proprietary Materials shall include, without
limitation, all PHA Material and PHA Formulations supplied as samples to ADM or
ADM Sub, all cell lines (including all master stocks and working stock whether
prepared by ADM or ADM Sub or MBX) and all fermentation media, supplied by MBX
to ADM or ADM Sub, and all progeny, derivatives and mutated forms developed
therefrom.

     "MBX SERVICES AGREEMENT" shall have the meaning set forth in Section 2.1.1.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       7

<Page>

     "MBX TECHNOLOGY" means, collectively, MBX Proprietary Materials, MBX
Background Technology and MBX Alliance Technology.

     "MBX TECHNOLOGY MANAGER" shall have the meaning set forth in Section 4.2.3.

     "MIT LICENSE" means that certain License Agreement dated July 15, 1993 by
and between MBX and Massachusetts Institute of Technology, as amended.

     "NEUTRAL PARTY" shall have the meaning set forth in Section 11.3.1.

     "NON-EXCLUSIVE PERIOD" means that period of time during the Term following
the end of the Exclusive Period.

     "OFFEREE PARTY" shall have the meaning set forth in Section 9.7.

     "OFFEROR PARTY" shall have the meaning set forth in Section 9.7.

     "OPERATING AGREEMENT" shall have the meaning set forth in Section 2.1.1.

     "OPERATING PAYMENT" AND "OPERATING PAYMENTS" shall each have the meaning
set forth in Section 4.5 hereof.

     "PATENT COMMITTEE" shall have the meaning set forth in Section 11.1.

     "PATENT RIGHTS" means the rights and interests in and to issued patents and
pending patent applications (which for purposes of this Agreement shall be
deemed to include certificates of inventions and applications for certificates
of invention and priority rights) in any country, including all provisional
applications, substitutions, continuations, continuations-in-part, divisionals,
and renewals, all letters patent granted thereon, and all reissues,
reexaminations and extensions thereof, Controlled by a Party.

     "PERMITTED ACTIVITIES" shall have the meaning set forth in Section 8.4.

     "PERSON" means any individual, partnership (whether general or limited),
limited liability company, corporation, trust, estate, association, nominee or
other entity.

     "PHA CELL PASTE" means the paste, containing the PHA Material, recovered
from whole fermentation broth and meeting the specifications set forth in
EXHIBIT H.

     "PHA FORMULATIONS" means PHA Material that has been processed by blending
different types of PHA Material together with other polymers and/or with other
additives, including nucleants, clarifiers, flow modifiers, plasticizers, flame
retardants and heat stabilizers.

     "PHA KNOW-HOW MATERIAL" means PHA Material, the manufacture, use, sale or
importation of which is accomplished or performed with the use of the MBX
Technology or Joint Alliance Technology.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       8

<Page>

     "PHA MATERIAL" means the following forms of polyhydroxyalkanoate: *, when
produced by any means other than via Plants, and any other forms of
polyhydroxyalkanoate, produced by any means other than via Plants, that are
substitutable by any customer with one or more of the above substances, are
generally technically and commercially feasible in the marketplace, and have a
potential adverse affect on the sales or profitability of the Joint Sales
Company in a material way. For avoidance of doubt, any PHB copolymers having at
least fifty percent (50%) of the *, when produced by any means other than via
Plants, are hereby deemed to be included in the definition of PHA Material.

     "PHA PATENTED MATERIAL" means PHA Material, the manufacture, use, sale or
importation of which within or into the United States by a Person other than
MBX, absent the licenses granted herein, would infringe a Valid Claim of the MBX
Patent Rights or a Valid Claim within Patent Rights claiming or covering any
Technology within the Joint Alliance Technology.

     "PHA-RELATED MATERIALS" means any polymer material consisting of one or
more hydroxyacids of the general formula: *.

     "PHA SUPPLEMENTAL KNOW-HOW MATERIAL" means PHA Material, the manufacture,
use, sale or importation of which is accomplished or performed with the use of a
cell line Controlled by MBX and delivered by MBX to the Joint Sales Company at
any time during the Term.

     "PILOT ACTIVITIES" means the activities related to Pilot Sourcing as
described in Section 4.4.2, the process development activities described in
Section 4.4.1 and the sales activities described in Section 4.4.3.

     "PILOT FACILITIES" means the facility, or facilities, at which the Pilot
PHA Material is produced, purified, formulated and packaged for sale.

     "PILOT PHA MATERIAL" shall have the meaning set forth in Section 4.4.2.

     "PILOT SOURCING" shall have the meaning set forth in Section 4.4.2.

     "PILOT SOURCING COSTS" shall have the meaning set forth in Section 4.4.2.

     "PLANTS" shall mean photosynthetic organisms when not raised through
fermentation, but in any case excluding*. For avoidance of doubt, * is included
within the definition of Plants.

     "PROJECT TEAMS" shall have the meaning set forth in Section 3.4.

     "PROJECTS" shall have the meaning set forth in Section 3.4.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       9

<Page>

     "PROPRIETARY MATERIALS" means any tangible chemical, biological or physical
research materials that are furnished by or on behalf of one Party to any other
Party in connection with this Agreement, regardless of whether such materials
are specifically designated as proprietary by the transferring Party.

     "ROFN" shall have the meaning set forth in Section 7.4.

     "ROFN RIGHTS" shall have the meaning set forth in Section 7.4.

     "ROYALTY TERM" means that period commencing upon * and continuing until the
later of the expiration or termination of * from the Effective Date.

     "SECTION 7 BREACH" shall have the meaning set forth in Section 10.2.1.

     "SENIOR EXECUTIVES" shall have the meaning set forth in Section 14.3.1.

     "STRATEGIC ALLIANCE" shall have the meaning set forth in Section 3.1.1.

     "STRATEGIC ALLIANCE PARTNER" shall have the meaning set forth in Section
3.1.1.

     "STEERING COMMITTEE" shall have the meaning set forth in Section 3.1.

     "SUPPLEMENTAL ROYALTY TERM" means that period commencing upon the delivery
by MBX to ADM, ADM Sub or the Joint Sales Company of a cell line Controlled by
MBX used in the production or manufacture of PHA Supplemental Know-How Material
and ending upon the * to occur of (i) the *, and (ii) * from the date of such
delivery.

     "TAC" shall have the meaning set forth in the Technology Alliance and
Option Agreement.

     "TECHNOLOGY" means and includes all inventions, discoveries, improvements,
trade secrets, know-how, trademarks, servicemarks, tradenames and proprietary
methods and Proprietary Materials, whether or not patentable.

     "TECHNOLOGY ALLIANCE AND OPTION AGREEMENT" shall have the meaning set forth
in the above recitals.

     "TECHNOLOGY TRANSFER" shall have the meaning set forth in Section 6.7.

     "TERM" shall have the meaning set forth in Section 10.1.

     "THIRD PARTY" shall mean any person, corporation, partnership or other
entity other than the Parties and their respective Affiliates.

     "THIRD PARTY ROYALTY OFFSET" shall have the meaning set forth in Section
9.8.4.

     "UNFUNDED TECHNOLOGY" shall have the meaning set forth in Section 4.4.1.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       10

<Page>

     "UNITS" shall have the meaning set forth in the Operating Agreement.

     "VALID CLAIM" means a claim within a patent application or patent that has
not been abandoned or finally determined to be unenforceable or invalid by a
court or administrative agency with competent jurisdiction where all appeal
rights have been exhausted or expired.

     "50,000 TON ANNUAL DESIGN CAPACITY" shall have the meaning set forth in
Section 4.2.1.

                                    ARTICLE 2
                   OVERVIEW AND COMMERCIAL ALLIANCE AGREEMENTS

     2.1 OVERVIEW OF THE COMMERCIAL ALLIANCE. The purpose and goal of the
Commercial Alliance is to advance and exploit the research, development and
marketing activities undertaken by ADM Sub and MBX in the performance of the
Technology Alliance and Option Agreement by combining, on a larger scale and for
a longer term, ADM Sub's fermentation capabilities, market knowledge and capital
with MBX's technology, formulation expertise, market knowledge and intellectual
property rights and to create and establish a commercial outlet for PHA Material
and PHA Formulations through the Joint Sales Company in order to create a
commercial venture in the Field. The Commercial Alliance shall be conducted by
MBX and ADM Sub, each on an individual basis and through their ownership and
participation as members in the Joint Sales Company, all in accordance with this
Agreement and the other Commercial Alliance Agreements.

          2.1.1 COMMERCIAL ALLIANCE AGREEMENTS. Unless otherwise indicated
below, the Parties, as of the Effective Date, have executed and delivered the
following Commercial Alliance Agreements as provided for therein. The following
summary description of the Commercial Alliance Agreements is provided solely for
informational purposes and is not to amend the terms set forth therein or to
inform the interpretation of such terms.

               (a) OPERATING AGREEMENT. The operating agreement, executed and
delivered by the Parties as of the Effective Date and appended hereto as Exhibit
A (the "Operating Agreement"), is the agreement pursuant to which the Joint
Sales Company was formed and shall operate and which defines the respective
rights and obligations of MBX and ADM Sub as the members of the Joint Sales
Company, all as and to the extent set forth therein and subject to the terms and
conditions set forth therein.

               (b) ADM SUB MANUFACTURING AGREEMENT. The manufacturing agreement,
executed and delivered by ADM Sub and the Joint Sales Company as of the
Effective Date and appended hereto as Exhibit B (the "ADM Sub Manufacturing
Agreement"), is the agreement pursuant to which ADM Sub shall manufacture PHA
Material for the Joint Sales Company.

               (c) MBX FORMULATION AGREEMENT. The formulation agreement, which
will be executed and delivered by MBX and the Joint Sales Company if and when
MBX commences the Construction of the MBX Formulation Facility or acquires the
MBX Formulation Facility, is appended hereto as Exhibit C (the "MBX Formulation
Agreement"), and

*    CONFIDENTIAL TREATMENT REQUESTED

                                       11

<Page>

is the agreement pursuant to which MBX shall produce PHA Formulations for the
Joint Sales Company from the PHA Material manufactured by ADM Sub.

               (d) ADM SUB SERVICES AGREEMENT. The services agreement, executed
and delivered by ADM Sub and the Joint Sales Company as of the Effective Date
and appended hereto as Exhibit D (the "ADM Sub Services Agreement"), is the
agreement pursuant to which ADM Sub will provide services to the Joint Sales
Company.

               (e) MBX SERVICES AGREEMENT. The services agreement, executed and
delivered by MBX and the Joint Sales Company as of the Effective Date and
appended hereto as Exhibit E (the "MBX Services Agreement"), is the agreement
pursuant to which MBX will provide services to the Joint Sales Company.

               (f) LOAN AND SECURITY AGREEMENT. The loan and security agreement,
executed and delivered by ADM Sub and the Joint Sales Company as of the
Effective Date and appended hereto as Exhibit F (the "Loan and Security
Agreement") is the agreement pursuant to which ADM Sub will make available to
the Joint Sales Company a credit facility.

                                    ARTICLE 3
                        STEERING COMMITTEE; PROJECT TEAMS

     3.1 STEERING COMMITTEE. MBX and ADM Sub hereby establish a joint steering
committee (the "Steering Committee") to plan and oversee the establishment and
activities of the Commercial Alliance in such instances where ADM Sub and MBX
are acting on an individual basis and in such instances where ADM Sub and MBX
are acting as members of the Joint Sales Company, all as further set forth
herein.

          3.1.1 RESPONSIBILITIES AND AUTHORITY OF THE STEERING COMMITTEE. The
Steering Committee shall have the rights and obligations provided for herein, in
the other Commercial Alliance Agreements and as agreed to by ADM Sub and MBX in
writing from time-to-time during the Term. Without limiting the foregoing, the
Steering Committee shall have the general responsibility of (i) coordinating the
planning and execution of the individual activities of ADM Sub and MBX in
connection with the Commercial Alliance, including without limitation by
controlling or participating (as specifically provided herein or in the other
Commercial Alliance Agreements) in decision-making on both a strategic and
tactical level, by assisting in setting priorities for performance and resource
allocation, and by assisting in avoiding or resolving disputes among ADM Sub,
MBX and the Joint Sales Company, and (ii) coordinating the planning and
execution of the activities of ADM Sub and MBX as members of the Joint Sales
Company, in all cases, subject to the right and authority of ADM Sub, MBX and
the Joint Sales Company to make decisions and take actions required to perform
their obligations hereunder and under the other Commercial Alliance Agreements
in accordance herewith and therewith, including without limitation, those
decisions and actions that are specifically identified as reserved to any of
them hereunder or thereunder. Without limiting the foregoing, the following
actions, designations and documents shall require the prior approval of the
Steering Committee before such actions may be taken or before such designations
or documents shall be valid and binding commitments:

*    CONFIDENTIAL TREATMENT REQUESTED

                                       12

<Page>

               (a) the designation of costs and expenses incurred in connection
     with the Construction of the ADM Sub Manufacturing Facility (pursuant to
     Section 4.2.5) or the Construction or acquisition of the MBX Formulation
     Facility (pursuant to Section 4.3.5) as "Construction Costs" to be credited
     or debited against the Ledger Account, as that term is defined in the
     Operating Agreement, as and to the extent provided for in the Operating
     Agreement;

               (b) the appointment of the following key personnel: (i) ADM Sub
     Project Manager (to be nominated by ADM Sub), (ii) ADM Sub Manufacturing
     Manager (to be nominated by ADM Sub); (iii) MBX Technology Manager (to be
     nominated by MBX); (iv) Marketing and Sales Manager of the Joint Sales
     Company (to be nominated by MBX pursuant to the terms of the Operating
     Agreement) and (v) Assistant Marketing and Sales Manager of the Joint Sales
     Company (to be nominated by ADM Sub pursuant to the terms of the Operating
     Agreement);

               (c) the decision to contract with a Third Party to perform
     strategic, ongoing research, development or commercial activities with or
     on behalf of either Party or the Joint Sales Company in connection with the
     Commercial Alliance as part of a contractual relationship (such Third Party
     is a "Strategic Alliance Partner" and such contractual relationship is a
     "Strategic Alliance");

               (d) the establishment of strategic and operational plans for
     performance hereunder and under the other Commercial Alliance Agreements,
     the preparation and finalization of budgets for funding such performance,
     the establishment of high-level procedures and policies, including without
     limitation, accounting policies and procedures, in connection with such
     performance;

               (e) any action that requires the consent of the members to the
     Joint Sales Company, as specified in the Operating Agreement.

          3.1.2 CERTAIN LIMITATIONS ON THE RESPONSIBILITIES AND AUTHORITY OF THE
STEERING COMMITTEE. The Steering Committee shall have no authority to act on
behalf of ADM, ADM Sub, MBX or the Joint Sales Company in connection with Third
Parties. Without limiting the foregoing, the Steering Committee shall have no
authority to, and shall not purport to or attempt to: (i) negotiate agreements
on behalf of ADM, ADM Sub, MBX or the Joint Sales Company, (ii) make
representations or warranties on behalf of ADM, ADM Sub, MBX or the Joint Sales
Company, (iii) waive rights of ADM, ADM Sub, MBX or the Joint Sales Company,
(iv) extend credit on behalf of ADM, ADM Sub, MBX or the Joint Sales Company, or
(v) take or grant licenses of intellectual property on behalf of ADM, ADM Sub,
MBX or the Joint Sales Company.

          3.1.3 DECISION-MAKING STANDARD FOR THE STEERING COMMITTEE. All
decisions and other actions of the Steering Committee shall be made in good
faith and with due care, after consideration of the information that is
reasonably available to the Steering Committee, with the intention that: (i) the
resulting decision or actions will conform to, or be consistent with, the
provisions and requirements of this Agreement and the other Commercial Alliance
Agreements and (ii) the resulting decision or action will maintain or increase
the likelihood that ADM Sub, MBX and the Joint Sales Company will achieve the
purposes and goal of the Commercial Alliance as set forth in Section 2.1.
Without limiting the foregoing, the Steering Committee is expressly prohibited
from taking into account interests of a Party, or of any members of the

*    CONFIDENTIAL TREATMENT REQUESTED

                                       13

<Page>

Steering Committee, other than their respective interests in achieving the
purposes and goal of the Commercial Alliance as set forth in Section 2.1.

     3.2 MEMBERSHIP OF STEERING COMMITTEE. ADM Sub and MBX shall each appoint an
equal number of members to the Steering Committee (not to exceed five (5)
members each), one of whom shall be designated by each of ADM Sub and MBX as its
"Co-Chair." ADM Sub and MBX shall have the right at any time to substitute
individuals, on a permanent or temporary basis, for any of its previously
designated representatives to the Steering Committee, including its Co-Chair, by
giving written notice thereof to the other Party. Initial designees to the
Steering Committee shall be as follows:

     For MBX:     James Barber (Co-Chair)
                  Oliver Peoples
                  Thomas Auchincloss
                  Johan van Walsem
                  Robert Findlen

     For ADM Sub: John Rice (Co-Chair)
                  Terry Stoa
                  Tom Binder
                  Kevin Moore
                  Nick Lawless

     3.3 MEETINGS.

          3.3.1 SCHEDULE OF MEETINGS. The Steering Committee shall establish a
schedule of times for its meetings, taking into account, without limitation, the
planning needs of the Commercial Alliance. The Steering Committee shall meet
monthly unless otherwise agreed upon by ADM Sub and MBX. Meetings shall also be
convened upon the determination of either or both of the Co-Chairs of the
Steering Committee by written notice (including notice via e-mail) thereof to
their respective members that a meeting is required to discuss or resolve any
matter or matters with respect to the Commercial Alliance. Meetings shall
alternate between the respective offices of ADM Sub or MBX or another mutually
agreed upon location; provided, however, that the Co-Chairs of the Steering
Committee may mutually agree to meet by teleconference or video conference or
may act by a written memorandum signed by the Co-Chairs of the Steering
Committee.

          3.3.2 QUORUM; VOTING; DECISIONS. At each meeting of the Steering
Committee, the participation of at least one member designated by each of ADM
Sub and MBX shall constitute a quorum. Each Steering Committee member shall have
one vote on all matters before the Steering Committee; provided, however, that
the member or members of each of ADM Sub and MBX present at any meeting shall
have the authority to cast the votes of any of such Party's members who are
absent from the meeting. All decisions of the Steering Committee shall be made
by majority vote of all of the members, except when acting in its capacity as a
representative committee of the members of the Joint Sales Company where
unanimous consent

*    CONFIDENTIAL TREATMENT REQUESTED

                                       14

<Page>

of the members is required, in which case the decisions of the Steering
Committee shall be made by unanimous vote of all of its members. Whenever any
action by the Steering Committee is called for hereunder during a time period in
which a meeting is not scheduled, the Co-Chairs shall cause the Steering
Committee to take the action in the requested time period by calling a special
meeting or by action without a formal meeting by written memorandum signed by
both Co-Chairs of the Steering Committee. Representatives of each of ADM Sub and
MBX, in addition to the members of the Steering Committee, may attend meetings
as non-voting observers with prior notice to the other Party. In the event that
the Steering Committee is unable to resolve any matter before it, such matter
shall be resolved as set forth in Section 14.3 hereof.

          3.3.3 MINUTES. A secretary shall be appointed to keep accurate minutes
of the deliberations of the Steering Committee recording all proposed decisions
and all actions recommended or taken. Drafts of such minutes shall be delivered
to the Co-Chairs of the Steering Committee within a reasonable period of time
not to exceed five (5) days after a Steering Committee meeting. Draft minutes
shall be edited by ADM Sub and MBX and shall be issued in final form within a
reasonable time not to exceed ten (10) days after the meeting only with their
approval and agreement as evidenced by their signatures on the minutes.
Responsibility for appointment of the secretary shall rotate annually between
MBX and ADM Sub.

          3.3.4 EXPENSES. MBX and ADM Sub shall each bear all expenses of their
respective Steering Committee members related to their participation on the
Steering Committee and attendance at Steering Committee meetings.

     3.4 PROJECT TEAMS. ADM Sub and MBX, either: (i) acting through the Steering
Committee, or (ii) as set forth herein or in the other Commercial Alliance
Agreements, may, from time-to-time, form project teams to support the activities
of the Steering Committee with respect solely to discrete, defined projects
("Projects") that are to be performed in support of, or as part of, the
Commercial Alliance ("Project Teams"). Each Project Team shall function in
accordance with the terms and conditions set forth herein, as set forth in the
other Commercial Agreements or as otherwise agreed to by the Steering Committee
in writing.

          3.4.1 RESPONSIBILITIES AND AUTHORITY OF THE PROJECT TEAMS. Each
Project Team shall have the rights and obligations provided for herein, in the
other Commercial Alliance Agreements, or as expressly delegated to it by the
Steering Committee in writing from time-to-time during the Term.

          3.4.2 CERTAIN LIMITATIONS ON THE RESPONSIBILITIES AND AUTHORITY OF THE
PROJECT TEAMS. The rights and authority of the Project Teams are derived from
and are subordinate to the rights and authority of the Steering Committee.
Without limiting the foregoing, no Project Team shall have any rights or
authority to make decisions or take actions that are not directly related to the
applicable Project and all Project Teams shall be subject to the same
limitations as are applicable to the Steering Committee as set forth in Section
3.1.2.

          3.4.3 DECISION-MAKING STANDARD FOR THE STEERING COMMITTEE. The Project
Teams shall make decisions and take actions subject to the same standards as are
applicable to the Steering Committee as set forth in Section 3.1.3 hereof.

     3.5 MEMBERSHIP OF PROJECT TEAMS. Each Project Team shall be comprised of
such number of members as is provided herein, in another Commercial Alliance
Agreement or as

*    CONFIDENTIAL TREATMENT REQUESTED

                                       15

<Page>

provided by the Steering Committee. Unless otherwise mutually agreed by ADM Sub
and MBX, any Project Team concerning the ADM Sub Manufacturing Facility shall be
comprised of a majority of members appointed by ADM Sub, and any Project Team
concerning the MBX Formulation Facility shall be comprised of a majority of
members appointed by MBX. Project Team members may also be members of the
Steering Committee. Each of ADM Sub and MBX shall have the right at any time to
substitute individuals, on a permanent or temporary basis, for any of its
previously designated representatives to a Project Team by giving written notice
thereof to the other Party.

     3.6 MEETINGS.

          3.6.1 SCHEDULE OF MEETINGS. Each Project Team shall establish a
schedule of times for its meetings, taking into account, without limitation, the
planning needs of the applicable Project. Meetings shall alternate between the
respective offices of ADM Sub and MBX or another mutually agreed upon location;
provided, however, that ADM Sub and MBX may mutually agree to meet by
teleconference or video conference or may act by a written memorandum signed by
the Co-Chairs of the Project Team.

          3.6.2 QUORUM; VOTING; DECISIONS. At each meeting of a Project Team,
the participation of at least one member designated by each of ADM Sub and MBX
shall constitute a quorum. Each Project Team member shall have one vote on all
matters before the Project Team; provided, however, that the member or members
of each of ADM Sub and MBX present at any meeting shall have the authority to
cast the votes of any of such Party's members who are absent from the meeting.
Unless provided otherwise herein or in another Commercial Alliance Agreement,
all decisions of the Project Team shall be made by majority vote of all of the
members. Representatives of each of ADM Sub and MBX, in addition to the members
of the Project Team, may attend meetings as non-voting observers with prior
notice to the other Party. In the event that a Project Team is unable to resolve
any matter before it, such matter shall be referred to the Steering Committee
for resolution.

          3.6.3 MINUTES. A secretary for each Project Team shall be appointed to
keep accurate minutes of the deliberations of such Project Team recording all
proposed decisions and all actions recommended or taken. Copies of such minutes
shall be made available to the Steering Committee as it shall request.

          3.6.4 EXPENSES. MBX and ADM Sub shall each bear all expenses of their
respective Project Team members related to their participation on Project Teams
and attendance at Project Team meetings.

          3.6.5 REPORTS. Each Project Team shall produce such reports for the
Steering Committee as the Steering Committee shall request from time-to-time.

     3.7 BUSINESS INTEGRATION AND COORDINATION. ADM Sub and MBX, with and
through the Commercial Alliance Business Team, subject to the terms and
conditions of the Commercial Alliance Agreements, shall coordinate and integrate
the efforts of the Parties to plan and execute manufacturing, formulation,
marketing and sales activities in such a manner as to establish and maintain an
efficient and profitable commercial operation.

          3.7.1 COMMERCIAL ALLIANCE BUSINESS TEAM. The Parties shall form a
Commercial Alliance Business Team (the "Commercial Alliance Business Team") to
assist in

*    CONFIDENTIAL TREATMENT REQUESTED

                                       16

<Page>

the integration and coordination of the manufacturing, formulation, marketing
and sales activities of the Parties. The Commercial Alliance Business Team shall
be a Project Team of the Steering Committee and shall function, and otherwise be
subject to, the provisions set forth in Sections 3.4 through 3.6, inclusive,
except that decisions shall be made by unanimous agreement. The Commercial
Alliance Business Team shall be composed of the Marketing and Sales Manager of
the Joint Sales Company, the Assistant Marketing and Sales Manager of the Joint
Sales Company, the ADM Sub Manufacturing Manager, the MBX Technology Manager and
during the Construction Phase, the ADM Sub Project Manager. The Marketing and
Sales Manager of the Joint Sales Company shall be the chair of the Commercial
Alliance Business Team. The Commercial Alliance Business Team may be expanded by
the Steering Committee in order to add persons with technical knowledge or to
ensure the integration of key functional areas within the Commercial Alliance
into the planning and coordination process.

          3.7.2 BUSINESS PLANNING. The Commercial Alliance Business Team will
have access to and review the plans and reports prepared by any established
Project Teams, ADM Sub and MBX relating to manufacturing, formulation and
marketing the PHA Material and PHA Formulations. The Commercial Alliance
Business Team will analyze such input and make reports or recommendations to the
Board of the Joint Sales Company, the Steering Committee or other Project Teams,
as appropriate, in order to ensure that: (i) complete, current and accurate
information is available across relevant Project Teams and functional groups,
(ii) the activities of any Project Teams do not conflict, and to the extent they
are interdependent, they are appropriately coordinated and (iii) input from
Third Parties, such as Strategic Alliance Partners, customer segments and key
customers are adequately taken into account in planning, prioritizing and
executing manufacturing, formulation, marketing and sales activities.

                                    ARTICLE 4
                               CONSTRUCTION PHASE

     4.1 OVERVIEW AND GOAL OF CONSTRUCTION PHASE. The primary goal of the
Construction Phase is to prepare for the commercial launch of PHA Material and
PHA Formulations manufactured in facilities owned by the Parties. In order to
achieve this goal, the Parties will pursue the following primary objectives: (i)
ADM Sub will arrange for and finance the construction of a facility in which it
will manufacture PHA Material pursuant to the terms of the ADM Sub Manufacturing
Agreement (the "ADM Sub Manufacturing Facility"), (ii) MBX will either arrange
for and finance the acquisition or construction of a facility in which it will
produce the PHA Formulations pursuant to the terms of the MBX Formulation
Agreement (the "MBX Formulation Facility") or it will use Commercially
Reasonable Efforts to arrange for other access to a facility in which a Third
Party will produce the PHA Formulations pursuant to the terms of an agreement
with the Joint Sales Company and (iii) MBX, acting in the name and on behalf of
the Joint Sales Company, will establish the market for the PHA Material and PHA
Formulations, in each case, with the support and participation of the other
Parties and the Steering Committee and as more fully set forth herein and in the
other Commercial Alliance Agreements.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       17

<Page>

     4.2 CONSTRUCTION OF THE ADM SUB MANUFACTURING FACILITY. ADM Sub shall have
primary responsibility for the Construction of the ADM Sub Manufacturing
Facility consistent with the ADM Sub Construction Master Plan and Budget to
produce PHA Material in accordance with the terms and conditions of the ADM Sub
Manufacturing Agreement. MBX will have the right to actively participate in each
of these activities, as set forth in more detail below, in order to assist ADM
Sub in achieving the foregoing goal.

          4.2.1 SPECIFICATIONS OF THE ADM SUB MANUFACTURING FACILITY. The ADM
Sub Manufacturing Facility will be designed to produce, through microbial
fermentation, approximately fifty thousand (50,000) tons of PHA Material, having
an acceptable level of purity, during each twelve (12) month period, on an
ongoing basis through a stable and robust operation, over a period of years. The
Parties acknowledge that the actual production of PHA Material from the ADM Sub
Manufacturing Facility will vary from year to year based upon multiple factors
and variables. The designed capacity, irrespective of the actual production
which may be achieved, is hereinafter defined as the "50,000 Ton Annual Design
Capacity". ADM Sub will use Commercially Reasonable Efforts to Construct the ADM
Sub Manufacturing Facility to enable and support state-of-the-art PHA Material
manufacturing operations, consistent with the ADM Sub Construction Master Plan
and Budget. ADM Sub shall proceed with the Construction in a manner intended to
complete Construction of the ADM Sub Manufacturing Facility within twenty-four
(24) to thirty-six (36) months following the Effective Date.

          4.2.2 ADM SUB CONSTRUCTION MASTER PLAN AND BUDGET. In the event the
ADM Sub Construction Master Plan and Budget was not developed pursuant to the
Technology Alliance and Option Agreement, ADM Sub, in consultation with any
appointed Project Team and the Metabolix Technology Manager, and with the
assistance of such Third Party consultants as shall be approved by the Steering
Committee, shall develop the ADM Sub Construction Master Plan and Budget and
submit same to the Steering Committee for approval. ADM Sub will use
Commercially Reasonable Efforts to implement the ADM Sub Construction Master
Plan and Budget. The ADM Sub Construction Master Plan and Budget shall be
amended, from time to time, in an effort to ensure that it remains sufficiently
accurate and complete so that if the activities called for in the ADM Sub
Construction Master Plan and Budget were to be executed in accordance with its
terms, ADM Sub would have satisfied all of its obligations hereunder with
respect to the Construction of the ADM Sub Manufacturing Facility. The ADM Sub
Construction Master Plan and Budget shall also be subject to amendment in the
event that ADM Sub reasonably expects that the total amount set forth in the
budget within the ADM Sub Construction Master Plan and Budget will not be
sufficient to fund the activities remaining to be performed under the ADM Sub
Construction Master Plan and Budget. Such amendments will include an updated
budget with a description and the amount of all additional costs and expenses
that ADM Sub desires to have designated as Construction Costs. All amendments to
the ADM Sub Construction Master Plan and Budget will be subject to the approval
of the Steering Committee, subject to the standards set forth in Section 3.1.3.
For avoidance of doubt, no amendment to the ADM Sub Construction Master Plan and
Budget will be required due to a variance in the actual cost of a particular
item or service as compared to the budgeted cost of such item or service unless
such variance (alone or cumulatively with other such variances) causes ADM Sub
to reasonably expect that the total amount set forth in the budget within the

*    CONFIDENTIAL TREATMENT REQUESTED

                                       18

<Page>

ADM Sub Construction Master Plan and Budget will not be sufficient to fund the
activities remaining to be performed under the ADM Sub Construction Master Plan
and Budget.

          4.2.3 MBX TECHNOLOGY MANAGER. Metabolix shall appoint, subject to the
approval of the Steering Committee, a representative to serve as its technology
manager (the "MBX Technology Manager"). The MBX Technology Manager, and up to
three (3) MBX employees having varied areas of technical expertise, shall be
given a reasonable opportunity to review, consult and sign off on key
engineering designs and documents relating to the Construction of the ADM Sub
Manufacturing Facility, in accordance with good engineering and process
management principles, including, without limitation, piping and instrumentation
diagrams, major plant item design calculations and data sheets, purchase
contract technical specifications for major plant items, sterile engineering
design and operating philosophy, pre-delivery performance and acceptance testing
of major plant items, conceptual functional specifications for control and
automation, analytical and quality control procedures, hazard and operability
studies, fermentation recipe specifications (including without limitation raw
material specifications) and change orders during the course of the contract.
Notwithstanding the foregoing, after providing the MBX Technology Manager and
any appointed Project Team with the requisite opportunities to review and to
provide input on decisions relating the Construction of the ADM Sub
Manufacturing Facility, and after giving reasonable consideration to such input,
ADM Sub shall have the right and responsibility to make final decisions with
respect to all such matters.

          4.2.4 ACCESS TO SITE, BOOKS AND RECORDS. The MBX Technology Manager,
and up to three (3) MBX employees, shall have reasonable access, after giving
reasonable prior notice, during hours of operation, to: (i) the site on which
the ADM Sub Manufacturing Facility is being Constructed, throughout the
Construction process, (ii) individuals involved in the Construction process,
including without limitation, construction managers, engineers and supervisors,
and (iii) all documents relating to the Construction of the ADM Sub
Manufacturing Facility, including without limitation, the ADM Sub Construction
Master Plan and Budget and the various documents and agreements that relate to
the preparation and amendment thereof, including without limitation all surveys,
blueprints, engineering studies, piping and instrumentation diagrams, equipment
design calculations and drawings, piping layouts, purchase contracts, sterile
engineering designs and construction details, equipment test reports, automation
and control designs, analytical and quality control procedures, hazard and
operability studies, fermentation recipe specifications (including without
limitation raw material specifications) and change orders during the course of
the contract, in each case, whether prepared by ADM Sub or a Third Party. For
purposes of the foregoing sentence, the term "reasonable access" means and
includes such access as is necessary or convenient for such individuals to
fulfill their obligations hereunder in the manner required hereby without unduly
burdening the other individuals involved in the Construction process or
unnecessarily delaying the Construction process. All site visits or record
reviews undertaken at ADM Sub facilities will be conducted in accordance with
policies and procedures in force at such facilities, including without
limitation, policies designed to promote safety and policies against sexual
harassment and discrimination.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       19

<Page>

          4.2.5 ADM SUB FINANCIAL RESPONSIBILITY. ADM Sub shall be solely
responsible for all costs incurred in connection with the ADM Sub Manufacturing
Facility, subject to application as a credit against the Ledger Account (as such
term is defined in the Operating Agreement), as and to the extent provided in
the Operating Agreement, of those costs and expenses that were designated as
Construction Costs by the TAC as part of the ADM Sub Construction Master Plan
and Budget as provided in the Technology Alliance and Option Agreement or as are
designated as Construction Costs as set forth herein and in Section 4.2.2. In
addition to the foregoing approval procedures, ADM Sub shall have the right to
seek a re-designation of any categories or items of costs and expenses that it
believes should be designated and approved as Construction Costs at anytime
during the Term. The Steering Committee shall, on a quarterly basis during the
Construction Period, or more frequently as reasonably requested by ADM Sub or
MBX, review the ADM Sub Construction Master Plan and Budget to evaluate and
approve any material additional or changed information concerning the design or
Construction of the ADM Sub Manufacturing Facility, subject to the standards set
forth in Section 3.1.3.

     4.3 ACQUISITION, CONSTRUCTION AND ACCESS TO FORMULATION FACILITY. MBX shall
have primary responsibility for arranging the acquisition or Construction of the
MBX Formulation Facility in a manner reasonably calculated to result in the
consistent production of PHA Formulations by MBX for the Joint Sales Company in
accordance with terms and conditions of the MBX Formulation Agreement, or to use
Commercially Reasonable Efforts to arrange for other access to a formulation
facility in a manner reasonably calculated to result in the consistent
production of PHA Formulations by a Third Party for the Joint Sales Company in
accordance with terms and conditions of an agreement between such Third Party
and the Joint Sales Company. ADM Sub will have the right to actively participate
in each of these activities, as set forth in more detail below, in order to
assist MBX in achieving the foregoing goal. Formulation activities to be
conducted at the MBX Formulation Facility or the Third Party formulation
facility, as the case may be, will include, without limitation, blending
different types of PHA Material together, and with other polymers and/or with
other additives, such as nucleants, clarifiers, flow modifiers, plasticizers,
flame retardants and heat stabilizers.

          4.3.1 SPECIFICATIONS OF THE MBX FORMULATION FACILITY. The MBX
Formulation Facility or the Third Party formulation facility, as the case may
be, will be sufficient to enable and support state-of-the-art PHA Material
formulation operations at a scale reasonably calculated to meet the formulation
needs of the Commercial Alliance with respect to the output from the ADM Sub
Manufacturing Facility and market demand. MBX shall proceed with the acquisition
or Construction of MBX Formulation Facility, or gaining access to a Third Party
formulation facility, in sufficient time to meet the formulation needs of the
Commercial Alliance with respect to the output from the ADM Sub Manufacturing
Facility and market demand.

          4.3.2 MBX FACILITY MASTER PLAN AND BUDGET. MBX, in consultation with
any appointed Project Team, and with the assistance of such Third Party
consultants as shall be approved by the Steering Committee, shall develop a plan
and budget for the acquisition or Construction of the MBX Formulation Facility
or gaining access to a Third Party formulation facility (the "MBX Facility
Master Plan and Budget") and submit same to the Steering Committee for approval.
MBX will use Commercially Reasonable Efforts to implement the

*    CONFIDENTIAL TREATMENT REQUESTED

                                       20

<Page>

MBX Facility Master Plan and Budget. The MBX Facility Master Plan and Budget
shall be amended, from time to time, in an effort to ensure that it remains
sufficiently accurate and complete so that if the activities called for in the
MBX Facility Master Plan and Budget were to be executed in accordance with its
terms, MBX would have satisfied all of its obligations hereunder with respect to
the acquisition or Construction of MBX Formulation Facility or gaining access to
a third Party formulation facility. The MBX Facility Master Plan and Budget
shall be subject to amendment in the event that MBX reasonably expects that the
total amount set forth in the budget within the MBX Facility Master Plan and
Budget will not be sufficient to fund the activities remaining to be performed
under the MBX Facility Master Plan and Budget. Such amendments to the MBX
Facility Master Plan and Budget will include an updated budget with a
description and the amount of all additional costs and expenses that MBX desires
to have designated as Construction Costs. Such amendments to the MBX Facility
Master Plan and Budget will be subject to the approval of the Steering
Committee, subject to the standards set forth in Section 3.1.3. For avoidance of
doubt, no amendment to the MBX Facility Master Plan and Budget will be required
due to a variance in the actual cost of a particular item or service as compared
to the budgeted cost of such item or service unless such variance (alone or
cumulatively with other such variances) causes MBX to reasonably expect that the
total amount set forth in the budget within the MBX Facility Master Plan and
Budget will not be sufficient to fund the activities remaining to be performed
under the MBX Facility Master Plan and Budget.

          4.3.3 PROJECT TEAM; FORMULATION ENGINEER. ADM Sub shall appoint,
subject to the approval of the Steering Committee, a representative to serve as
its formulation engineer (the "ADM Sub Formulation Engineer"). The ADM Sub
Formulation Engineer, and up to three (3) employees of ADM Sub, shall be given a
reasonable opportunity to review, consult and sign off on key aspects of the MBX
Facility Master Plan and Budget. If the MBX Formulation Facility is to be
Constructed by MBX, the ADM Sub Formulation Engineer, and up to three (3)
employees of ADM Sub or its Affiliates, shall be given reasonably opportunity to
review, consult and sign off on key engineering designs and documents relating
to the Construction of the MBX Manufacturing Facility, in accordance with good
engineering and process management principles, including without limitation,
piping and instrumentation diagrams, major plant item design calculations and
data sheets purchase contract technical specifications for major plant items,
sterile engineering design and operating philosophy, pre-delivery performance
and acceptance testing of major plant items, conceptual functional
specifications for control and automation, analytical and quality control
procedures, hazard and operability studies, and change orders during the course
of the contract. If the MBX Formulation Facility is to be acquired or in the
event MBX is gaining access to a Third Party formulation facility, the ADM Sub
Formulation Engineer, and up to three (3) employees of ADM Sub or its
Affiliates, shall be given reasonable opportunity to inspect the facilities and
review, consult and sign off on key engineering designs and documents relating
to the operation of any such facility to produce PHA Formulations.
Notwithstanding the foregoing, after providing the ADM Sub Formulation Engineer
and any appointed Project Team with the requisite opportunities to review and to
provide input on material decisions relating to the MBX Facility Master Plan and
Budget, and after giving reasonable consideration to such input, MBX shall have
the right and responsibility to make final decisions with respect to all such
matters.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       21

<Page>

          4.3.4 ACCESS TO SITE, BOOKS AND RECORDS. If the MBX Formulation
Facility is to be Constructed by MBX, then the ADM Sub Formulation Engineer, and
up to three (3) employees of ADM Sub, shall have reasonable access, after giving
prior notice, during regular business hours, to (i) the site on which the MBX
Formulation Facility is being Constructed, throughout the Construction process,
(ii) individuals involved in the Construction process, including without
limitation, construction managers, engineers and supervisors, and (iii) all
documents relating to the Construction of the MBX Formulation Facility,
including without limitation, the MBX Facility Master Plan and Budget and the
various documents and agreements that relate to the preparation and amendment
thereof, including without limitation all surveys, blueprints, engineering
studies, piping and instrumentation diagrams, equipment design calculations and
drawings, piping layouts, purchase contracts, sterile engineering designs and
construction details, equipment test reports, automation and control designs,
analytical and quality control procedures, hazard and operability studies, and
change orders during the course of the contract, in each case, whether prepared
by MBX or a Third Party. If the MBX Formulation Facility is not going to be
Constructed by MBX, then the ADM Sub Formulation Engineer shall have reasonable
access, during regular business hours, to the site of the MBX Formulation
Facility and all documents relating to the potential MBX Formulation Facilities
or Third Party formulation facilities that MBX has in its control, including
without limitation, the MBX Facility Master Plan and Budget and the various
documents and agreements that relate to the preparation and amendment thereof,
including without limitation a survey of available facilities, detailed
documentation of the capabilities of the most highly-rated facilities, cost,
schedule of availability and other relevant information and data, whether
prepared by MBX or a Third Party. For purposes of the foregoing sentence, the
term "reasonable access" means and includes such access as is necessary or
convenient for such individuals to fulfill their obligations hereunder in the
manner required hereby without unduly burdening the other individuals involved
in the execution of the MBX Facility Master Plan and Budget unnecessarily
delaying the execution of the MBX Facility Master Plan and Budget. All site
visits or record reviews undertaken at MBX facilities will be conducted in
accordance with policies and procedures in force at such facilities, including
without limitation, policies designed to promote safety and policies against
sexual harassment and discrimination.

          4.3.5 MBX FINANCIAL RESPONSIBILITY. MBX shall be solely responsible
for all costs incurred in connection with the MBX Formulation Facility, subject
to application as a debit against the Ledger Account (as such term is defined in
the Operating Agreement), as and to the extent provided in the Operating
Agreement, of those costs and expenses that are designated by the Steering
Committee as Construction Costs as set forth herein and in Section 4.3.2. The
Steering Committee shall conduct a complete review of the MBX Facility Master
Plan and Budget, promptly after the completion of such document, and shall
designate and approve those items or categories of costs and expenses provided
in such documents as Construction Costs and shall indicate whether and why
certain items or categories of costs and expenses do not qualify as Construction
Costs, in whole or in part, and whether such costs and expenses could so qualify
under other circumstances, for example, if more information were provided as the
necessity and reasonableness of the particular costs and expenses or the
features or facilities to which such costs and expenses relate. The Steering
Committee shall, on a quarterly basis during the Construction Phase, or more
frequently as reasonably requested by MBX, review the MBX Facility Master Plan
and Budget to evaluate any material additional or changed information

*    CONFIDENTIAL TREATMENT REQUESTED

                                       22

<Page>

concerning the design of the MBX Formulation Facility, subject to the standards
set forth in Section 3.1.3. In addition to the foregoing review procedures, MBX
shall have the right to seek a re-designation of any categories or items of
costs and expenses that it believes should be designated as Construction Costs
at anytime during the Term.

          4.3.6 PHA FORMULATION FEE. The Joint Sales Company will pay to MBX a
formulation fee equal to * on all sales or other conveyances of PHA Material
contained within PHA Formulations, on a one hundred percent (100%) purity basis,
that is not formulated for the Joint Sales Company by MBX in the MBX Formulation
Facility. The formulation fee shall be due and payable on a monthly basis. The
formulation fee for sales or conveyances completed during any month shall be due
and payable to MBX on or before the last business day of the succeeding month.
Amounts due under this Section 4.3.6 shall be payable by wire transfer of
immediately available funds to an MBX bank account in accordance with
instructions to be provided to the Joint Sales Company by MBX. Any amounts that
are not paid when due hereunder shall accrue interest at the rate of four
percent (4%) per annum in excess of the one year London Interbank Offered Rate
(LIBOR) then most recently published in THE WALL STREET JOURNAL. The right to
demand and receive the interest provided hereunder shall be in addition to any
other rights available to MBX hereunder or at law.

     4.4 PILOT ACTIVITIES.

          4.4.1 RESEARCH AND DEVELOPMENT; FUNDED TECHNOLOGY. During the
Construction Phase and thereafter during the Term, MBX will continue its
research and development efforts, on its own and with Third Parties, provided
that MBX shall pursuant to a written agreement with such Third Party own or
obtain an option to exclusively license all Technology arising from such
activity, aimed at improving the MBX Technology relating to the production of
PHA Cell Paste, PHA Material and PHA Formulations, including without limitation,
MBX's microbial strains, fermentation processes and recovery technology. The
goal of these efforts is for MBX to develop a microbial strain and processes
capable of producing PHA Material at a cost of approximately * at a
manufacturing scale of * per year and to develop related Technology that will
expand and enhance the commercial potential of the PHA Material for use in the
Field. Beginning with the commencement of the Commercial Phase, MBX and ADM Sub
shall each, from time to time, have the option of proposing to the Steering
Committee certain studies or other research efforts in the Field. The Joint
Sales Company shall have the option to fund such studies or research efforts in
accordance with a work plan and budget to be prepared by the Party making such
proposal. If the Steering Committee approves, and the Joint Sales Company
commits to, and in fact does, fund such a study or research effort, any
Technology developed, conceived or reduced to practice in the course of such
study or research effort shall be deemed to be funded technology ("Funded
Technology") and will automatically be subject to the licenses and rights
granted herein as part of the Joint Alliance Technology without further action
by either Party. Subject to the standards set forth in Section 3.1.3, the
Steering Committee shall determine the party best able to perform the work
outlined in an approved proposal, considering all relevant factors, including,
for example, the availability of particular human or the resources, access to
Technology, materials or know-how, or technical experience. If the Steering
Committee determines that ADM Sub and MBX are both equally able to perform such
work, then the Steering Committee shall request MBX to perform such

*    CONFIDENTIAL TREATMENT REQUESTED

                                       23

<Page>

work. If the Steering Committee does not approve, or if the Joint Sales Company
declines to, or in fact fails to, fund such a study or research effort, and the
Party which proposes the study or research performs such study or research, any
Technology developed, conceived or reduced to practice in the course of such
study or research effort shall be deemed to be unfunded technology ("Unfunded
Technology") and shall be solely owned by MBX or ADM Sub, as the case may be,
and, anything herein to the contrary notwithstanding, shall not be subject to
the rights and licenses granted herein, subject to the Parties subsequently
agreeing to a license or similar agreement to the contrary. For the avoidance of
doubt, the parties acknowledge that the research and development projects that
may be subject to the proposals described above may be performed by Third
Parties to be identified in such proposals, and in such cases the Steering
Committee shall either accept or reject the proposal on behalf of the Joint
Sales Company but shall have no right to require that a different Third Party or
any of the Parties shall perform such research and development project.

          4.4.2 PILOT MANUFACTURING. During the Term, the Parties will use
reasonable efforts to obtain access to pilot quantities of PHA Material from a
combination of one or more contract manufacturers, ADM Sub personnel and
facilities and MBX personnel and facilities, for use solely in research and
development efforts and to support or facilitate marketing and sales efforts of
PHA Material and/or PHA Formulations, but, after the First Commercial Sale, not
to supply all, or a segment, of the commercial market for PHA Material as part
of an ongoing commercial sales operation (such activity is "Pilot Sourcing"). To
the extent the Pilot Sourcing utilizes the personnel and facilities of Third
Party contract manufacturers and/or the personnel and facilities of MBX, MBX
shall control the selection and operations of such personnel and facilities. To
the extent the Pilot Sourcing utilizes the personnel and facilities of ADM Sub,
ADM Sub shall control the selection and operations of such personnel and
facilities. During the Construction Phase, MBX will investigate available
options for Pilot Sourcing and, if MBX identifies a viable option, then MBX will
present a proposal to the Steering Committee for the Steering Committee's
consideration and approval. The proposal shall include the identity of the
manufacturer(s), the personnel and facilities that ADM Sub and MBX would devote
to the efforts, the site(s) of the Pilot Sourcing, the anticipated quantity to
be produced under the proposal, the anticipated delivery schedule for PHA
Material under the proposal and the estimated capital and operating cost to ADM
Sub and MBX under the proposal (each such proposal is hereinafter a "Pilot
Sourcing Proposal"). MBX will use reasonable efforts to implement any Pilot
Sourcing Proposal approved by the Steering Committee. ADM Sub and MBX shall
share equally the total cost and expenses incurred by them in connection with
any approved Pilot Sourcing Proposal, including the cost of ADM Sub personnel
and facilities and MBX personnel and facilities all of which will be accounted
for on a cost basis, defined in a manner to be agreed upon as part of any such
proposal ("Pilot Sourcing Costs"), and any Technology developed in connection
with such activities shall be part of the Joint Alliance Technology. After the
Construction Phase, MBX will present any Pilot Sourcing Proposal to the Joint
Sales Company for the Joint Sales Company's consideration and approval. MBX will
use reasonable efforts to implement any Pilot Sourcing Proposal approved by the
Steering Committee. The Joint Sales Company shall bear the Pilot Sourcing Costs
in connection with any approved Pilot Sourcing Proposal and any Technology
developed in connection with such activities shall be part of the Joint Alliance
Technology. In the event that the Steering Committee or the Joint Sales Company,
as applicable, do not approve a particular Pilot Sourcing

*    CONFIDENTIAL TREATMENT REQUESTED

                                       24

<Page>

Proposal, MBX may proceed to implement the proposal at its own expense and any
Technology developed in connection with such activities shall be part of the MBX
Alliance Technology. Any PHA Cell Paste or PHA Material obtained in connection
with the Pilot Sourcing ("Pilot PHA Material") shall be used solely for internal
research and development purposes or shall be provided to Third Parties as set
forth in Section 4.4.3 below.

          4.4.3 DISPOSITION OF PILOT PHA MATERIAL. During the Construction
Phase, MBX will market and sell the Pilot PHA Material in the name of and on
behalf of the Joint Sales Company and, during the Construction Phase, the
proceeds of such sales will be distributed as set forth in this Section 4.4.3
rather than as set forth in the Operating Agreement. Proceeds from the sale of
Pilot PHA Material will be distributed to the Parties on a pro rata basis to
reimburse them for the Pilot Sourcing Costs with the remainder, if any, to be
distributed to the Parties on a pro rata basis to reimburse them for their
respective reasonable costs and expenses incurred in connection with marketing
and sales activities carried out by them in furtherance of the Commercial
Alliance and approved by the Steering Committee. After the Construction Phase,
the Joint Sales Company will market and sell the Pilot PHA Material and the
proceeds of sales of Pilot PHA Material will be distributed, if at all, in
accordance with the terms and conditions set forth in the Operating Agreement.

          4.4.4 IN-LICENSE TECHNOLOGY. Beginning with the Effective Date, MBX
and ADM Sub shall each, from time to time, have the option of proposing to the
Steering Committee certain in-licensing or acquisition of Technology that may be
useful in connection with the activities of the Parties hereunder, or under the
other Commercial Alliance Agreements. The Joint Sales Company shall have the
option to so in-license or acquire such Technology at its expense, in which
case, the Joint Sales Company shall negotiate the terms and conditions of such
license or acquisition. If the Steering Committee approves, and the Joint Sales
Company commits to, and in fact does, license or acquire such Technology then
such Technology shall be deemed part of the Joint Alliance Technology and will
automatically be subject to the licenses and rights granted herein without
further action by either Party. If the Steering Committee does not approve, or
if the Joint Sales Company declines to, or in fact fails to, in-license or
acquire such Technology, then if either Party supported the proposal then such
Party shall have the right to in-license or acquire such Technology at its
expense, and shall be deemed a part of the Unfunded Technology and shall be
solely owned by MBX or ADM Sub, as the case may be, and, anything herein to the
contrary notwithstanding, shall not be subject to the rights and licenses
granted herein, subject to the Parties subsequently agreeing to a license or
similar agreement to the contrary.

     4.5 CERTAIN FINANCIAL COMMITMENTS DURING THE CONSTRUCTION PHASE. In partial
consideration of the rights and licenses granted herein to the Joint Sales
Company, the Joint Sales Company shall make the non-refundable payments
described herein to MBX during the Construction Phase. The Joint Sales Company
shall pay to MBX up to (a) two (2) equal payments of one million, five hundred
and seventy-five thousand dollars ($1,575,000) each, and (b) up to: (i) ten (10)
equal payments of one million, five hundred and seventy-five thousand dollars
($1,575,000) during each Calendar Quarter during the Construction Phase. Such
twelve (12) payments are each an "Operating Payment" and together the "Operating
Payments"). The first two Operating Payments totaling three million one hundred
fifty thousand dollars

*    CONFIDENTIAL TREATMENT REQUESTED

                                       25

<Page>

($3,150,000) shall be due and payable within ten (10) days after the Effective
Date and each Operating Payment thereafter shall become due and payable on the
first Business Day of each successive Calendar Quarter during the Construction
Phase. The Steering Committee shall have the right to increase the amount of the
Operating Payments at any time during the Term to support additional work by MBX
in support of the Commercial Alliance. If the Construction Phase ends before all
twelve (12) Operating Payments become due and payable hereunder, and this
Agreement remains in effect, then the Joint Sales Company shall make a final
payment to MBX within thirty (30) days of the end of the Construction Phase as
determined in accordance with the following formula:

                             X = $250,000 x (12 - Y)

For the purposes of the above formula, "X" equals the amount of the final
payment in dollars and "Y" equals the number of Operating Payments that became
due and payable during the Construction Phase. Amounts due under this Section
4.5 shall be payable by wire transfer of immediately available funds to an MBX
bank account in accordance with instructions to be provided to the Joint Sales
Company by MBX. Any amounts that are not paid when due hereunder shall accrue
interest at the rate of four percent (4%) per annum in excess of the one year
London Interbank Offered Rate (LIBOR) then most recently published in THE WALL
STREET JOURNAL. The right to demand and receive the interest provided hereunder
shall be in addition to any other rights available to MBX hereunder or at law.
For avoidance of doubt, the failure by ADM Sub to provide funds to the Joint
Sales Company to make the Operating Payments as and when provided for herein
shall be deemed a breach of this Agreement by ADM Sub.

                                    ARTICLE 5
                JOINT SALES COMPANY; MARKETING AND SALES ACTIVITY

     5.1 FORMATION AND PURPOSE OF JOINT SALES COMPANY.

          5.1.1 GENERAL PURPOSES. As is referenced above, the Joint Sales
Company is a limited liability company, formed and owned by the Parties, and
intended to: (i) serve as the commercial entity to establish and develop the
commercial market for the PHA Material and PHA Formulations, and to conduct the
marketing and sales of PHA Material and PHA Formulations in furtherance of the
goals of the Commercial Alliance, (ii) assist in the coordination and
integration of the manufacturing, formulation and marketing activities in such a
manner as to establish and maintain an efficient and profitable commercial
operation and (iii) administer and account for certain financial matters
relating to the investments of the Parties in the Commercial Alliance and the
allocation and distribution of losses and profits therefrom to the Parties, as
more fully set forth in the Operating Agreement.

     5.2 MARKETING AND SALES ROLE. During the Construction Phase, MBX will use
Commercially Reasonable Efforts to establish the market for the PHA Material and
PHA Formulations in the name of the Joint Sales Company. ADM Sub shall have the
right to appoint a representative to participate in such efforts. During the
Commercial Phase, the Joint Sales

*    CONFIDENTIAL TREATMENT REQUESTED

                                       26

<Page>

Company will develop, expand and supply the global market for PHA Material and
PHA Formulations.

          5.2.1 STRATEGIC ALLIANCE PARTNERS. During the Construction Phase, MBX
will have primary responsibility for determining whether it is advisable to seek
a Strategic Alliance Partner to support and participate in the activities
described in this Article 5 and for identifying, contacting and negotiating, on
behalf of the Joint Sales Company, with potential Strategic Alliance Partners.
Notwithstanding the foregoing, MBX shall obtain the approval of the Steering
Committee and the Joint Sales Company before entering into any contractual
arrangement with a Third Party to assume responsibility for an active and
ongoing role in executing a strategic plan to establish the market for the PHA
Material or PHA Formulations.

          5.2.2 FINANCIAL MATTERS RELATING TO MARKETING AND SALES. Subject to
reimbursement of certain costs and expenses to the extent available under
Section 4.4.2, ADM Sub and MBX shall each be solely responsible for its own
costs and expenses incurred in connection with performing marketing and sales
activities undertaken during the Construction Phase.

     5.3 FUNDING OF JOINT SALES COMPANY.

          5.3.1 CAPITAL CONTRIBUTIONS. ADM Sub and MBX shall each make an
investment of capital in the Joint Sales Company in the amount of * as set forth
herein. ADM Sub shall remit such amount in cash to the Joint Sales Company
within ten (10) days after the Effective Date. MBX shall be credited with a
capital investment of * in exchange for foregoing receipt of the payment of the
License Fee by the Joint Sales Company to MBX. As is more fully set forth in the
Operating Agreement, future investments of capital by ADM Sub credited to the
Ledger Account pursuant to the Operating Agreement shall not cause ADM Sub to
acquire additional Units in the Joint Sales Company or to otherwise effect the
Parties' equal ownership of the Joint Sales Company.

          5.3.2 LOAN FACILITY. ADM Sub shall, as more fully set forth in the
Loan and Security Agreement, make available a loan facility to the Joint Sales
Company to fund certain cash requirements of the Joint Sales Company.

                                    ARTICLE 6
                      COMMERCIAL PHASE; ANCILLARY SERVICES

     6.1 OVERVIEW AND GOAL OF THE COMMERCIAL PHASE. The primary goal of the
Commercial Phase is to leverage the Parties' assets, including without
limitation, assets developed during the Construction Phase, such as the ADM Sub
Manufacturing Facility, the MBX Formulation Facility, the market developed
through the efforts of the Parties, including the sale of the Pilot PHA
Material, and the business relationships established by and on behalf of the
Joint Sales Company, in order to manufacture at the 50,000 Ton Annual Design
Capacity and sell the resulting PHA Material and PHA Formulations during the
Commercial Phase as a profitable, ongoing business venture. In order to achieve
this goal, the Parties will pursue the

*    CONFIDENTIAL TREATMENT REQUESTED

                                       27

<Page>

following primary objectives: (i) ADM Sub will, as and to the extent required in
the ADM Sub Manufacturing Agreement, dedicate the ADM Sub Manufacturing Facility
and its personnel to manufacturing PHA Material for sale to the Joint Sales
Company, (ii) MBX will, as and to the extent required in the MBX Formulation
Agreement, arrange for formulating PHA Material, whether in a dedicated facility
or not, (iii) the Parties will, as and to the extent set forth herein and in the
other Commercial Alliance Agreements, participate in and support, financially
and otherwise, the efforts of the Joint Sales Company to develop, expand and
supply the global market for PHA Material and PHA Formulations.

     6.2 ADM SUB MANUFACTURING. Throughout the Commercial Phase, ADM Sub shall
provide PHA Material to the Joint Sales Company in accordance with the terms and
conditions set forth in the ADM Sub Manufacturing Agreement. The ADM Sub
manufacturing services will be overseen by a manager appointed for this purpose
by ADM Sub with the approval of the Steering Committee (the "ADM Sub
Manufacturing Manager"). The performance parameters, including without
limitation, the product specifications, and procedures for forecasting,
ordering, delivery and payment for such PHA Materials are all as provided in the
ADM Sub Manufacturing Agreement. Distribution of amounts received by the Joint
Sales Company upon sale of the PHA Material and PHA Formulations shall be as
provided in the Operating Agreement.

     6.3 MBX FORMULATION. Throughout the Commercial Phase, MBX shall provide
formulation services with respect to the PHA Formulations for the Joint Sales
Company in accordance with the terms and conditions set forth in the MBX
Formulation Agreement. The performance parameters and procedures by which the
Joint Sales Company will access those services are all as provided in the MBX
Formulation Agreement. The distribution of amounts received by the Joint Sales
Company upon sale of the PHA Materials and PHA Formulations shall be as provided
in the Operating Agreement.

     6.4 JOINT SALES COMPANY. Unless expressly stated otherwise in this
Agreement or the other Commercial Alliance Agreements, or unless the Parties
agree otherwise in writing, once the Commercial Phase commences, all PHA
Material and PHA Formulations, excepting Pilot PHA Material, to be sold, or
otherwise disposed of, by or for the benefit of the Commercial Alliance, shall
be purchased solely from ADM Sub by the Joint Sales Company, and, if formulation
services for PHA Formulations are required, they shall be purchased solely from
MBX by the Joint Sales Company.

          6.4.1 ANCILLARY SERVICES. The Parties hereby acknowledge that MBX will
provide certain ancillary services to the Joint Sales Company as set forth in
the MBX Services Agreement. The Parties further acknowledge that ADM Sub will
provide certain ancillary services to the Joint Sales Company as set forth in
the ADM Sub Services Agreement.

                                    ARTICLE 7
           INTELLECTUAL PROPERTY; LICENSES; TECHNOLOGY TRANSFER; ROFN

     7.1 OWNERSHIP.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       28

<Page>

          7.1.1 SOLE OWNERSHIP. Subject to the rights and licenses granted
herein and in the other Commercial Alliance Agreements, ADM Sub shall own all
right, title and interest in and to any: (i) ADM Sub Background Technology, (ii)
ADM Sub Alliance Technology and (iii) ADM Sub Proprietary Materials. Subject to
the rights and licenses granted herein and in the other Commercial Alliance
Agreements, MBX shall own all right, title and interest in and to any: (x) MBX
Background Technology, (y) MBX Alliance Technology and (z) MBX Proprietary
Materials.

          7.1.2 JOINT OWNERSHIP. Subject to Section 7.1.1, and subject to the
rights and licenses granted herein and in the other Commercial Alliance
Agreements, MBX and ADM Sub shall jointly own all Joint Alliance Technology. ADM
Sub hereby grants to MBX a perpetual, royalty-free, fully-sublicenseable license
to ADM Sub's rights in Joint Alliance Technology for the research, development,
manufacture, use, sale and importation of PHA-Related Material produced via
Plants. MBX hereby grants to ADM Sub a perpetual, royalty-free, exclusive,
fully-sublicenseable license to MBX's rights in Joint Alliance Technology for
use in all fields that are part of ADM's and its Affiliates' commercial
activities at any time during the Term of the Commercial Alliance, but
excluding: (i) uses that are within the Field, (ii) uses that are within the
term "Field of Use" as that term is defined in the License Agreement by and
between MBX and Tepha, Inc. dated October 1, 1999, as amended on December 17,
2002 and (iii) any and all uses of PHA-Related Material produced via Plants.
Subject to the rights and licenses granted herein and in the other Commercial
Alliance Agreements, MBX and ADM Sub hereby agree that they shall each have the
right to assign, sell, license or otherwise convey their rights in the Joint
Alliance Technology without notice to or consent of the other Party and without
any obligation to share the proceeds of such activity with the other Party, or
otherwise to account to the other Party in connection with such activities. In
all other respects, the rights of the Parties as joint owners shall be
determined by the laws of the United States of America and the State of
Delaware. Trademarks that are developed by or on behalf of the Joint Sales
Company for use in connection with the marketing and sale of PHA Material or PHA
Formulations during the Term shall be included within the Joint Alliance
Technology and the Parties agree and covenant not to use any such trademarks, or
other trademarks licensed hereunder, in a manner that would cause a diminution
in value of such trademarks, including without limitation, by using such
trademarks in connection with other goods, by using such trademarks in a
misleading or confusing manner or by using any trademarks that are confusingly
similar to any such trademark.

          7.1.3 DISCLOSURE; ASSIGNMENTS. MBX shall promptly disclose in writing
to ADM Sub the making, conception or reduction to practice of any Alliance
Technology. ADM Sub shall promptly disclose in writing to MBX the making,
conception or reduction to practice of any Alliance Technology. Each Party
hereby assigns all of its right, title and interest in and to any Alliance
Technology to the other Party to the extent necessary to conform to the
allocation of ownership rights set forth in this Section 7.1. The Parties agree
to take such actions, including without limitation, executing and delivering
such documents, as the other Party may reasonably request in order to give
effect to and to evidence the foregoing assignments of rights.

     7.2. LICENSE GRANTS BY MBX.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       29

<Page>

          7.2.1 GRANT BY MBX TO ADM SUB. Subject to the terms and conditions set
forth herein, MBX hereby grants to ADM Sub a royalty-free, exclusive license,
without the right to sublicense, under MBX's right, title and interest in and to
the MBX Technology, the MBX Patent Rights and the Joint Alliance Technology,
solely to manufacture PHA Material and PHA Formulations in North America during
the Construction Phase in the quantities and form requested in writing by MBX,
or the Joint Sales Company, and agreed to by ADM Sub, and solely for sale by ADM
Sub to MBX and/or the Joint Sales Company for use within the Field, such
exclusivity to be subject to MBX's right to conduct the Permitted Activities as
set forth in Section 8.4. MBX shall not itself, or grant any license to any
third party to, manufacture, have made, offer for sale, sell, have sold or
import PHA Cell Paste, PHA Material or PHA Formulations, subject to MBX's right
to conduct the Permitted Activities as set forth in Section 8.4.

          7.2.2 GRANT BY MBX TO THE JOINT SALES COMPANY; GRANT OF SUBLICENSE.
Subject to the terms and conditions set forth herein, including without
limitation Section 9.8, MBX hereby grants to the Joint Sales Company the
following licenses, with Limited Sublicense Right: (i) upon completion of the
Construction Phase, a royalty-bearing, exclusive license during the Term, under
MBX's right, title and interest in and to the MBX Technology, the MBX Patent
Rights and the Joint Alliance Technology, solely to make and have made PHA
Material and PHA Formulations in North America, such exclusivity to be subject
to MBX's right to conduct the Permitted Activities as set forth in Section 8.4,
and (ii) upon the Effective Date, a royalty-bearing, exclusive license under
MBX's right, title and interest in and to the MBX Technology, the MBX Patent
Rights and the Joint Alliance Technology to offer for sale, sell, have sold and
import PHA Material and PHA Formulations for use in the Field worldwide. The
foregoing licenses shall, in all instances, be limited such that the Joint Sales
Company shall only be permitted to make and have made that amount of PHA
Material (including, without limitation, PHA Material that is contained within
PHA Formulations) that is produced by the ADM Sub Manufacturing Facility, having
a 50,000 Ton Annual Design Capacity, during any period of twelve (12)
consecutive months during the Term. MBX shall not itself, or grant any license
to any third party to, manufacture, have made, offer for sale, sell, have sold
or import PHA Cell Paste, PHA Material or PHA Formulations, subject to MBX's
right to conduct the Permitted Activities as set forth in Section 8.4. The Joint
Sales Company hereby grants an exclusive, royalty free sublicense of its right
to make and have made PHA Material to ADM Sub; provided, however, that such
sublicense shall be limited solely to permit ADM Sub to make such PHA Material
for sale to the Joint Sales Company under the ADM Sub Manufacturing Agreement
and solely for delivery directly to, or as directed by, the Joint Sales Company.
MBX hereby grants its consent to the foregoing grant of such limited sublicense
by the Joint Sales Company to ADM Sub. Notwithstanding anything to the contrary
herein, ADM, ADM Sub and the Joint Sales Company shall not transfer or convey
any cell line constituting part of the MBX Proprietary Materials to any Third
Party.

          7.2.3 PAYMENT OF ROYALTIES. In consideration of the grant of the
license by MBX under Section 7.2.2, the Joint Sales Company shall pay to MBX an
upfront license fee (the "License Fee") equal to *. Notwithstanding the
foregoing, MBX and the Joint Sales Company hereby agree that MBX shall forego
receipt of the payment of the License Fee, and the Joint Sales Company shall
retain the License Fee and shall treat such amount as a capital contribution

*    CONFIDENTIAL TREATMENT REQUESTED

                                       30

<Page>

by MBX to the Joint Sales Company as further set forth in Section 5.3.1. During
the Royalty Term, the Joint Sales Company will pay to MBX a royalty equal to:
(i) * on all sales or other conveyances of PHA Patented Material (including,
without limitation, PHA Material that is contained within PHA Formulations), on
a one hundred percent (100%) purity basis; and (ii) * on all sales or other
conveyances of PHA Know-How Material (including, without limitation, PHA
Material that is contained within PHA Formulations), on a one hundred percent
(100%) purity basis. During the Supplemental Royalty Term, the Joint Sales
Company will pay to MBX a royalty equal to * on all sales or other conveyances
of PHA Supplemental Know-How Material (including, without limitation, PHA
Material that is contained within PHA Formulations), on a one hundred percent
(100%) purity basis. In the event more than one royalty applies to the
manufacture, use, sale or importation of a particular product, then the highest
royalty shall be the only applicable royalty hereunder. The royalties on sales
or conveyances completed during any month shall be due and payable to MBX on or
before the last business day of the succeeding month. Amounts due under this
Section 7.2.3 shall be payable by wire transfer of immediately available funds
to an MBX bank account in accordance with instructions to be provided to the
Joint Sales Company by MBX. Any amounts that are not paid when due hereunder
shall accrue interest at the rate of four percent (4%) per annum in excess of
the one year London Interbank Offered Rate (LIBOR) then most recently published
in THE WALL STREET JOURNAL. The right to demand and receive the interest
provided hereunder shall be in addition to any other rights available to MBX
hereunder or at law.

     7.3 LICENSE GRANTS BY ADM SUB.

          7.3.1 GRANT BY ADM SUB TO MBX. Subject to the terms and conditions set
forth herein, ADM Sub hereby grants to MBX a *, non-exclusive license, without
the right to sublicense (except in connection with the Pilot Activities), under
ADM Sub's right, title and interest in and to the ADM Technology and the ADM Sub
Patent Rights, solely to use, offer for sale, sell, have sold and import PHA
Material and PHA Formulations during the Construction Phase in the quantities
and form requested in writing by MBX, or the Joint Sales Company, and agreed to
by ADM Sub, in connection with the Commercial Alliance as expressly permitted
under this Agreement, including without limitation, in connection with the Pilot
Activities.

          7.3.2 GRANT BY ADM SUB TO THE JOINT SALES COMPANY. Subject to the
terms and conditions set forth herein, ADM Sub hereby grants to the Joint Sales
Company a *, exclusive, fully-sublicenseable license during the Term, under ADM
Sub's right, title and interest in and to the ADM Technology, the ADM Sub Patent
Rights and the Joint Alliance Technology, solely to make and have made PHA
Material and PHA Formulations in North America and to offer for sale, sell, have
sold and import PHA Material and PHA Formulations worldwide. The foregoing
license shall be limited such that the Joint Sales Company shall only be
permitted to make and have made that amount of PHA Material (including, without
limitation, PHA Material that is contained within PHA Formulations) that is
produced by the ADM Sub Manufacturing Facility, having a 50,000 Ton Annual
Design Capacity, during any period of twelve (12) consecutive months during the
Term.

     7.4. RIGHT OF FIRST NEGOTIATION. MBX hereby grants to the Joint Sales
Company, a right of first negotiation as set forth in this Section 7.4 (the
"ROFN"). If MBX comes to Control

*    CONFIDENTIAL TREATMENT REQUESTED

                                       31

<Page>

Technology or Patent Rights pertaining * (the "ROFN Rights"), and MBX decides to
offer a Third Party a license or similar rights under the ROFN Rights at anytime
during the Term and prior to the expiration of the JV Option (including the
expiration of the possibility that the JV Option could reset under Section
9.8.5), then MBX shall first offer to the Joint Sales Company the right to
negotiate towards a license under which such ROFN Rights would be licensed by
MBX to the Joint Sales Company and, if ADM Sub accepts such offer on behalf of
the Joint Sales Company, then ADM Sub, on behalf of the Joint Sales Company, and
MBX shall negotiate in good faith towards such a license on such terms as each,
in its sole discretion, shall determine to be acceptable. In the event that MBX
and the Joint Sales Company have not executed a written agreement including the
terms of a license agreed upon by ADM Sub and MBX within one hundred twenty
(120) days after the initial offer from MBX to the Joint Sales Company, then MBX
shall be free to offer a license or similar rights under the ROFN Rights to a
Third Party; provided, however, (i) any such license or similar rights offered
to a Third Party shall not include economic terms that are more favorable to
such Third Party than the economic terms MBX last proposed to the Joint Sales
Company; and (ii) MBX shall remain subject to, and by granting any such license
or similar rights to any Third Party shall not breach, the restrictions and
obligations set forth in this Agreement (including without limitation Section
8.4, to the extent then-applicable) and the other Commercial Alliance
Agreements.

     7.5 NO IMPLIED RIGHTS. The Parties hereby agree and acknowledge that no
rights or licenses under their respective intellectual property rights are
granted hereunder, by implication, estoppel or otherwise, by any of them.

     7.6 TECHNOLOGY TRANSFER; LIMITED ACCESS. MBX and ADM Sub hereby acknowledge
the technology transfer conducted pursuant to the Technology Alliance and Option
Agreement. MBX hereby agrees to use Commercially Reasonable Efforts to conduct
an additional transfer of MBX Technology, which technology transfer will be
periodically updated during the Construction Phase to include improvements to
the MBX Technology, including without limitation, process improvements developed
as described under Section 4.4.1, as and to the extent reasonably necessary to
enable ADM Sub to perform its obligations under the ADM Sub Manufacturing
Agreement (the "Technology Transfer"). MBX and ADM Sub shall each devote such
personnel and other resources as are reasonably required to complete the
Technology Transfer in an efficient manner. ADM Sub acknowledges that some of
the MBX Technology that will be transferred to ADM Sub is in the form of trade
secrets. In an effort to ensure the maximum continued protection of MBX's rights
in such trade secrets, and in keeping with the confidentiality obligations
herein, ADM Sub covenants that it will provide access to the MBX Technology only
to employees of ADM and ADM Sub who have a need to have access to such MBX
Technology in order to complete the Technology Transfer and perform ADM Sub's
obligations under the ADM Sub Manufacturing Agreement.

     7.7 ACKNOWLEDGEMENT REGARDING MIT LICENSE. The Parties hereby acknowledge
that certain of the MBX Patent Rights and MBX Technology are Controlled by MBX
pursuant and subject to the MIT License. All licenses granted herein to such MBX
Patent Rights and MBX Technology are subject to certain rights retained by MIT
in the MIT License and the Parties agree that the obligations to MIT set forth
in Articles 2, 5, 7, 8, 9, 10, 12, 13 and 15

*    CONFIDENTIAL TREATMENT REQUESTED

                                       32

<Page>

(copies of said articles are attached hereto as EXHIBIT G) are binding upon the
Joint Sales Company and ADM Sub as if they were parties to the MIT License.

                                    ARTICLE 8
           DUE DILIGENCE; REPRESENTATIONS AND WARRANTIES; EXCLUSIVITY

     8.1 CONDUCT OF COMMERCIAL ALLIANCE. The Parties shall use Commercially
Reasonable Efforts to perform their respective obligations under the Commercial
Alliance, in accordance with the provisions herein and the provisions set forth
in the other Commercial Alliance Agreements.

          8.1.1 CERTAIN MUTUAL REPRESENTATIONS. Each Party hereby represents and
warrants to the other Parties as follows: (i) it shall use Commercially
Reasonable Efforts to perform its obligations in connection with the Commercial
Alliance in accordance with high scientific and engineering principles and
procedures, and in compliance in all material respects with all requirements of
applicable laws, rules, and regulations, (ii) it shall use Commercially
Reasonable Efforts to achieve the objectives of the Commercial Alliance
efficiently and expeditiously and (iii) it shall proceed diligently with the
Commercial Alliance, using Commercially Reasonable Efforts, including by
allocating time, effort, equipment, and skilled personnel to complete the
Commercial Alliance successfully and promptly.

     8.2 REPRESENTATIONS AND WARRANTIES.

          8.2.1 MBX REPRESENTATIONS. Except as otherwise disclosed on Schedule
8.2.1 attached hereto and incorporated herein by reference, MBX represents and
warrants, as of the Effective Date, that: (a) MBX possesses the full legal
right, authority and power to enter into this Agreement and to grant the
licenses to the Joint Sales Company as set forth herein, and that no consent or
approval is required in connection therewith; (b) to MBX's Knowledge, the MBX
Patent Rights are valid and enforceable within the Field, and MBX has no
Knowledge of any current or threatened claim by a Third Party that any of the
MBX Patent Rights are invalid or unenforceable within the Field or that
practicing any of the MBX Patent Rights or MBX Technology within the Field would
infringe a Third Party's Patent Rights; (c) there is no existing or, to MBX's
Knowledge, threatened litigation concerning the ownership or use within the
Field of the MBX Technology or MBX Patent Rights; (d) all MBX Patent Rights that
have been prosecuted by MBX (directly or through legal counsel) have been
prosecuted in good faith; (e) to the Knowledge of MBX, all MBX Patent Rights
that have been prosecuted by a Third Party (directly or through legal counsel)
have been prosecuted in good faith; (f) MBX has not sold, transferred, granted
any licenses, or otherwise conveyed any rights in or to the MBX Technology or
MBX Patent Rights that would prevent MBX from granting the rights and licenses
granted herein; (g) MBX shall not Knowingly provide any false or misleading
information to ADM Sub in connection with the Technology Transfer or the
performance of the Commercial Alliance; (h) MBX has disclosed to ADM Sub any
information, which, to MBX's Knowledge, identifies significant health or safety
risks associated with the production or recovery of PHA Material or PHA
Formulations; (i) to its Knowledge, MBX can fulfill its obligations hereunder
without violating, infringing or misappropriating any rights, including any
contract, statutory or

*    CONFIDENTIAL TREATMENT REQUESTED

                                       33

<Page>

intellectual property rights or any confidentiality rights of any Third Party;
(j) MBX has no Knowledge of any existing or threatened acts by any Third Party
that would infringe the MBX Technology or the MBX Patent Rights; (k) MBX has no
Knowledge of any prior art that would render the MBX Patent Rights unpatentable,
(l) the MBX Patent Rights include all of the patents and patent applications
which MBX Controls which would be infringed by the research, development,
manufacture, use, sale or importation of PHA Material and PHA Formulations;
provided, that if any such patents or patent applications are not encompassed
within the definition of the term "MBX Patent Rights", such definition shall be
construed as if such patents or patent applications were so included, (m) MBX
has provided ADM Sub with true copies of the agreements listed on Schedule 8.2.1
and that these agreements are all the agreements that are currently effective or
that are entered into but that are to become effective after the Effective Date
that MBX or its Affiliates have entered into with Third Parties pursuant to
which: (1) MBX or its Affiliates have granted to a Third Party the right to
practice the MBX Patent Rights within the Field (2) a Third Party granted to MBX
or its Affiliates the right to practice such Third Party's intellectual property
rights within the Field, (3) MBX or its Affiliates and a Third Party have or
shall conduct activities relating to the production or sale of PHA Material or
PHA Formulations, or (4) MBX or its Affiliates shall have transferred or
conveyed a cell line intended to produce PHA Material to a Third Party, (n)
Schedule 8.2.1 contains a summary description of all agreements to which MBX or
its Affiliates are a party concerning the manufacture, distribution or sale of
polyhydroxyalkanoates or concerning the license of Technology or Patent Rights
concerning the manufacture, distribution or sale of polyhydroxyalkanoates, (o)
except as summarized in Schedule 8.2.1, neither MBX nor its Affiliates is
currently negotiating any agreements or arrangements with Third Parties that
contemplate the licensing, research, manufacture or other production of
polyhydroxyalkanoates; (p) Schedule 8.2.1 contains a complete list of all
written opinions of counsel MBX has received concerning the patentability or
enforceability of any MBX Patent Rights or Patent Rights Controlled by any Third
Party and (q) Schedule 8.2.1 contains a complete list of all written notices MBX
has received from any Third Parties alleging that MBX is or may be infringing a
Third Party's patent or other intellectual property right; (r) Schedule 8.2.1
contains a complete list of all written notices MBX has provided to any Third
Party alleging that such Third Party is or may be infringing MBX Technology or
MBX Patent Rights. Anything herein to the contrary notwithstanding, MBX shall
only be required to provide copies to ADM Sub of those material transfer
agreements entered into with Third Parties pursuant to which MBX or its
Affiliates shall have transferred or conveyed a cell line intended to produce
PHA Material or that does not conform in all material respects with the form of
material transfer agreement attached hereto to Schedule 8.2.1. Anything herein
to the contrary notwithstanding, the Parties hereby agree and acknowledge as
follows: (i) with respect to such of the Technology and Patent Rights that are
Controlled by MBX and that include or claim processes or methods ("Methods IP")
of manufacturing, processing or using compositions of matter, it is acknowledged
that MBX may not have, or be able to license to ADM Sub or the Joint Sales
Company hereunder, the freedom to practice such Methods IP with respect to
compositions that are owned or controlled by Third Parties and that MBX makes no
representation or warranty as to such freedom to operate; (ii) with respect to
such of the Technology and Patent Rights that are Controlled by MBX and that
include or claim compositions of matter of PHA Formulations ("Formulations IP"),
it is acknowledged that MBX may not have, or be able to license to ADM Sub or
the Joint Sales Company hereunder, the right to make, use or sell PHA
Formulations that are claimed by such Formulations IP to the extent

*    CONFIDENTIAL TREATMENT REQUESTED

                                       34

<Page>

that a Third Party owns or controls the right to manufacture, use or sell a
component, ingredient or combination that is included within a particular PHA
Formulation and that MBX makes no representation or warranty as to such freedom
to operate; provided, however, that except to the extent recently allowed US
Patent Application US 2003/0236358 (published December 25, 2003) is valid,
enforceable and applicable, this exception shall not apply to the formulations
listed on Schedule 8.2.1 as "Core Formulations"; (iii) with respect to such of
the Technology and Patent Rights that are Controlled by MBX and that include or
claim a method producing PHA Material through the use of engineered microbial
cell lines, MBX believes that *, (iv) with respect to such of the Technology and
Patent Rights that are Controlled by MBX and that include or claim the
manufacture, use or sale of *; and (v) with respect to patent applications that
are included within the MBX Patent Rights, MBX only makes the representations
and warranties set forth in items 8.2.1(a), (c), (d), (e), (f), (g), (j), (k),
(l), (m) and (n). MBX DOES NOT MAKE ANY OTHER REPRESENTATION OR WARRANTY
WHATSOEVER CONCERNING THE MBX PATENT RIGHTS, THE MBX TECHNOLOGY OR ITS RIGHTS
THEREIN. MBX HEREBY SPECIFICALLY DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND
FITNESS FOR A PARTICULAR PURPOSE.

          8.2.2 ADM SUB REPRESENTATIONS. Except as otherwise disclosed on
Schedule 8.2.2 attached hereto and incorporated herein by reference, ADM Sub
represents and warrants, as of the Effective Date, that: (a) ADM Sub possesses
the full legal right, authority and power to enter into this Agreement and to
grant the licenses to the Joint Sales Company as set forth herein, and that no
consent or approval is required in connection therewith; (b) to ADM Sub's
Knowledge, the ADM Sub Patent Rights that, to ADM Sub's Knowledge, have specific
application within the Field, are valid and enforceable within the Field, and
ADM Sub has no Knowledge of any current or threatened claim by a Third Party
that any of the ADM Sub Patent Rights that, to ADM Sub's Knowledge, have
specific application within the Field, are invalid or unenforceable within the
Field or would infringe a Third Party's Patent Rights if practiced in the Field;
(c) there is no existing or, to ADM Sub's Knowledge, threatened litigation
concerning the ownership or use within the Field of the ADM Sub Technology or
ADM Sub Patent Rights that, to ADM Sub's Knowledge, have specific application
within the Field; (d) all ADM Sub Patent Rights that have been prosecuted by ADM
Sub (directly or through legal counsel) have been prosecuted in good faith; (e)
to the Knowledge of ADM Sub, all ADM Sub Patent Rights that have been prosecuted
by a Third Party (directly or through legal counsel) have been prosecuted in
good faith; (f) ADM Sub has not sold, transferred, granted any licenses, or
otherwise conveyed any rights in or to the ADM Sub Technology or ADM Sub Patent
Rights that, to ADM Sub's Knowledge, have specific application within the Field,
which sale, transfer, license or conveyance would prevent ADM Sub from granting
the rights and licenses granted herein; (g) ADM Sub shall not Knowingly provide
any false or misleading information to MBX in connection with the Technology
Transfer or the performance of the Commercial Alliance; (h) ADM Sub has
disclosed to MBX any information, which, to ADM Sub's Knowledge, identifies
significant health or safety risks associated with the production or recovery of
PHA Material or PHA Formulations; (i) to its Knowledge, ADM Sub can fulfill its
obligations hereunder without violating, infringing or misappropriating any
rights, including any contract, statutory or intellectual property rights or any
confidentiality rights of any Third Party; (j) ADM Sub has no Knowledge of any
existing or threatened acts by any Third Party that would infringe the ADM

*    CONFIDENTIAL TREATMENT REQUESTED

                                       35

<Page>

Sub Technology or the ADM Sub Patent Rights that, to ADM Sub's Knowledge, have
specific application within the Field; (k) ADM Sub has no Knowledge of any prior
art that would render unpatentable those ADM Sub Patent Rights that, to ADM
Sub's Knowledge, have specific application within the Field, (l) the ADM Sub
Patent Rights include all of the patents and patent applications which ADM Sub
Controls which would be infringed by the research, development, manufacture,
use, sale or importation of PHA Material and PHA Formulations; provided, that if
any such patents or patent applications are not encompassed within the
definition of the term "ADM Sub Patent Rights", such definition shall be
construed as if such patents or patent applications were so included, (m) ADM
Sub has provided MBX with true copies of the agreements listed on Schedule 8.2.2
and that these agreements are all the agreements that are currently effective or
that are entered into but that are to become effective after the Effective Date
that ADM Sub or its Affiliates have entered into with Third Parties pursuant to
which: (1) ADM Sub or its Affiliates have granted to a Third Party the right to
practice within the Field the ADM Sub Patent Rights that, to ADM Sub's
Knowledge, have a specific application within the Field, (2) a Third Party
granted to ADM Sub or its Affiliates the right to practice such Third Party's
intellectual property rights specifically within the Field, (3) ADM Sub or its
Affiliates and a Third Party have or shall conduct activities relating to the
production or sale of PHA Material or PHA Formulations, or (4) ADM Sub or its
Affiliates shall have transferred or conveyed a cell line intended to produce
PHA Material to a Third Party, (n) Schedule 8.2.2 contains a summary description
of all agreements to which ADM Sub or its Affiliates are a party concerning the
manufacture, distribution or sale of polyhydroxyalkanoates or concerning the
license of Technology or Patent Rights concerning the manufacture, distribution
or sale of polyhydroxyalkanoates, (o) except as summarized in Schedule 8.2.2,
neither ADM Sub nor its Affiliates is currently negotiating any agreements or
arrangements with Third Parties that contemplate the licensing, research,
manufacture or other production of polyhydroxyalkanoates; (p) Schedule 8.2.2
contains a complete list of all written opinions of counsel ADM Sub has received
concerning the patentability or enforceability of any ADM Sub Patent Rights or
Patent Rights Controlled by any Third Party that, to ADM Sub's Knowledge, have
specific application within the Field, and (q) Schedule 8.2.2 contains a
complete list of all written notices ADM Sub has received from any Third Parties
alleging that ADM Sub is or may be infringing a Third Party's patent or other
intellectual property right within the Field; (r) Schedule 8.2.2 contains a
complete list of all written notices ADM Sub has provided to any Third Party
alleging that such Third Party is or may be infringing ADM Sub Technology or ADM
Sub Patent Rights within the Field. Anything herein to the contrary
notwithstanding, ADM Sub shall only be required to provide copies to MBX of
those material transfer agreements entered into with Third Parties pursuant to
which ADM Sub or its Affiliates shall have transferred or conveyed a cell line
intended to produce PHA Material or that do not provide that ADM Sub will own,
or have an option to take an exclusive license to inventions that relate to the
manufacture, use or sale of PHA Material that are made in connection with the
work done pursuant to the material transfer agreement. Anything herein to the
contrary notwithstanding, the Parties hereby agree and acknowledge as follows:
with respect to patent applications that are included within the ADM Sub Patent
Rights, ADM only makes the representations and warranties set forth in items
8.2.2(a), (c), (d), (e), (f), (g), (j), (k), (l), (m) and (n). ADM SUB DOES NOT
MAKE ANY OTHER REPRESENTATION OR WARRANTY WHATSOEVER CONCERNING THE ADM SUB
PATENT RIGHTS, THE ADM SUB TECHNOLOGY OR ITS RIGHTS THEREIN. ADM SUB HEREBY
SPECIFICALLY DISCLAIMS ALL OTHER WARRANTIES, EXPRESS

*    CONFIDENTIAL TREATMENT REQUESTED

                                       36

<Page>

OR IMPLIED, INCLUDING BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY
AND FITNESS FOR A PARTICULAR PURPOSE.

     8.3 RECORDS. ADM Sub and MBX shall maintain records with respect to the
Commercial Alliance in sufficient detail and in a good scientific manner
appropriate to support patent filings, which shall be complete and accurate and
shall fully and properly reflect all work done and results achieved in the
performance of the Commercial Alliance. All such records shall be retained for
at least five (5) years after the termination of this Agreement, or for such
longer period as may be required by applicable law. Each of MBX and ADM Sub
shall have the right, during normal business hours and upon reasonable notice,
to inspect and copy any such records that are maintained in accordance with this
Section 8.3.

     8.4 EXCLUSIVITY. Except as otherwise provided herein, during the Exclusive
Period, neither ADM Sub nor MBX shall, directly or through one or more
Affiliates or agents, discuss, negotiate or establish, business operations,
agreements or transactions with any Third Party concerning or relating to *,
including without limitation any business operation, agreement or transaction
that would have as a purpose, the research, development, manufacture, use, sale
or importation of *. Notwithstanding the foregoing, MBX shall at all times be
permitted to: (i) conduct Pilot Activities in the manner and to the extent set
forth in Section 4.4, (ii) communicate with and, with the approval of the
Steering Committee, establish arrangements with Strategic Alliance Partners in
the manner and to the extent set forth in Section 5.2.1, (iii) performing its
obligations concerning formulation activities in the manner and to the extent
set forth in Section 4.3 (provided that the Joint Sales Company shall have the
sole and exclusive right to grant any licenses of intellectual property rights
required for a Third Party to provide the formulation services described in
Section 4.3, if applicable), and both MBX and ADM Sub shall at all times be
permitted to (iv) conduct research and development efforts in the manner and to
the extent set forth in Section 4.4.1; and (v) in-license or otherwise acquire
rights to Technology in the manner and to the extent set forth in Section 4.4.4
(the activities listed in the foregoing clauses (i) through (v) inclusive are
the "Permitted Activities") and provided further that, for avoidance of doubt,
MBX shall not grant any right or license to any MBX Technology for use within
the Field to any Person other than to carry out any of the Permitted Activities.
For the avoidance of doubt, at any time when MBX or ADM Sub purchases PHA Cell
Paste, PHA Material or PHA Formulations from the Joint Sales Company, MBX or ADM
Sub, as the case may be, shall be free to use such PHA Cell Paste, PHA Material
or PHA Formulations to the same extent as a Third Party customer that would
purchase such material.

     8.5 PROHIBITION ON SOLICITATION. No Party nor any of its Affiliates shall,
during the period commencing on the Effective Date and continuing until the
expiration or termination of this Agreement and two (2) years thereafter,
specifically solicit any person who is employed by the other Party or its
Affiliates and who was involved in the Commercial Alliance during the Term of
this Agreement, whether such person is solicited to be hired as an employee or
consultant, unless authorized in writing by the other Party. The Parties
acknowledge that generally listing a position for hire in a newspaper, trade
journal or similar publication shall not constitute a specific solicitation in
violation of the terms of this provision. The Parties further acknowledge for
the avoidance of doubt that this Section only applies to those persons that
remain employees of a Party and not to former employees of a Party.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       37

<Page>

                                    ARTICLE 9
                               GRANT OF JV OPTION

     9.1 GRANT OF JV OPTION. MBX hereby grants to ADM Sub the right and option
to enter into a commercial joint venture for the further manufacture and sale of
the PHA Material on the terms and conditions set forth in this Article 9 (the
"JV Option").

          9.1.1 JV OPTION MECHANICS. If, at any time during the Term, either ADM
Sub or MBX reasonably determines that within two (2) years, the Joint Sales
Company would likely be able to sell, on a consistent and on-going basis, more
than fifty thousand (50,000) tons of PHA Material (including, without
limitation, PHA Material that is contained within PHA Formulations) per twelve
(12) month period, then either ADM Sub or MBX may prepare and deliver a written
proposal (the "Expansion Proposal") to the other such Party to form a separate
entity joint venture or to expand the scope of the Joint Sales Company (in
either case, the "Joint Venture Entity") with a goal and purpose of expanding
the manufacturing capacity and PHA Material sales to in excess of seventy
thousand (70,000) tons per year (the "Joint Venture"). The Expansion Proposal
shall merely be a proposal to expand manufacturing capacity and PHA Material
sales through the Joint Venture Entity as set forth herein; the specific manner
and method of accomplishing any such expansion shall be left to the Joint
Venture Entity in the event ADM Sub exercises the JV Option. Upon receipt of an
Expansion Proposal, ADM Sub shall have a period of one hundred twenty (120) days
during which it shall decide whether or not, in its sole discretion, to exercise
the JV Option. During such period, ADM Sub and MBX shall, in good faith, share
information relating to the market for PHA Material and other matters relevant
to the exercise of the JV Option. If ADM Sub decides to exercise the JV Option,
then ADM Sub and MBX shall promptly proceed to prepare, execute and deliver
documents, and take such other actions as are reasonably necessary, to form a
Joint Venture Entity and commence the Joint Venture on the terms and conditions
set forth in this Article 9. If ADM Sub does not exercise the JV Option within
such period, then the JV Option shall expire (subject to the revival of the JV
Option pursuant to Section 9.8) and the other consequences set forth in Section
9.8 shall be given full force and effect. For avoidance of doubt, at any time
during the Term, the Parties shall be permitted to negotiate temporary or
permanent increases to the annual capacity limit in the licenses granted in
Sections 7.2 and 7.3 above, which increases shall be given effect, if at all, in
one or more written amendments to this Agreement.

     9.2 FORMATION OF JV ENTITY. If ADM Sub exercises the JV Option in
accordance with Section 9.1.1 and the Parties determine to form a new separate
entity, ADM Sub and MBX shall form a new entity under the laws of the State of
Delaware, to serve as the Joint Venture Entity and to own and operate the Joint
Venture.

          9.2.1 JV ASSETS. All assets that are owned by ADM Sub and MBX, that
are solely dedicated to the activities of the Commercial Alliance as of the date
the JV Option is exercised, and that may reasonably be divested from ADM Sub or
MBX, as applicable, without undue liability, including without limitation, tax
liability, shall promptly be transferred to the JV Entity as requested by the JV
Entity, along with any other assets as MBX and ADM Sub agree

*    CONFIDENTIAL TREATMENT REQUESTED

                                       38

<Page>

shall be transferred to the JV Entity, on terms and conditions to be agreed upon
by ADM Sub, MBX and the JV Entity.

          9.2.2 OTHER ASSETS. Ownership of those assets of ADM Sub and MBX that
have been dedicated in part to the activities of the Commercial Alliance,
including without limitation, the ADM Sub Manufacturing Facility and the MBX
Formulation Facility, shall be retained by ADM Sub or MBX, as applicable,
provided however, that such assets shall be dedicated to the Joint Venture, as
and to the extent the Joint Venture Entity shall desire, on terms consistent
with those established during the Commercial Phase, including without limitation
the price payable to ADM Sub or MBX for such manufacturing or formulation
services. The Joint Venture Entity shall purchase PHA Material from ADM Sub, in
an amount to be determined by ADM Sub and the Joint Venture Entity; provided,
however, that the Joint Venture Entity shall not purchase any PHA Material from
any other source (with the exception of pilot-scale production quantities)
without the prior consent of ADM Sub during any period unless and until the
Joint Venture Entity has purchased all of ADM Sub's output of the PHA Material
from the ADM Sub Manufacturing Facility (and including any amounts then in
inventory at the ADM Sub Manufacturing Facility). In addition, the Joint Venture
Entity shall determine whether additional supplies of PHA Material in addition
to that produced by the ADM Sub Manufacturing Facility shall be acquired from
ADM Sub or from a Third Party; provided, however, that ADM Sub shall have the
right and option to expand the manufacturing capacity at the ADM Sub
Manufacturing Facility to a design capacity of up to one hundred and fifty
thousand (150,000) tons per year, and the Joint Venture Entity will purchase
such supply from ADM Sub, if the projected profitability of the Joint Venture
Entity would be the same or greater than if it acquired such additional supply
from another source. If the Joint Venture Entity is to obtain such additional
supply from ADM Sub, then ADM Sub will finance an expansion of the ADM Sub
Manufacturing Facility, and MBX will reimburse ADM Sub for fifty percent (50%)
of such reasonable expenditures, from preferential dividends or otherwise, plus
an annual rate of interest equal to ADM's long term average borrowing rate plus
1.25%.

     9.3 EXPANSION; FUTURE INVESTMENTS. Except as otherwise expressly provided
in this Agreement, the manner of expansion of manufacturing capacity and PHA
Material sales shall be determined by the Joint Venture Entity. Subject to the
provisions in Section 9.2.1 and 9.2.2, future investments in the Joint Venture
activities, including without limitation, the acquisition of additional
equipment, facilities and personnel, shall be made by the Joint Venture Entity
and not ADM, ADM Sub or MBX on an individual basis, so that the Joint Venture
Entity shall become an independently-financeable entity that the owners may
sell, sell equity in to Third Parties or otherwise exploit in whatever
reasonable fashion they may determine. In the event the Joint Venture Entity is
unable to obtain necessary independent financing, then ADM Sub and MBX shall
equally finance the Joint Venture Entity subject to certain limits, terms and
conditions to be determined upon the formation of the Joint Venture Entity. In
the event ADM Sub, on the one hand, or MBX, on the other hand, is financially
incapable of committing to provide an equal share of the financing, then none of
them shall have an obligation to provide such financing, such failure to finance
shall not constitute a breach of any obligation or otherwise alter the
respective rights of the Parties and the Parties shall diligently pursue
alternative financing or other means to accomplish the goal of the Joint Venture
as set forth in Section 9.1.1.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       39

<Page>

     9.4 CONTRACTS; LICENSES. The operations and assets of the Joint Sales
Company will be dedicated or transferred to the Joint Venture Entity in
accordance with the foregoing requirements of this Article 9, and ADM Sub and
MBX hereby consent to the same. In keeping with the foregoing, the Joint Sales
Company shall assign such of the Commercial Alliance Agreements to the Joint
Venture Entity as are reasonably necessary or useful for the Joint Venture
Entity to conduct the Joint Venture. ADM Sub and MBX shall take, or cause the
Joint Sales Company to take, such actions as are required to comply with and
give effect to this Article 9. ADM Sub and MBX shall also grant such licenses,
and provide such services, on commercially reasonable terms in light of the
licenses and services that ADM Sub and MBX provided to the Joint Sales Company,
as are reasonably necessary to enable the Joint Venture Entity to conduct the
business of the Joint Venture on the terms set forth herein. Without limiting
the foregoing, ADM Sub and MBX shall grant to the Joint Venture Entity exclusive
licenses of similar scope as the licenses each granted herein to the Joint Sales
Company but without the limitation on production volume.

     9.5 OWNERSHIP; RETURN ON INVESTMENT. ADM Sub and MBX shall each own fifty
percent (50%) of the total equity of the Joint Venture Entity. In keeping with
the foregoing, capital contributions, profit distributions and control of
management and operations of the Joint Venture Entity shall be shared equally by
ADM Sub and MBX; provided, however, the Ledger Account shall continue in the
manner set forth in the Operating Agreement, and all profit distributions by the
Joint Venture Entity shall be made to ADM Sub until such time as the Ledger
Account is reduced to zero. The agreements or other documents governing the
distributions of profit from the Joint Venture Entity will provide for periodic
preferential distributions in order to maintain equal investments by both ADM
Sub and MBX.

     9.6 MANAGEMENT. ADM Sub and MBX intend for the Joint Venture Entity to be
managed by a steering committee or board of directors, on which they have equal
representation, in a manner that is similar to that provided herein for
management of the Commercial Alliance by the Steering Committee. The overriding
principle for such management will be equal representation and cooperative
decision-making in the best interest of the long term profitability of the Joint
Venture Entity, and not on the basis of ADM Sub's or MBX's separate commercial
goals and interests.

     9.7 TRANSFER OF INTEREST. If either MBX or ADM Sub desires to transfer its
ownership interest in the Joint Venture Entity to a Third Party (the Party
desiring to so transfer shall be the "Offeror Party" and the other such Party
shall be the "Offeree Party"), then the Offeror Party shall first offer to the
Offeree Party the opportunity to negotiate towards a purchase of such ownership
interest and, if the Offeree Party accepts such offer, then the Offeror Party
and the Offeree Party shall negotiate in good faith towards a purchase of such
ownership interest on such terms as each, in its sole discretion, shall
determine to be acceptable. In the event that the Offeror Party and the Offeree
Party have not completed a purchase and sale transaction for such ownership
interest within sixty (60) days after the initial offer, then the Offeror Party
shall be free to transfer its ownership interest in the Joint Venture Entity to
a Third Party without restriction or obligation hereunder; provided, however,
any such transfer shall be on terms and conditions no less favorable than the
terms and conditions the Offeror Party last proposed to the Offeree Party. Both
ADM Sub and MBX shall have the right to transfer their respective

*    CONFIDENTIAL TREATMENT REQUESTED

                                       40

<Page>

ownership interest in the Joint Venture Entity to a Third Party who acquires all
or substantially all of the assets or equity interest of ADM Sub or MBX without
having to comply with the foregoing right of first negotiation; provided,
however, that such Party's successor in interest shall be bound by such right of
first negotiation.

     9.8 ADM SUB DECLINES JV OPTION. If ADM Sub does not exercise the JV Option
as set forth herein, MBX shall have a period of twenty four (24) months
following the expiration of the JV Option during which it shall be free to
commence the establishment of manufacturing capacity for PHA Material outside of
the Commercial Alliance that is comparable to or greater than the manufacturing
capacity of the ADM Sub Manufacturing Facility, including without limitation,
commencing construction of its own manufacturing facility for PHA Material or by
entering into a legally binding agreement with a Third Party to jointly
manufacture PHA Material with such Third Party; provided however, that MBX shall
not be permitted to commence the manufacture or sale of PHA Material outside of
the Commercial Alliance unless and until the Ledger Account has been repaid so
that the balance thereof is less than ten million dollars ($10,000,000) as
further described in Section 9.8.2.

          9.8.1 SUSPENSION OF EXCLUSIVITY. If ADM Sub does not exercise the JV
Option and if MBX is able to commence the establishment of manufacturing
capacity for PHA Material outside of the Commercial Alliance within a
twenty-four (24) month period as set forth in Section 9.8 above, then, upon that
date, this Agreement shall be automatically amended such that Section 8.4 shall
be deleted in its entirety. However, if MBX fails to commence the establishment
of manufacturing capacity for PHA Material outside of the Commercial Alliance
within a twenty-four (24) month period as set forth in Section 9.8 above, then,
upon the expiration of that period, the JV Option shall reset, the suspension of
Section 8.4 shall terminate and Section 8.4 shall again be binding on the
Parties in accordance with its terms, and this Agreement shall continue as if
the Expansion Proposal had never been made.

          9.8.2 PAY-DOWN OF LEDGER ACCOUNT. During the Term, MBX shall not be
permitted, directly or through its Affiliates, agents or any Third Party, to
manufacture or have made any PHA Material and PHA Formulations, other than in
connection with Pilot Activities or through the Joint Sales Company as part of
the Commercial Alliance, unless and until the restrictions provided in Section
8.4 have been suspended or terminated in accordance with Section 9.8.1 and the
Ledger Account has been repaid (including without limitation, directly by MBX to
ADM Sub in one or more payments) so that the balance thereof is less than ten
million dollars ($10,000,000) when calculated in the manner provided for in the
Operating Agreement. In the event that the restrictions provided in Section 8.4
have been so suspended or terminated and the Ledger Account has been repaid so
that the balance is less than ten million dollars ($10,000,000) as described in
this Section 9.8.2, this Agreement shall, as of such date, be automatically
amended such that the licenses granted under Section 7.2.1, 7.2.2 and 7.3.2
convert from exclusive licenses to non-exclusive licenses.

          9.8.3 WIND-DOWN OF JOINT SALES COMPANY. Promptly after the Ledger
Account is paid down and the licenses are converted to non-exclusive licenses as
set forth in Section 9.8.2 above, the Parties will discuss in good faith
alternative arrangements for developing and serving the global marketplace for
PHA Material and PHA Formulations, including sustaining the

*    CONFIDENTIAL TREATMENT REQUESTED

                                       41

<Page>

operation of the Joint Sales Company. At anytime following the conversion of the
licenses, the Parties may mutually agree to trigger, or any one of them may by
ninety (90) days prior written notice to the other Parties may trigger, the
dissolution and winding down of the Joint Sales Company and the liquidation of
its assets, in accordance with the Operating Agreement. Upon such winding-down
of the Joint Sales Company, MBX shall grant a license to ADM Sub as described in
Section 9.8.4. For avoidance of doubt, once the conversion of the licenses from
exclusive to non-exclusive described in Section 9.8.2 occurs, anything herein to
the contrary notwithstanding, MBX shall be free to exploit the MBX Technology
and MBX Patent Rights in any manner it shall determine in its sole discretion,
including without limitation by manufacturing and selling PHA Material and PHA
Formulations.

          9.8.4 GRANT OF LICENSE. If, as described in Section 9.8.3, the Parties
or any one of them triggers the dissolution and winding down of the Joint Sales
Company, then, effective upon such date, MBX shall grant to ADM Sub a
royalty-bearing, non-exclusive, perpetual, irrevocable license, with Limited
Sublicense Right, under MBX's right, title and interest in and to the MBX
Technology and the MBX Patent Rights, solely to make, have made, use, offer for
sale, sell, have sold and import PHA Material and PHA Formulations for use in
the Field worldwide and this Agreement shall terminate. The foregoing license
shall be limited such that ADM Sub shall only be permitted to make and have made
the amount of PHA Material (including PHA Material contained within PHA
Formulations) permitted under the then-current license under Section 7.2.2
during each consecutive period of twelve (12) months during the term of the
license. During the Royalty Term, ADM Sub will pay to MBX a royalty equal to:
(i) * on all sales or other conveyances of PHA Patented Material (including,
without limitation, PHA Material that is contained within PHA Formulations), on
a one hundred percent (100%) purity basis; and (ii) * on all sales or other
conveyances of PHA Know-How Material (including, without limitation, PHA
Material that is contained within PHA Formulations), on a one hundred percent
(100%) purity basis. During the Supplemental Royalty Term, ADM Sub will pay to
MBX a royalty equal to * on all sales or other conveyances of PHA Supplemental
Know-How Material (including, without limitation, PHA Material that is contained
within PHA Formulations), on a one hundred percent (100%) purity basis. In the
event more than one royalty applies to the manufacture, use, sale or importation
of a particular product, then the highest royalty shall be the only applicable
royalty hereunder. Provided, however, that any such royalty shall be reduced by
the amount of royalties payable to any Third Party under a license required to
obtain freedom to practice the MBX Technology and/or MBX Patent Rights for the
manufacture, use or sale of PHA Material within the Field provided that MBX
breached an obligation under Section 8.2.1 to disclose: (i) the existence of
such Third Party's intellectual property rights in such Technology, or (ii)
claims by such Third Party that any of the MBX Patent Rights are invalid or
unenforceable, or that the practice of any of the MBX Patent Rights would
constitute an infringement or misappropriation of such Third Party's
intellectual property rights (such royalty reduction right is "Third Party IP
Royalty Offset"). The royalty shall be payable within thirty (30) days following
the end of each Calendar Quarter during the term of the applicable license for
sales or other conveyances that occur during such Calendar Quarter. Amounts due
under this Section 9.8.3 shall be payable by wire transfer of immediately
available funds to an MBX bank account in accordance with instructions to be
provided to the ADM Sub by MBX. Any amounts that are not paid when due hereunder
shall accrue interest at the rate of four percent (4%) per annum in excess of
the one year London Interbank Offered Rate (LIBOR)

*    CONFIDENTIAL TREATMENT REQUESTED

                                       42

<Page>

then most recently published in THE WALL STREET JOURNAL. The right to demand and
receive the interest provided hereunder shall be in addition to any other rights
available to MBX hereunder or at law.

                                   ARTICLE 10
                              TERM AND TERMINATION

     10.1. TERM. This Agreement shall commence as of the Effective Date and
shall expire upon the first to occur of: (i) the expiration or termination of
the last Valid Claim within the Patent Rights granted by the United States
Patent and Trademark Office and claiming MBX Technology or Alliance Technology
and (ii) the exercise of the JV Option by ADM Sub and the Parties have taken all
necessary actions to implement the Joint Venture pursuant to Article 9, unless
terminated in accordance with this Article 10 prior to such date (the "Term").

*    CONFIDENTIAL TREATMENT REQUESTED

                                       43

<Page>

     10.2 TERMINATION. This Agreement may be terminated at any time by either
Party as follows:

          10.2.1 TERMINATION FOR BREACH. In the event that MBX materially
defaults on any material obligation hereunder or under any other Commercial
Alliance Agreement (including an "Adverse Act" as defined in the Operating
Agreement), or materially breaches any material term herein or therein to be
performed or observed, then ADM Sub shall have the right to terminate this
Agreement: (a) by giving thirty (30) days prior written notice to MBX in the
case of a breach of any payment term, and (b) by giving ninety (90) days prior
written notice to MBX in the case of any other breach; provided, however, that
in the case of a default or breach capable of being cured, if MBX shall cure the
said default or breach within such notice period after said notice shall have
been given, then said notice shall not be effective and the Agreement shall
continue in full force and effect. In the event that ADM Sub materially defaults
on any material obligation hereunder or under any other Commercial Alliance
Agreement (including an "Adverse Act" as defined in the Operating Agreement), or
materially breaches any material term herein or therein to be performed or
observed, then MBX shall have the right to terminate this Agreement: (a) by
giving thirty (30) days prior written notice to ADM Sub in the case of a breach
of any payment term, and (b) by giving ninety (90) days prior written notice to
ADM Sub in the case of any other breach; provided, however, that in the case of
a default or breach capable of being cured, if ADM Sub shall cure the said
default or breach within such notice period after said notice shall have been
given, then said notice shall not be effective and the Agreement shall continue
in full force and effect. In the event that MBX commits a breach of this
Agreement by granting a license under the MBX Technology to a Third Party in
violation of the terms of the license granted to ADM Sub under Section 7.2.1 or
to the Joint Sales Company under Section 7.2.2, and such breach remains uncured
for sixty (60) days following notice from ADM Sub, then such breach (a "Section
7 Breach") shall trigger certain additional rights for ADM Sub as set forth in
Section 10.5.

          10.2.2 ADM SUB TERMINATION DUE TO CHANGED CIRCUMSTANCES. In the event
that, based upon a change in circumstances beyond the reasonable control of ADM
and ADM Sub, the projected financial return from the Commercial Alliance is
deemed by ADM Sub to be either too uncertain or inadequate, ADM Sub shall have
the right to terminate this Agreement upon thirty (30) days prior written notice
to MBX. The Parties acknowledge that, without limitation, a Third Party
challenge to the validity or enforceability of the MBX Patent Rights or MBX
Technology, the emergence of a third party's superior technology, an increase in
the projected cost required to Construct the ADM Sub Manufacturing Facility or
to manufacture PHA Material and/or PHA Formulations, a decrease in the projected
sales volume of PHA Material and/or PHA Formulations, and a decrease in the
projected sales price of PHA Material and/or PHA Formulations are all examples
of a change in circumstances beyond the reasonable control of ADM and ADM Sub.

          10.2.3 MUTUAL AGREEMENT. MBX and ADM Sub may, at any time during the
Term, terminate this Agreement by written agreement with such consequences as
they shall provide therein.

          10.2.4 MBX TERMINATION DUE TO CHANGED CIRCUMSTANCES. Commencing upon
ADM Sub declining the JV Option and continuing unless and until such time as the
JV Option resets pursuant to Section 9.8.5, in the event that based upon a
change in circumstances during

*    CONFIDENTIAL TREATMENT REQUESTED

                                       44

<Page>

this period beyond the reasonable control of MBX, the projected financial return
from the Commercial Alliance is deemed by MBX to be either too uncertain or
inadequate, MBX shall have the right to terminate this Agreement upon thirty
(30) days prior written notice to ADM Sub.

     10.3 GENERAL CONSEQUENCES OF TERMINATION OR EXPIRATION; GRANT OF LICENSES.

          10.3.1 CONSEQUENCES OF TERMINATION OR EXPIRATION. Upon the termination
or expiration of the Agreement, the following shall occur:

               (a)  MBX shall immediately cease using, and shall promptly return
                    to ADM Sub, all ADM Technology, except to the extent MBX has
                    a license to practice such Technology under this Article 10;

               (b)  ADM Sub shall immediately cease using, and shall promptly
                    return to MBX all MBX Technology, except to the extent ADM
                    Sub has a license to practice such Technology under this
                    Article 10;

               (c)  the Joint Sales Company shall immediately cease using all
                    MBX Technology and all ADM Technology, and shall promptly
                    return to MBX all MBX Technology and to ADM Sub all ADM
                    Technology;

               (d)  the license granted to MBX pursuant to Section 7.3.1 shall
                    immediately terminate;

               (e)  the license granted to ADM Sub pursuant to Section 7.2.1
                    shall immediately terminate;

               (f)  the licenses granted to the Joint Sales Company pursuant to
                    Section 7.2.2 and Section 7.3.2 shall immediately terminate;

               (g)  each Party shall promptly pay to the other any amounts due
                    and payable hereunder as of the effective date of
                    termination or expiration;

               (h)  subject to those rights and obligations of the Parties that
                    survive termination or expiration by their terms or pursuant
                    to Section 10.6, this Agreement shall terminate and be of no
                    further force or effect; and

               (i)  the other Commercial Alliance Agreements shall terminate
                    with the effects set forth therein, including without
                    limitation, that the Joint Sales Company shall be dissolved
                    and wind up its operations in accordance with the Operating
                    Agreement.

     10.4 SPECIFIC CONSEQUENCES OF TERMINATION BY MBX.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       45

<Page>

          10.4.1. TERMINATION DUE TO ADM SUB BREACH Upon a termination of this
Agreement by MBX pursuant to Section 10.2.1, the following shall occur as of the
effective date of termination.

               (a) MANUFACTURING OBLIGATION. In the event the effective date of
termination occurred during the Construction Phase, ADM Sub shall provide
fermentation services to produce PHA Cell Paste in up to * fermentors for a
period of * at the Manufacturing Cost (as such term is defined in the ADM Sub
Manufacturing Agreement), plus depreciation on assets to the extent used to
perform such manufacturing calculated on a ten-year straight-line basis, but
otherwise pursuant to the terms and conditions set forth in the ADM Sub
Manufacturing Agreement. In the event the effective date of termination occurred
during the Commercial Phase, ADM Sub would for a period of three and one-half
years, at MBX's election, to be exercised once at the time MBX places it first
purchase order, (i) provide fermentation services to produce PHA Cell Paste in
up to * fermentors at the Manufacturing Cost, plus depreciation on assets to the
extent used to perform such manufacturing calculated on a ten-year straight-line
basis; or (ii) manufacture PHA Material in the ADM Sub Manufacturing Facility
(subject to the limitations of such facility as of the time of termination) at
Manufacturing Cost, plus depreciation on assets to the extent used to perform
such manufacturing calculated on a ten-year straight-line basis, in either case,
otherwise pursuant to the terms and conditions set forth in the ADM Sub
Manufacturing Agreement.

               (b) GRANT OF LICENSES. Upon the effective date of termination by
MBX, ADM Sub hereby grants to MBX the following licenses: (i) an exclusive,
fully sublicenseable, *, perpetual, irrevocable license, under all intellectual
property rights Controlled by ADM Sub and claiming or covering Alliance
Technology to research, develop, make, have made, use, offer for sale, sell,
have sold and import PHA-Related Material, produced by any means or methods, for
any and all uses and (ii) a non-exclusive, fully sublicenseable, *, perpetual,
irrevocable license, under all intellectual property rights Controlled by ADM
Sub and claiming or covering ADM Sub Background Technology to research, develop,
make, have made, use, offer for sale, sell, have sold and import PHA-Related
Material, produced by any means or methods, for any and all uses.

          10.4.2 TERMINATION DUE TO CHANGED CIRCUMSTANCES.

               (a) GRANT OF LICENSE. Upon a termination of this Agreement by MBX
pursuant to Section 10.2.4, MBX hereby grants to ADM Sub a royalty-bearing,
non-exclusive, perpetual, irrevocable license, with Limited Sublicense Right,
under MBX's right, title and interest in and to the MBX Technology and the MBX
Patent Rights, solely to make, have made, use, offer for sale, sell, have sold
and import PHA Material and PHA Formulations for use in the Field worldwide. The
foregoing license shall be limited such that ADM Sub shall only be permitted to
make and have made the amount of PHA Material (including PHA Material contained
within PHA Formulations) permitted under the then-current license under Section
7.2.2 during each consecutive period of twelve (12) months during the term of
the license. During the Royalty Term, ADM Sub will pay to MBX a royalty equal
to: (i) * on all sales or other conveyances of PHA Patented Material (including,
without limitation, PHA Material that is contained within PHA Formulations), on
a one hundred percent (100%) purity basis; and (ii) *

*    CONFIDENTIAL TREATMENT REQUESTED

                                       46

<Page>

on all sales or other conveyances of PHA Know-How Material (including, without
limitation, PHA Material that is contained within PHA Formulations), on a one
hundred percent (100%) purity basis. During the Supplemental Royalty Term, ADM
Sub will pay to MBX a royalty equal to * on all sales or other conveyances of
PHA Supplemental Know-How Material (including, without limitation, PHA Material
that is contained within PHA Formulations), on a one hundred percent (100%)
purity basis. In the event more than one royalty applies to the manufacture,
use, sale or importation of a particular product, then the highest royalty shall
be the only applicable royalty hereunder. Provided, however, that any such
royalty shall be subject to Third Party IP Royalty Offset. The royalty shall be
payable within thirty (30) days following the end of each Calendar Quarter
during the term of the applicable license for sales or other conveyances that
occur during such Calendar Quarter. Amounts due under this Section 10.4.2 shall
be payable by wire transfer of immediately available funds to an MBX bank
account in accordance with instructions to be provided to the ADM Sub by MBX.
Any amounts that are not paid when due hereunder shall accrue interest at the
rate of four percent (4%) per annum in excess of the one year London Interbank
Offered Rate (LIBOR) then most recently published in THE WALL STREET JOURNAL.
The right to demand and receive the interest provided hereunder shall be in
addition to any other rights available to MBX hereunder or at law.

     10.5 SPECIFIC CONSEQUENCES OF TERMINATION BY ADM SUB.

          10.5.1 TERMINATION DUE TO CHANGED CIRCUMSTANCES. Upon a termination of
this Agreement by ADM Sub pursuant to Section 10.2.2, the following shall occur
as of the effective date of termination.

               (a) MANUFACTURING OBLIGATION. In the event the effective date of
termination occurred during the Construction Phase, ADM Sub shall provide
fermentation services to produce PHA Cell Paste in up to * fermentors for a
period of * at the Manufacturing Cost, plus depreciation on assets in the ADM
Sub Manufacturing Facility that are not allocated to other uses calculated on a
ten-year straight-line basis, *, but otherwise pursuant to the terms and
conditions of the ADM Sub Manufacturing Agreement. In the event the effective
date of termination occurred during the Commercial Phase, ADM Sub would for a
period of three and one-half (3.5) years, at MBX's election, to be exercised
once at the time MBX places it first purchase order, (i) provide fermentation
services to produce PHA Cell Paste in up to * fermentors at the Manufacturing
Cost, plus depreciation on assets in the ADM Sub Manufacturing Facility that are
not allocated to other uses calculated on a ten-year straight-line basis, *; or
(ii) manufacture PHA Material in the ADM Sub Manufacturing Facility (subject to
the limitations of such facility as of the time of termination) at Manufacturing
Cost, plus depreciation on assets in the ADM Sub Manufacturing Facility that are
not allocated to other uses calculated on a ten-year straight-line basis, *, in
either case, otherwise under the terms set forth in the ADM Sub Manufacturing
Agreement.

               (b) GRANT OF LICENSE. Upon the effective date of termination by
ADM Sub, ADM Sub hereby grants to MBX a fully sublicenseable, *, perpetual,
irrevocable license, under all intellectual property rights Controlled by ADM
Sub and claiming or covering Alliance Technology to research, develop, make,
have made, use, offer for sale, sell, have sold and import PHA-Related Material,
produced by any means or methods, for any and all uses. Such license

*    CONFIDENTIAL TREATMENT REQUESTED

                                       47

<Page>

shall be exclusive in the field of PHA-Related Material for a period of ten (10)
years from the date of grant, and non-exclusive thereafter.

          10.5.2 TERMINATION DUE TO MBX BREACH

               (a) Upon the effective date of termination by ADM Sub for a
Section 7 Breach, MBX hereby grants to ADM Sub a non-exclusive, *, perpetual,
irrevocable license, with Limited Sublicense Right, under MBX's right, title and
interest in and to the MBX Technology, the MBX Patent Rights and the Joint
Alliance Technology, solely to make, have made, use, offer for sale, sell, have
sold and import PHA Material and PHA Formulations for use in the Field
worldwide, without any limitation on production volume.

               (b) Upon the effective date of termination by ADM Sub under
Section 10.2.1 for any reason other than a Section 7 Breach, MBX hereby grants
to ADM Sub a royalty-bearing, non-exclusive, perpetual, irrevocable license,
with Limited Sublicense Right, under MBX's right, title and interest in and to
the MBX Technology and the MBX Patent Rights, solely to make, have made, use,
offer for sale, sell, have sold and import PHA Material and PHA Formulations for
use in the Field worldwide. The foregoing license shall be limited such that ADM
Sub shall only be permitted to make and have made a maximum of * (or such
greater amount if the then-current license under Section 7.2.2 has been
expanded) of PHA Material (including PHA Material contained within PHA
Formulations) during each consecutive period of twelve (12) months during the
term of the license. During the Royalty Term, ADM Sub will pay to MBX a royalty
equal to: (i) * on all sales or other conveyances of PHA Patented Material
(including, without limitation, PHA Material that is contained within PHA
Formulations), on a one hundred percent (100%) purity basis; and (ii) * on all
sales or other conveyances of PHA Know-How Material (including, without
limitation, PHA Material that is contained within PHA Formulations), on a one
hundred percent (100%) purity basis. During the Supplemental Royalty Term, ADM
Sub will pay to MBX a royalty equal to * on all sales or other conveyances of
PHA Supplemental Know-How Material (including, without limitation, PHA Material
that is contained within PHA Formulations), on a one hundred percent (100%)
purity basis. In the event more than one royalty applies to the manufacture,
use, sale or importation of a particular product, then the highest royalty shall
be the only applicable royalty hereunder. Provided, however, that any such
royalty shall be subject to Third Party IP Royalty Offset. The royalty shall be
payable within thirty (30) days following the end of each Calendar Quarter
during the term of the applicable license for sales or other conveyances that
occur during such Calendar Quarter. Amounts due under this Section 10.5.2 shall
be payable by wire transfer of immediately available funds to an MBX bank
account in accordance with instructions to be provided to the ADM Sub by MBX.
Any amounts that are not paid when due hereunder shall accrue interest at the
rate of four percent (4%) per annum in excess of the one year London Interbank
Offered Rate (LIBOR) then most recently published in THE WALL STREET JOURNAL.
The right to demand and receive the interest provided hereunder shall be in
addition to any other rights available to MBX hereunder or at law.

     10.6 RIGHTS UPON BANKRUPTCY.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       48

<Page>

               (a) In the event ADM Sub files for protection under Chapter 11 of
the U.S. Bankruptcy Code, and ADM Sub, directly or indirectly in connection with
such proceedings, rejects this Agreement as an executory contract (or on similar
grounds), then ADM Sub shall and hereby does agree to perform the following
obligations:

                    (i) In the event the effective date of rejection occurred
during the Construction Phase, ADM Sub shall provide fermentation services to
produce PHA Cell Paste in up to * fermentors for a period of * at the
Manufacturing Cost (as such term is defined in the ADM Sub Manufacturing
Agreement), plus depreciation on assets to the extent used to perform such
manufacturing calculated on a ten-year straight-line basis, but otherwise
pursuant to the terms and conditions set forth in the ADM Sub Manufacturing
Agreement. In the event the effective date of termination occurred during the
Commercial Phase, ADM Sub would for a period of three and one-half (3.5) years,
at MBX's election, to be exercised once at the time MBX places it first purchase
order, (i) provide fermentation services to produce PHA Cell Paste in up to *
fermentors at the Manufacturing Cost, plus depreciation on assets to the extent
used to perform such manufacturing calculated on a ten-year straight-line basis;
or (ii) manufacture PHA Material in the ADM Sub Manufacturing Facility (subject
to the limitations of such facility as of the time of termination) at
Manufacturing Cost, plus depreciation on assets to the extent used to perform
such manufacturing calculated on a ten-year straight-line basis, in either case,
otherwise pursuant to the terms and conditions set forth in the ADM Sub
Manufacturing Agreement.

                    (ii) Upon the effective date of rejection by MBX, ADM Sub
hereby grants to MBX the following licenses: (i) an exclusive, fully
sublicenseable, *, perpetual, irrevocable license, under all intellectual
property rights Controlled by ADM Sub and claiming or covering Alliance
Technology to research, develop, make, have made, use, offer for sale, sell,
have sold and import PHA-Related Material, produced by any means or methods, for
any and all uses and (ii) a non-exclusive, fully sublicenseable, fully paid-up,
royalty-free, perpetual, irrevocable license, under all intellectual property
rights Controlled by ADM Sub and claiming or covering ADM Sub Background
Technology to research, develop, make, have made, use, offer for sale, sell,
have sold and import PHA-Related Material, produced by any means or methods, for
any and all uses.

               (b) In the event MBX files for protection under Chapter 11 of the
U.S. Bankruptcy Code, and MBX, directly or indirectly in connection with such
proceedings, rejects this Agreement as an executory contract (or on similar
grounds), then, effective as of the effective date of such rejection, MBX shall
and hereby does grant to ADM Sub a royalty-bearing, non-exclusive, perpetual,
irrevocable license, with Limited Sublicense Right, under MBX's right, title and
interest in and to the MBX Technology and the MBX Patent Rights, solely to make,
have made, use, offer for sale, sell, have sold and import PHA Material and PHA
Formulations for use in the Field worldwide. The foregoing license shall be
limited such that ADM Sub shall only be permitted to make and have made a
maximum of one hundred fifty thousand (150,000) tons (or such greater amount if
the then-current license under Section 7.2.2 has been expanded) of PHA Material
(including PHA Material contained within PHA Formulations) during each
consecutive period of twelve (12) months during the term of the license. During
the Royalty Term, ADM Sub will pay to MBX a royalty equal to: (i) * on all sales
or other conveyances of PHA Patented Material (including, without limitation,
PHA Material that is contained within PHA Formulations), on a one hundred
percent (100%) purity basis; and (ii) * on all sales or other conveyances of PHA
Know-How Material (including, without limitation, PHA

*    CONFIDENTIAL TREATMENT REQUESTED

                                       49

<Page>

Material that is contained within PHA Formulations), on a one hundred percent
(100%) purity basis. During the Supplemental Royalty Term, ADM Sub will pay to
MBX a royalty equal to * on all sales or other conveyances of PHA Supplemental
Know-How Material (including, without limitation, PHA Material that is contained
within PHA Formulations), on a one hundred percent (100%) purity basis. In the
event more than one royalty applies to the manufacture, use, sale or importation
of a particular product, then the highest royalty shall be the only applicable
royalty hereunder. Provided, however, that any such royalty shall be subject to
Third Party IP Royalty Offset. The royalty shall be payable within thirty (30)
days following the end of each Calendar Quarter during the term of the
applicable license for sales or other conveyances that occur during such
Calendar Quarter. Amounts due under this Section 10.5.2 shall be payable by wire
transfer of immediately available funds to an MBX bank account in accordance
with instructions to be provided to the ADM Sub by MBX. Any amounts that are not
paid when due hereunder shall accrue interest at the rate of four percent (4%)
per annum in excess of the one year London Interbank Offered Rate (LIBOR) then
most recently published in THE WALL STREET JOURNAL. The right to demand and
receive the interest provided hereunder shall be in addition to any other rights
available to MBX hereunder or at law.

     10.7 SURVIVING PROVISIONS; RESERVATION OF RIGHTS. Termination or expiration
of this Agreement for any reason, and the implementation or exercise of the
consequences of termination as set forth in Sections 10.3, 10.4, 10.5, or 10.6
shall be without prejudice to any rights and obligations of the Parties that
have accrued as of the Effective Date of termination and:

               (a) the rights and obligations of the Parties provided in
Articles 1, 8, 11, 12, 13 and 14, Sections 7.1, 7.5, 7.6, 9.8.4, 10.3, 10.4,
10.5, or 10.6 and 10.7 and any other provision which would reasonably be
expected to survive termination in accordance with the terms of this Agreement,
all of which shall survive such termination; and

               (b) any other rights or remedies provided at law or equity which
either Party may otherwise have against the other.

                                   ARTICLE 11
                                 PATENT MATTERS

     11.1 PATENT COMMITTEE. ADM Sub and MBX shall each appoint two (2)
representatives to serve on a patent committee (the "Patent Committee") to
administer and coordinate certain activities described in this Article 11. ADM
Sub and MBX may replace their respective representatives on the Patent Committee
from time to time during the Term, at their sole discretion, by notice to the
other Party.

          11.1.1 MEETINGS. The Patent Committee shall meet as frequently and at
such times as its members shall determine.

          11.1.2 MINUTES. A secretary for the Patent Committee shall be
appointed by its members to keep accurate minutes of the deliberations of the
Patent Committee recording all

*    CONFIDENTIAL TREATMENT REQUESTED

                                       50

<Page>

proposed decisions and all actions recommended or taken. Copies of such minutes
shall be made available to the Steering Committee as it shall request.

          11.1.3 EXPENSES. MBX and ADM Sub shall each bear all expenses of their
respective representatives to the Patent Committee related to their
participation on the Patent Committee and attendance at Patent Committee
meetings.

          11.1.4 REPORTS. The Patent Committee shall produce such reports for
the Steering Committee as the Steering Committee shall request from
time-to-time.

     11.2 PATENT FILING, PROSECUTION AND MAINTENANCE.

          11.2.1 ADM SUB PATENT RIGHTS. ADM Sub shall have the sole right and
authority to file, prosecute and maintain the ADM Sub Patent Rights during the
Term at its own expense and using patent counsel of its own choosing. ADM Sub
represents that it will continue to file, prosecute and maintain the ADM Sub
Patent Rights in accordance with reasonable commercial practices during the
Term.

          11.2.2 MBX PATENT RIGHTS. MBX shall have the sole right and authority
to file, prosecute and maintain the MBX Patent Rights during the Term at its own
expense and using patent counsel of its own choosing. MBX represents that it
will continue to file, prosecute and maintain the MBX Patent Rights in
accordance with reasonable commercial practices during the Term.

          11.2.3 JOINT ALLIANCE TECHNOLOGY. ADM Sub and MBX, acting through the
Patent Committee, will file, prosecute and maintain Patent Rights claiming Joint
Alliance Technology in accordance with this Section 11.2.3 with the primary goal
of maximizing the commercial potential of the PHA Material and PHA Formulations
in a commercially reasonable manner. During the Term, the cost of such
activities shall be borne by the Joint Sales Company, and thereafter it shall be
shared equally by ADM Sub and MBX, except as otherwise set forth herein. ADM Sub
and MBX, acting through the Patent Committee and patent attorneys or agents
agreed upon by the Patent Committee, shall prepare, file, prosecute and maintain
all Patent Rights relating to Joint Alliance Technology. If either ADM Sub or
MBX decides to withdraw from the continued prosecution of any Patent Rights on
Joint Alliance Technology, such Party shall so inform the other Party at least
thirty (30) days prior to the effective date of such decision and the other
Party shall have the right, through patent attorneys or agents of its choice, to
assume the cost and responsibility for the continued prosecution of such Patent
Rights. Promptly after the effective date of the decision to withdraw, the
withdrawing Party shall assign its right, title and interest in and to such
Patent Rights to the other Party. Notwithstanding such assignment, such Patent
Rights will continue to be subject to the licenses granted herein to the extent
applicable.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       51

<Page>

     11.3 INFRINGEMENT AND DEFENSE.

          11.3.1 ACTUAL OR THREATENED INFRINGEMENT. In the event either ADM Sub
or MBX becomes aware of any possible infringement or unauthorized possession,
knowledge or use of any Technology, which is the subject matter of this
Agreement, in the Field (collectively, an "Infringement"), that Party shall
promptly notify the other Party and provide it with available details. ADM Sub
hereby reserves the exclusive right (but not obligation) to take whatever action
it deems appropriate to prevent or terminate any third party infringement of ADM
Sub Patent Rights claiming the ADM Sub Technology. MBX hereby reserves the
exclusive right (but not obligation) to take whatever action it deems
appropriate to prevent or terminate any third party infringement of MBX Patent
Rights claiming the MBX Technology. Notwithstanding the foregoing, during the
term, if either ADM Sub or MBX (the "Defending Party") decides to take any
action to prevent or terminate any Third Party infringement of its Patent Rights
within the Field, it shall first give notice to the other Party (the "Neutral
Party") and, if the Neutral Party can produce a written legal opinion of an
independent patent attorney concluding that there is a reasonable likelihood
that such Third Party could, in good faith, in connection with such action,
allege that a claim or claims within Patent Rights Controlled by the Neutral
Party are invalid or unenforceable, then the Defending Party shall not take such
action against such Third Party without the prior, written consent of the
Neutral Party. ADM Sub and MBX, sharing expenses equally and acting through
patent attorneys or agents agreed upon by them, shall take whatever action they
shall agree upon to prevent or terminate any third party infringement of Patent
Rights relating to Joint Alliance Technology; provided, however, that if the
Parties cannot agree, MBX shall have the right to make the final determination
with respect to third party infringement within the Field. In all cases, all
decisions by a Party pursuant to this Section 11.2 shall be made in good faith
and in the best interest of the Commercial Alliance.

          11.3.2 DEFENSE OF CLAIMS. In the event that any action, suit or
proceeding is brought against any Party based on its actions in performance of
the Commercial Alliance and alleging the infringement of the Technology or
intellectual property rights of a Third Party, the Parties shall cooperate with
each other in the defense of any such suit, action or proceeding. The Parties
will give each other prompt written notice of the commencement of any such suit,
action or proceeding or claim of infringement and will furnish each other with a
copy of each communication relating to the alleged infringement. Each Party
shall cooperate in the defense of such actions. If as a consequence of such
action, suit or proceeding by a Third Party, a prohibition, restriction or other
condition is imposed upon one or both of the Parties, the Parties shall examine
and discuss in good faith the consequences of such prohibition or restriction or
other conditions on this Agreement and on possible modifications hereto.

                                   ARTICLE 12
                                 INDEMNIFICATION

     12.1 INDEMNIFICATION BY MBX. During the course of, and upon and after
termination of this Agreement for any reason whatsoever, MBX and its Affiliates
shall indemnify, defend and hold ADM Sub, its Affiliates and their respective
directors, officers and employees (collectively, "ADM Sub Indemnitees") harmless
against any claims (including without limitation claims for product liability,
personal injury or death, or property damage), liability, damage, loss, cost or
expense (including reasonable attorneys' fees) incurred by any of them, to

*    CONFIDENTIAL TREATMENT REQUESTED

                                       52

<Page>

the extent resulting from: (i) the * of MBX, or any of its Affiliates, or their
employees, representatives or agents; or (ii) MBX's *. Notwithstanding anything
to the contrary, this provision shall not apply to any claims or suits to the
extent attributable to the negligence or willful misconduct of an ADM Sub
Indemnitee or a breach of any Commercial Alliance Agreement by ADM Sub.

     12.2 INDEMNIFICATION BY ADM SUB. During the course of, and upon and after
termination of this Agreement for any reason whatsoever, ADM Sub and its
Affiliates shall, jointly and severally, indemnify, defend and hold MBX, its
Affiliates and their respective directors, officers and employees (collectively,
"MBX Indemnitees") harmless against any claims (including without limitation
claims for product liability, personal injury or death, or property damage),
liability, damage, loss, cost or expense (including reasonable attorneys' fees)
incurred by any of them, to the extent resulting from: (i) the * of ADM Sub, or
any of its Affiliates, or their employees, representatives or agents; or (ii)
ADM Sub's *. Notwithstanding anything to the contrary, this provision shall not
apply to any claims or suits to the extent attributable to the negligence or
willful misconduct of an MBX Indemnitee or a breach of any Commercial Alliance
Agreement by MBX.

     12.3 CONDITIONS TO INDEMNIFICATION. A Party seeking indemnification under
this Article 10 (the "Indemnified Party") shall give prompt notice of the claim
to the other Party (the "Indemnifying Party") and, provided that the
Indemnifying Party is not contesting the indemnity obligation, shall permit the
Indemnifying Party to control any litigation relating to such claim and
disposition of any such claim, provided that the Indemnifying Party shall act
reasonably and in good faith with respect to all matters relating to the
settlement or disposition of any claim as the settlement or disposition relates
to Parties being indemnified under this Article 10 and provided, further, that
the Indemnifying Party shall not settle or otherwise resolve any claim without
prior notice to the Indemnified Party and the consent of the Indemnified Party
(which consent shall not be unreasonably withheld, conditioned or delayed) if
such settlement involves anything other than the payment of money by the
Indemnifying Party. The Indemnified Party shall cooperate with the Indemnifying
Party in its defense of any claim for which indemnification is sought under this
Article 12 and shall have the right to be present in person or through counsel
at all legal proceedings giving rise to the right of indemnification.

     12.4 ATTRIBUTION. For purposes of this Article 12, except as provided
below: (i) none of the Joint Sales Company, MBX or MBX's Affiliates (or their
respective employees) shall be deemed to be an employee, agent or representative
of ADM or ADM Sub, (ii) none of the Joint Sales Company, ADM Sub or ADM Sub's
Affiliates (or their respective employees) shall be deemed to be an employee,
agent or representative of MBX, (iii) none of MBX or ADM Sub or their respective
Affiliates (or their respective employees) shall be deemed to be an employee,
agent or representative of the Joint Sales Company; and, notwithstanding (i),
(ii) and (iii) above, an employee of ADM, ADM Sub or MBX providing services to
the Joint Sales Company on substantially a full-time basis, pursuant either to
the ADM Sub Services Agreement or the MBX Services Agreement, shall be deemed to
be an agent or representative of the Joint Sales Company.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       53

<Page>

                                   ARTICLE 13
                                 CONFIDENTIALITY

     13.1 CONFIDENTIALITY OBLIGATIONS. MBX, ADM Sub and the Joint Sales Company
each recognize that the other Party's Confidential Information and Proprietary
Materials constitute highly valuable and proprietary confidential information.
Each of MBX, ADM Sub and the Joint Sales Company agrees that it will keep
confidential, and will cause its employees, consultants, agents and Affiliates
to keep confidential, all Confidential Information and Proprietary Materials of
the other Parties. MBX, ADM Sub, the Joint Sales Company and their respective
employees, consultants, agents or Affiliates shall not use Confidential
Information or Proprietary Materials of any other Party for any purpose
whatsoever except as expressly permitted in this Agreement. MBX and Joint Sales
Company acknowledge that the corn costs that constitute a portion of the
Manufacturing Cost shall constitute ADM Sub Confidential Information.

     13.2 LIMITED DISCLOSURE. MBX, ADM Sub and the Joint Sales Company each
agree that any disclosure of another Party's Confidential Information or any
transfer of another Party's Proprietary Materials to any employee, consultants
or agents of MBX, ADM Sub, or the Joint Sales Company or any of their respective
Affiliates, shall be made only if and to the extent necessary to carry out its
rights and responsibilities under this Agreement and shall be limited to the
maximum extent possible consistent with such rights and responsibilities. MBX,
ADM Sub and the Joint Sales Company each further agree that any disclosure of
another Party's Confidential Information or any transfer of another Party's
Proprietary Materials as permitted by the preceding sentence shall only be made
to such of the recipient Party's employees, consultants, agents and Affiliates
who are bound by written confidentiality obligations to maintain the
confidentiality thereof and not to use such Confidential Information or
Proprietary Materials except as expressly permitted by this Agreement. MBX, ADM
Sub and the Joint Sales Company each further agree not to disclose or transfer
the other Party's Confidential Information or Proprietary Materials to any third
parties under any circumstance without the prior written approval from the
relevant other Party (such approval not to be unreasonably withheld), except as
otherwise required by law, or except as otherwise expressly permitted by this
Agreement. Each Party shall take such action, and shall cause its Affiliates to
take such action, to preserve the confidentiality of the other Party's
Confidential Information and Proprietary Materials as it would customarily take
to preserve the confidentiality of its own Confidential Information and
Proprietary Materials, and in no event, less than reasonable care. Each Party,
upon the request of another Party, will return all of such other Party's
Proprietary Information and Confidential Materials disclosed or transferred to
it pursuant to this Agreement which does not constitute Joint Program
Technology, including all copies and extracts of documents and all
manifestations in whatever form, within two (2) months of the request or, within
two (2) weeks of the termination or expiration of this Agreement; provided,
however, that a Party may retain Confidential Information and Proprietary
Materials of the other Party relating to any license which survives such
termination and one copy of all other Confidential Information may be retained
in its legal files solely for the purpose of monitoring compliance with this
Article 13.

     13.3 EMPLOYEES AND CONSULTANTS. MBX, ADM Sub, and the Joint Sales Company
each hereby represent that all of its employees, consultants and agents to such
Party or its

*    CONFIDENTIAL TREATMENT REQUESTED

                                       54

<Page>

Affiliates, participating in the activities of the Commercial Alliance who shall
have access to the Confidential Information or Proprietary Materials of the
other Party are bound by written obligations to maintain such information in
confidence and not to use such information except as expressly permitted herein
and to assign any inventions or discoveries made in connection with such
activities to MBX, ADM Sub or the Joint Sales Company as applicable. Each Party
agrees to be held responsible for the confidentiality obligations to which its
employees, consultants and agents (and those of its Affiliates) are obligated.

     13.4 PUBLICITY. No Party may publicly disclose the existence or terms of
this Agreement without the prior written consent of the other Parties; provided,
however, that any Party may make such a disclosure: (a) to the extent required
by law (including the filing of a redacted copy of the Agreement as an exhibit
to a legally required filing) or by the requirements of any nationally
recognized securities exchange, quotation system or over-the-counter market on
which such Party has its securities listed or traded, and (b) to any investors
(including without limitation, entities interested in acquiring the stock or
assets of such Party or merging with or into such Party), prospective investors,
lenders, other potential financing sources, prospective customers and
prospective strategic marketing partners who are obligated to keep such
information confidential. In the event that such disclosure is required as
aforesaid, the disclosing Party shall make reasonable efforts to provide the
other Party with reasonable notice prior to such disclosure and to coordinate
with the other Party with respect to the wording and timing of any such
disclosure. The Parties will from time to time mutually agree on the wording of
press releases publicizing the Commercial Alliance. Once such press release or
any other written statement is approved for disclosure by both Parties, either
Party may make subsequent public disclosure of the contents of such statement,
but no more than the contents of such statement, without the further approval of
the other Party.

     13.6 TERM. The obligations and restrictions set forth in this Article 13
shall survive the termination or expiration of this Agreement for a period of
twenty (20) years.

                                   ARTICLE 14
                                  MISCELLANEOUS

     14.1 NO ASSIGNMENT; CHANGE OF CONTROL. No Party shall sell, transfer or
permit any transfer of, in whole or in part, this Agreement without prior
written consent of the other Parties, which consent may be withheld for any
reason. The merger or acquisition of MBX by, with or into a third party shall
not be deemed to effect an assignment of this Agreement by MBX and this
Agreement shall be binding upon and inure to the benefit of such third party, or
new entity, in the case of a merger or similar transaction in which MBX does not
continue as the same corporate entity and shall continue to bind and inure to
the benefit of MBX in the case of an acquisition or similar transaction in which
MBX survives as the same corporate entity. ADM Sub shall not enter into any
merger, acquisition or similar transaction without the prior, written consent of
MBX. Nothing herein shall restrict ADM from entering into a merger or
acquisition of ADM by, with or into a Third Party and no such transaction shall
be deemed to effect an assignment of this Agreement by ADM Sub and this
Agreement shall be binding upon and inure to the benefit of such Third Party, or
new entity, in the case of a merger or similar transaction in which ADM does not
continue as the same corporate entity and shall continue to bind and inure to
the benefit of ADM Sub in the case of an acquisition or similar transaction in
which ADM

*    CONFIDENTIAL TREATMENT REQUESTED

                                       55

<Page>

survives as a the same corporate entity. Any purported assignment or transfer in
violation of this provision shall be null and void. In the event that, at
anytime *, MBX receives a bona fide offer from a Third Party to acquire all, or
a majority, of the outstanding shares of voting equity of MBX (such an
acquisition is hereinafter an "Acquisition Transaction"), MBX shall provide
notice to ADM Sub of the proposed Acquisition Transaction at least * from ADM
Sub to enter into an Acquisition Transaction with ADM Sub (such an agreement is
a "No-Shop Agreement"). Such notice will set forth the *. ADM Sub shall not,
directly or indirectly, contact such proposing party without MBX's prior written
consent, provided however, that if such proposing party contacts ADM Sub without
direct or indirect prompting or solicitation by ADM Sub, then nothing in this
Section 14.1 shall restrict ADM Sub's ability to communicate with such proposing
party. In the event that the * period, or thereafter at anytime before MBX has
entered into a No-Shop Agreement *, MBX will provide notice to ADM Sub of the
terms of such modified bona fide offer, including the same level of detail and
information as is required to be included in the original notice, at least forty
eight (48) hours (which forty eight (48) hour period must include at least one
(1) full business day) prior to entering into a No-Shop Agreement. For avoidance
of doubt, provided that MBX has complied with the foregoing notice requirements,
MBX shall have no obligation to provide any additional notice to ADM Sub of
changes to the terms of an offer after MBX has entered into a No-Shop Agreement
with respect to such transaction. Notwithstanding the foregoing, if MBX *, the
foregoing notice requirements shall not apply, and *.

     14.2 SUCCESSORS. In the event of a permitted assignment, this Agreement
shall be binding upon, and inure to the benefit of, all the Parties and their
respective successors and legal assigns.

     14.3 DISPUTE RESOLUTION. Any dispute or claim arising out of or relating to
this Agreement or any other Commercial Alliance Agreement, or a breach hereof or
thereof, shall be resolved in accordance with this Section 14.3. Except with
respect to any dispute as to whether ADM Sub properly exercised its rights to
terminate pursuant to Section 10.2.2, during the course of resolving any such
dispute, the Parties shall continue to perform their obligations hereunder and
under the other Commercial Alliance Agreements (including by making payment of
any undisputed portion of any payment obligation that is the subject of a
dispute hereunder or thereunder). Notwithstanding the foregoing, the obligation
of the Parties to continue to perform hereunder and under the other Commercial
Alliance Agreements during the resolution of disputes shall not require a Party
to perform obligations (other any undisputed portion of any payment obligation)
where such performance is rendered impossible, or would otherwise not maintain
or increase the likelihood that the Parties will achieve the purpose and goal of
the Commercial Alliance as set forth in Section 2.1, because of circumstances
created by or directly related to the dispute itself.

          14.3.1 GOOD FAITH CONSULTATION. In the event of a dispute between the
Parties, the Parties shall attempt in good faith to settle such dispute through
mutual consultation. If, after such consultation, the dispute cannot be
resolved, the Parties shall wait for not less than sixty (60) days after the
dispute arises and at the end of such period meet for a second consultation. If
the dispute is not resolved after the second consultation, the matter shall be
referred to the

*    CONFIDENTIAL TREATMENT REQUESTED

                                       56

<Page>

President of ADM Sub and the Chief Executive Officer of MBX (together, the
"Senior Executives") for resolution in accordance with Section 14.4.2.

          14.3.2 SENIOR EXECUTIVES. The Senior Executives shall diligently
attempt to resolve the dispute, including, if they deem it necessary, meeting
directly in order to provide full consideration of the dispute. If the Senior
Executives are unable to resolve the dispute within sixty (60) additional days
after the second consultation then the dispute shall be referred to arbitration.

          14.3.3 ARBITRATION. Any arbitration to be conducted hereunder shall be
brought and conducted in accordance with the following provisions:

               (1)  The arbitration shall be held in Chicago, Illinois if
                    initiated by MBX and in Boston, Massachusetts if initiated
                    by ADM Sub.

               (2)  The arbitration shall be conducted by three (3) arbitrators
                    in accordance with the commercial arbitration rules of the
                    American Arbitration Association. Each of ADM Sub and MBX,
                    upon notice to the other Party, shall appoint one
                    arbitrator. The two arbitrators appointed by such Parties
                    shall appoint a third arbitrator. The arbitrators shall be
                    lawyers who will have substantial patent law or patent
                    litigation experience and substantial commercial law or
                    commercial litigation experience. The arbitrators shall be
                    instructed to follow federal precedents, laws and
                    evidentiary rules that would be applicable to litigation in
                    the Federal Court of the jurisdiction in which the
                    arbitration is held, except for those issues which involve
                    patent issues, in which case the arbitrators shall be
                    instructed to follow federal precedents, laws and
                    evidentiary rules that would be applicable to litigation in
                    the Federal Circuit Court of Appeals.

               (3)  The arbitration shall be conducted in English, and all
                    written submissions shall be in English.

               (4)  ADM Sub and MBX agree that the decision of the arbitrators
                    shall be final and binding on the Parties. The decision of
                    the arbitrators shall be carried out voluntarily and without
                    delay.

               (5)  The fees and expenses of the arbitrators shall be shared
                    equally by ADM Sub and MBX. ADM Sub and MBX will bear its
                    own costs and expenses, including without limitation, its
                    own legal fees and expert witness fees. Notwithstanding the
                    foregoing, ADM Sub and MBX agree to be bound by and obey any
                    order of the arbitrators relating to either Party being
                    liable for any such costs, including without limitation, the
                    legal fees of the other Party.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       57

<Page>

          14.3.4 EQUITABLE RELIEF. Nothing in this Agreement shall prevent or
limit ADM Sub's or MBX's right to file and prosecute in any court of competent
jurisdiction an action to seek injunctive relief to prevent or stay a breach of
this Agreement or any action necessary to enforce the award of the arbitrators.

          14.3.5 BUSINESS ISSUE DEADLOCKS. In the event an issue relating to the
conduct of the business of the Commercial Alliance comes before the Steering
Committee or the conduct of the business of the Joint Sales Company comes before
the Board of the Joint Sales Company, and such business decision is not governed
by the terms of the Commercial Alliance Agreements, but rather is specifically
or by omission left to the business judgment of the Steering Committee or the
Board, and the Steering Committee or Board, acting in accordance with Section
3.1.3 in the case of the Steering Committee, and acting in accordance with the
Operating Agreement in the case of the Board, is unable to reach a decision on
how (or whether) to address or resolve such business issue, then provisions set
forth in Sections 14.3.1 and 14.3.2 shall apply, but the provisions set forth in
Section 14.3.3 shall not apply. During such time as the Ledger Account is less
than ten million dollars ($10,000,000), in the event that the Parties do not
reach a resolution of such a business dispute as provided in Section 14.3.1 or
14.3.2, then the provisions set forth in Section 14.3.3 shall apply, but the
arbitrators' decision shall be rendered as follows: At the conclusion of the
arbitration hearings, each party shall submit a proposed resolution of the
business dispute to the arbitrators. The arbitrators shall choose among the
proposed resolutions and adopt one as the arbitrators' decision, and shall
render that decision as the arbitrators' final determination. The arbitrators do
not have discretion to render any decision other than one submitted by one of
the Parties. For the avoidance of doubt, whether a Party has met the decision
making standards set forth in 3.1.3 shall not be subject to this Section, but
shall be treated as a dispute subject to the provisions of Sections 14.3.1,
14.3.2 and 14.3.3.

     14.4 GOVERNING LAW. Except as specifically otherwise provided herein, this
Agreement shall be governed by and construed in accordance with the laws of the
State of Delaware.

     14.5 FORCE MAJEURE. In the event of the intervention of a force majeure,
which term shall include, without limitation, acts of God, strikes, labor
disturbances, lockouts, riots, epidemics, quarantines, wars or conditions of
war, actions, inactions or regulations of any government, fires, acts of
terrorists, insurrections, embargoes or trade restrictions, or any other reasons
beyond a Party's reasonable control, the Party affected by the force majeure
shall use Commercially Reasonable Efforts to comply with the Agreement. In the
case that such Commercially Reasonable Efforts fail or are futile, such Party
shall not be responsible for delays or a failure to perform under this Agreement
caused by a force majeure. Provided, however, that any payment obligations of a
Party shall not be affected or excused by such force majeure. If a Party's delay
or failure to perform continues for more than one hundred twenty (120) days, the
other Party may terminate this Agreement. In the event that either Party shall
incur a delay in delivery or performance for a reason permitted by this Article,
that Party shall notify the other Party within five (5) days from the date of
the actual occurrence of the cause for such delay

*    CONFIDENTIAL TREATMENT REQUESTED

                                       58

<Page>

     14.6 NOTICES. All notices, requests and other communication hereunder shall
be in writing and sent by facsimile with confirmation sent by courier requiring
acknowledgment of receipt by the respective Parties as follows:

          To MBX:       Metabolix Corporation
                        21 Erie Street
                        Cambridge, MA 02139-4260
                        Attn: President and CEO

          With copy to: Goodwin Procter
                        Exchange Place
                        53 State Street
                        Boston, MA 02109
                        Attn: Christopher J. Denn, Esq.

          To ADM Sub:   ADM Polymer Corporation
                        4666 Faries Parkway
                        Decatur, IL 62526
                        Attn: President

          With copy to: Archer-Daniels-Midland Company
                        4666 Faries Parkway
                        Decatur, IL 62526
                        Attn: General Counsel

          To JSC:       ADM / Metabolix Sales Company, LLC
                        21 Erie Street
                        Cambridge, MA 02139-4260

          With a copy to: ADM Sub, at the address set forth above, and
                          MBX, at the address set forth above

Either Party may change the registered address to which such notice should be
sent by giving written notice to the other Party.

     14.7 INTEGRATION; ENTIRE AGREEMENT. This Agreement contains the entire
agreement of the Parties with regard to the subject matter contained herein and
supersedes all prior written and oral agreements, understandings and
negotiations, with regard to such subject matter.

     14.8 AMENDMENTS. This Agreement, including this provision, may not be
amended without a written instrument signed by duly authorized representatives
of all Parties.

     14.9 SEVERABILITY. In the event that any part of this Agreement is
adjudicated to be invalid or unenforceable because it contravenes any applicable
law or regulation, the Parties shall perform this Agreement in accordance with
their original intentions as set forth herein,

*    CONFIDENTIAL TREATMENT REQUESTED

                                       59

<Page>

corresponding as closely as possible to the invalid or unenforceable part
insofar as it is still valid under such law or regulation and reflects the
original intention of the Parties. The validity of the remaining permissible
portions of this Agreement shall remain unaffected thereby.

     14.10 WAIVER/CUMULATIVE RIGHTS. No failure by any Party to insist upon the
strict performance of any covenant, duty, agreement or condition of this
Agreement or to exercise any right or remedy upon a breach thereof shall
constitute a waiver of any such breach or any other covenant, duty, agreement or
condition. All rights and remedies which a Party may have hereunder or by
operation of law are cumulative, and the pursuit of one right or remedy shall
not be deemed an election to waive or renounce any other right or remedy.

     14.11 NO JOINT VENTURE OR PARTNERSHIP RELATIONSHIP. Nothing contained in or
relating to this Agreement is or shall be deemed to constitute a joint venture,
partnership or agency relationship between any of the Parties hereto and no
Party shall have any authority to act for or to assume any obligation or
responsibility on behalf of the other Party

     14.12 FURTHER ASSURANCES. Each Party shall duly execute and deliver, or
cause to be duly executed and delivered, such further instruments and do and
cause to be done such further acts and things, including without limitation the
filing of such assignments, agreements, documents and instruments, as may be
necessary or as the other Party may reasonably request in connection with this
Agreement or to carry out more effectively the provisions and purposes hereof,
or to better assure and confirm unto such other Party its rights and remedies
under this Agreement.

     14.13 CONSTRUCTION. Except where the context otherwise requires, wherever
used the singular shall include the plural, the plural the singular, the use of
any gender shall be applicable to all genders, the word "or" is used in the
inclusive sense and the word "any" shall mean any one item, or all items, in a
referenced category. The captions of this Agreement are for convenience of
reference only and in no way define, describe, extend, or limit the scope or
intent of this Agreement or the intent of any provision contained in this
Agreement. The language of this Agreement shall be deemed to be the language
mutually chosen by the Parties and no rule of strict construction shall be
applied against either Party hereto.

     14.14 ACKNOWLEDGMENT. The Parties hereby acknowledge that all licenses
granted herein are, for the purposes of Section 365(n) of Title 11 of the U.S.
Code, licenses of rights to intellectual property as defined in said Title 11.

     14.14 COUNTERPARTS. This Agreement may be executed in any number of
counterparts, each of which shall be deemed to be an original, and all of which,
taken together, shall constitute one and the same instrument.

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed
by their duly authorized representatives as of the day and year above written.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       60

<Page>

                                        ADM POLYMER CORPORATION

                                        By: /s/ John D. Rice
                                            ------------------------------------
                                        Name: John D. Rice
                                        Title: President

                                        METABOLIX, INC.

                                        By: /s/ James J. Barber
                                            ------------------------------------
                                        Name: James J. Barber
                                        Title: President and CEO

                                        ADM/ METABOLIX SALES
                                        COMPANY, LLC

                                        By: /s/ John D. Rice
                                            ------------------------------------
                                        Name: John D. Rice
                                        Title: Director

                                        By: /s/ James J. Barber
                                            ------------------------------------
                                        Name: James J. Barber
                                        Title: Director

*    CONFIDENTIAL TREATMENT REQUESTED

                                       61<Page>

WHENEVER CONFIDENTIAL INFORMATION IS OMITTED HEREIN (SUCH OMISSIONS ARE DENOTED
BY AN ASTERISK*), SUCH CONFIDENTIAL INFORMATION HAS BEEN SUBMITTED SEPARATELY TO
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT.

                               OPERATING AGREEMENT

                                       OF

                       ADM / METABOLIX SALES COMPANY, LLC

                                 BY AND BETWEEN

                             ADM POLYMER CORPORATION

                                        &

                                 METABOLIX INC.

*    CONFIDENTIAL TREATMENT REQUESTED

<Page>

                                TABLE OF CONTENTS

OPERATING AGREEMENT                                                            1

BY AND BETWEEN                                                                 1

ADM POLYMER CORPORATION                                                        1

METABOLIX INC.                                                                 1

TABLE OF CONTENTS                                                              I

OPERATING AGREEMENT                                                            1

SECTION 1: THE JOINT SALES COMPANY                                             1

   1.1   FORMATION                                                             1
   1.2   NAME                                                                  1
   1.3   PURPOSE; POWERS                                                       1
   1.4   PRINCIPAL PLACE OF BUSINESS                                           2
   1.5   TERM                                                                  2
   1.6   FILINGS; AGENT FOR SERVICE OF PROCESS                                 2
   1.7   TITLE TO PROPERTY                                                     3
   1.8   PAYMENTS OF INDIVIDUAL OBLIGATIONS                                    3
   1.9   INDEPENDENT ACTIVITIES; TRANSACTIONS WITH AFFILIATES                  3
   1.10  DEFINITIONS                                                           4

SECTION 2: MEMBERS' CAPITAL CONTRIBUTIONS                                     17

   2.1   ORIGINAL CAPITAL CONTRIBUTIONS                                       17
   2.2   CONTRIBUTIONS                                                        17
   2.3   ADDITIONAL CAPITAL CONTRIBUTIONS                                     17

SECTION 3: ALLOCATIONS                                                        18

   3.1   PROFITS                                                              18
   3.2   LOSSES                                                               18
   3.3   SPECIAL ALLOCATIONS                                                  18
   3.4   CURATIVE ALLOCATIONS                                                 20
   3.5   LOSS LIMITATION                                                      20
   3.6   OTHER ALLOCATION RULES                                               20
   3.7   TAX ALLOCATIONS: CODE SECTION 704(c)                                 21

SECTION 4: DISTRIBUTIONS                                                      21

   4.1   NET CASH FLOW                                                        21
   4.4   LIMITATIONS ON DISTRIBUTIONS                                         22

SECTION 5: MANAGEMENT                                                         22

   5.1   DIRECTORS; BOARD OF DIRECTORS                                        22
   5.2   MEETINGS OF THE BOARD OF DIRECTORS                                   23
   5.3   BOARD OF DIRECTORS POWERS                                            24
   5.4   DUTIES AND OBLIGATIONS OF THE BOARD OF DIRECTORS                     27
   5.5   REIMBURSEMENTS                                                       27
   5.6   INDEMNIFICATION OF THE DIRECTORS AND OFFICERS                        28
   5.7   APPOINTMENT OF OFFICERS, AGENTS AND REPRESENTATIVES:                 28

*    CONFIDENTIAL TREATMENT REQUESTED

                                        i

<Page>

SECTION 6: ROLE OF MEMBERS                                                    31

   6.1   RIGHTS OR POWERS                                                     31
   6.2   VOTING RIGHTS                                                        31
   6.3   REQUIRED MEMBER CONSENTS                                             31
   6.5   WITHDRAWAL/RESIGNATION                                               33
   6.6   MEMBER COMPENSATION                                                  33
   6.7   MEMBERS LIABILITY                                                    33
   6.8   PARTITION                                                            33
   6.9   CONFIDENTIALITY                                                      34
   6.10  TRANSACTIONS BETWEEN A MEMBER AND THE JOINT SALES COMPANY            34
   6.11  OTHER INSTRUMENTS                                                    34
   6.12  NUMBER OF MEMBERS                                                    34
   6.13  EQUALIZATION PAYMENTS                                                34

SECTION 7: REPRESENTATIONS AND WARRANTIES                                     35

   7.1   IN GENERAL                                                           35
   7.2   REPRESENTATIONS AND WARRANTIES                                       35

SECTION 8: ACCOUNTING, BOOKS AND RECORDS                                      36

   8.1   ACCOUNTING, BOOKS AND RECORDS                                        36
   8.2   REPORTS                                                              37
   8.3   TAX MATTERS                                                          38

SECTION 9: AMENDMENTS                                                         39

   9.1   AMENDMENTS                                                           39

SECTION 10: TRANSFERS                                                         40

   10.1  RESTRICTIONS ON TRANSFERS                                            40
   10.2  PERMITTED TRANSFERS                                                  40
   10.3  CONDITIONS TO PERMITTED TRANSFERS                                    40
   10.4  [RESERVED]                                                           41
   10.5  PROHIBITED TRANSFERS                                                 41
   10.6  TAX TERMINATION RESTRICTIONS                                         41
   10.7  RIGHTS OF UNADMITTED ASSIGNEES                                       42
   10.8  ADMISSION OF SUBSTITUTED MEMBERS                                     42
   10.9  REPRESENTATIONS REGARDING TRANSFERS; LEGEND                          43
   10.10 DISTRIBUTIONS AND ALLOCATIONS IN RESPECT OF TRANSFERRED UNITS        44

SECTION 11: ADVERSE ACT                                                       45

   11.1  REMEDIES                                                             45

SECTION 12: DISSOLUTION AND WINDING UP                                        46

   12.1  DISSOLUTION EVENTS                                                   46
   12.2  WINDING UP                                                           47
   12.3  COMPLIANCE WITH CERTAIN REQUIREMENTS OF REGULATIONS; DEFICIT
            CAPITAL ACCOUNTS                                                  48
   12.4  DEEMED DISTRIBUTION AND RECONTRIBUTION                               48
   12.5  RIGHTS OF MEMBERS                                                    49
   12.6  NOTICE OF DISSOLUTION/TERMINATION                                    49
   12.7  ALLOCATIONS DURING PERIOD OF LIQUIDATION                             49
   12.8  CHARACTER OF LIQUIDATING DISTRIBUTIONS                               49
   12.9  THE LIQUIDATOR                                                       50
   12.10 FORM OF LIQUIDATING DISTRIBUTIONS                                    50

SECTION 13: MISCELLANEOUS                                                     50

*    CONFIDENTIAL TREATMENT REQUESTED

                                       ii

<Page>

   13.1  NOTICES                                                              50
   13.2  BINDING EFFECT                                                       52
   13.3  CONSTRUCTION                                                         52
   13.4  TIME                                                                 52
   13.5  HEADINGS                                                             52
   13.6  SEVERABILITY                                                         52
   13.7  INCORPORATION BY REFERENCE                                           52
   13.8  VARIATION OF TERMS                                                   53
   13.9  GOVERNING LAW                                                        53
   13.10 COUNTERPART EXECUTION                                                53

*    CONFIDENTIAL TREATMENT REQUESTED

                                       iii

<Page>

                               OPERATING AGREEMENT

                                       OF

                       ADM / METABOLIX SALES COMPANY, LLC

     This OPERATING AGREEMENT is entered into and shall be effective as of the
14th day of July, 2006, by and between the Persons who are identified as Members
on Exhibit A attached hereto and who have executed a counterpart of this
Agreement as Members pursuant to the provisions of the Act, on the following
terms and conditions:

                       SECTION 1: THE JOINT SALES COMPANY

          1.1 FORMATION.

     The Members hereby agree to form the Joint Sales Company as a limited
liability company under and pursuant to the provisions of the Act and upon the
terms and conditions set forth in this Agreement. The fact that the Certificate
is on file in the office of the Secretary of State, State of Delaware, shall
constitute notice that the Joint Sales Company is a limited liability company.
Simultaneously with the execution of this Agreement and the formation of the
Joint Sales Company, each of the Members shall be admitted as a member of the
Joint Sales Company. The rights and liabilities of the Members shall be as
provided under the Act, the Certificate and this Operating Agreement.

          1.2 NAME.

     The name of the Joint Sales Company shall be ADM / Metabolix Sales Company,
LLC and all business of the Joint Sales Company shall be conducted in such name.
The Board of Directors may change the name of the Joint Sales Company upon ten
(10) Business Days' notice to the Members.

          1.3 PURPOSE; POWERS.

     (a) The purposes of the Joint Sales Company are (i) to operate the
Business, (ii) to make such additional investments and engage in such additional
activities as the Members may approve pursuant to the terms and conditions of
this Operating Agreement, and (iii) to engage in any and all activities related
or incidental to the purposes set forth in clauses (i) and (ii).

     (b) The Joint Sales Company has the power to do any and all acts necessary,
appropriate, proper, advisable, incidental or convenient to or in furtherance of
the purposes of

*    CONFIDENTIAL TREATMENT REQUESTED

<Page>

the Joint Sales Company set forth in this Section 1.3 and has, without
limitation, any and all powers that may be exercised on behalf of the Joint
Sales Company by the Board of Directors pursuant to Section 5 hereof.

          1.4 PRINCIPAL PLACE OF BUSINESS.

     The principal place of business of the Joint Sales Company shall be at 21
Erie Street, Cambridge, MA 02139. The Board of Directors may change the
principal place of business of the Joint Sales Company to any other place within
or without the State of Delaware upon ten (10) Business Days notice to the
Members. The registered office of the Joint Sales Company in the State of
Delaware initially is located at c/o The Corporation Trust Company, Corporation
Trust Center, 1209 Orange Street, Wilmington, Delaware 19801.

          1.5 TERM.

     The term of the Joint Sales Company shall commence on the date the
certificate of formation of the Joint Sales Company as such term is described in
the Act (the "Certificate") is filed in the office of the Secretary of State of
the State of Delaware in accordance with the Act and shall continue until the
winding up and liquidation of the Joint Sales Company and its business is
completed following a Dissolution Event, as provided in Section 12 hereof. Prior
to the time that the Certificate is filed, no Person shall represent to third
parties the existence of the Joint Sales Company or hold himself out as a Member
or Director.

          1.6 FILINGS; AGENT FOR SERVICE OF PROCESS.

     (a) The Directors are hereby severally authorized to and at least one of
them shall cause the Certificate to be filed in the office of the Secretary of
State of the State of Delaware in accordance with the Act. The Board of
Directors shall take any and all other actions reasonably necessary to perfect
and maintain the status of the Joint Sales Company as a limited liability
company under the laws of the State of Delaware, including the preparation and
filing of such amendments to the Certificate and such other assumed name
certificates, documents, instruments and publications as may be required by law,
including, without limitation, action to reflect:

          (i)  a change in the Joint Sales Company name; or

          (ii) a correction of false or erroneous statements in the Certificate
          or the desire of the Members to make a change in any statement therein
          in order that it shall accurately represent the agreement among the
          Members.

     (b) The Members and the Board of Directors shall execute and cause to be
filed original or amended certificates and shall take any and all other actions
as may be reasonably necessary to perfect and maintain the status of the Joint
Sales Company as a limited liability company or similar type of entity under the
laws of any other jurisdictions in which the Joint Sales Company engages in
business.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       2

<Page>

     (c) The registered agent for service of process on the Joint Sales Company
in the State of Delaware shall be The Corporation Trust Company, or any
successor as appointed by the Members in accordance with the Act.

     (d) Upon the dissolution and completion of the winding up and liquidation
of the Joint Sales Company in accordance with Section 12, the Board of Directors
shall promptly execute and cause to be filed a certificate of cancellation in
accordance with the Act and the laws of any other jurisdictions in which the
Board of Directors deems such filing necessary or advisable.

          1.7 TITLE TO PROPERTY.

     All Property owned by the Joint Sales Company shall be owned by the Joint
Sales Company as an entity and no Member shall have any ownership interest in
such Property in its individual name, and each Member's interest in the Joint
Sales Company shall be personal property for all purposes. At all times after
the Effective Date, the Joint Sales Company shall hold title to all of its
Property in the name of the Joint Sales Company and not in the name of any
Member.

          1.8 PAYMENTS OF INDIVIDUAL OBLIGATIONS.

     Except as expressly set forth in the Commercial Alliance Agreements, the
Joint Sales Company's credit and assets shall be used solely for the benefit of
the Joint Sales Company, and no asset of the Joint Sales Company shall be
Transferred or encumbered for, or in payment of, any individual obligation of
any Member without the unanimous consent of the Members.

          1.9 INDEPENDENT ACTIVITIES; TRANSACTIONS WITH AFFILIATES.

     (a) Each Director shall be required to devote such time to the affairs of
the Joint Sales Company as may be necessary to manage and operate the Joint
Sales Company, and shall be free to serve any other Person or enterprise in any
capacity that such Director may deem appropriate in his, her or its discretion.

     (b) Insofar as permitted by applicable law and except as otherwise provided
in the Commercial Alliance Agreements, neither this Agreement nor any activity
undertaken pursuant hereto shall prevent any Member or Director or their
Affiliates from engaging in whatever activities they choose, whether the same
are competitive with the Joint Sales Company or otherwise, and any such
activities may be undertaken without having or incurring any obligation to offer
any interest in such activities to the Joint Sales Company or any Member, or
require any Member or Director to permit the Joint Sales Company or any other
Director or Member or its Affiliates to participate in any such activities, and
as a material part of the consideration for the execution of this Agreement by
each Member, each Member hereby waives, relinquishes, and renounces any such
right or claim of participation.

     (c) To the extent permitted by applicable law and subject to the provisions
of the Commercial Alliance Agreements, the Board of Directors is hereby
authorized to cause the

*    CONFIDENTIAL TREATMENT REQUESTED

                                       3

<Page>

Joint Sales Company to purchase Property from, sell Property to or otherwise
deal with any Member or Director, acting on its own behalf, or any Affiliate of
any Member or Director; PROVIDED that, except as set forth in Section 6.10
hereof, any such purchase, sale or other transaction shall be made on terms and
conditions which are no less favorable to the Joint Sales Company than if the
sale, purchase or other transaction had been made with an independent third
party.

          1.10 DEFINITIONS.

     Capitalized words and phrases used in this Agreement have the following
meanings:

     "ACT" means the Delaware Limited Liability Company Act, 6 Del. C.
section 18-101, et seq., as amended from time to time (or any corresponding
provisions of succeeding law).

     "ADDITIONAL CAPITAL CONTRIBUTIONS" means, with respect to each Member, the
Capital Contributions made by such Member pursuant to Section 2.3 hereof. In the
event Units are Transferred in accordance with the terms of this Agreement, the
transferee shall succeed to the Additional Capital Contributions of the
transferor to the extent they relate to the Transferred Units.

     "ADJUSTED CAPITAL ACCOUNT DEFICIT" means, with respect to any Member, the
deficit balance, if any, in such Member's Capital Account as of the end of the
relevant Allocation Year, after giving effect to the following adjustments:

               (i) Credit to such Capital Account any amounts which such Member
          is deemed to be obligated to restore pursuant to the penultimate
          sentences in Sections 1.704-2(g)(1) and 1.704-2(i)(5) of the
          Regulations; and

               (ii) Debit to such Capital Account the items described in
          Sections 1.704-1(b)(2)(ii)(d)(4), 1.704-1(b)(2)(ii)(d)(5) and
          1.704-1(b)(2)(ii)(d)(6) of the Regulations.

The foregoing definition of Adjusted Capital Account Deficit is intended to
comply with the provisions of Section 1.704-1(b)(2)(ii)(d) of the Regulations
and shall be interpreted consistently therewith.

     "ADM POLYMER CORPORATION" means ADM Polymer Corporation.

     "ADM POLYMER CORPORATION MANUFACTURING AGREEMENT" means the Manufacturing
Agreement by and between ADM Polymer Corporation and the Joint Sales Company
entered into simultaneously herewith.

     "ADM POLYMER CORPORATION MANUFACTURING FACILITY" means the facility to be
constructed by ADM Polymer Corporation, pursuant to the Commercial Alliance
Agreement, to manufacture PHA Material pursuant to the ADM Polymer Corporation
Manufacturing Agreement.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       4

<Page>

     "ADM POLYMER CORPORATION MARGIN" has the meaning assigned to the term
"Manufacturing Margin" in the ADM Polymer Corporation Manufacturing Agreement.

     "ADM POLYMER CORPORATION SERVICES AGREEMENT" means the agreement entitled
ADM Polymer Corporation Services Agreement entered into simultaneously herewith
between ADM Polymer Corporation and the Joint Sales Company pursuant to which
ADM Polymer Corporation shall provide the Joint Sales Company with certain
specified services, all for the Joint Sales Company's Business.

     "ADVERSE ACT" means, with respect to any Member, any of the following:

               (i) A failure of such Member to make any Capital Contribution
          required pursuant to any provision of this Agreement;

               (ii) A material breach of any Commercial Alliance Agreement by
          such Member resulting in the termination of such Commercial Alliance
          Agreement by another party thereto;

               (iii) A Transfer of all or any portion of such Member's Units
          except as expressly permitted or required by this Agreement; and

               (iv) Any dissolution or liquidation of a Member, unless
          substantially all assets of the Member (including, without limitation,
          this Agreement and all rights hereunder) are transferred or are to be
          transferred to a Wholly Owned Affiliate of such Member.

     An "ADVERSE MEMBER" is any Member with respect to whom an Adverse Act has
occurred.

     "AFFILIATE" of a Person means any other Person that, directly or
indirectly, through one or more intermediaries, controls, is controlled by, or
is under common control with, such Person. "Control" and, with correlative
meanings, the terms "controlled by" and "under common control with" shall mean
the power to direct or cause the direction of the management or policies of a
Person, whether through the ownership of voting securities, by contract,
resolution, regulation, or otherwise.

     "AGREEMENT" or "OPERATING AGREEMENT" means this Operating Agreement
including all Exhibits and Schedules attached hereto, as amended from time to
time. Words such as "herein," "hereinafter," "hereof," "hereto" and "hereunder"
refer to this Agreement as a whole, unless the context otherwise requires.

     "ALLOCATION YEAR" means (i) the period commencing on the Effective Date and
ending on December 31, 2006, (ii) any subsequent twelve (12) month period
commencing on January 1 and ending on December 31 or (iii) any portion of the
period described in clauses (i)

*    CONFIDENTIAL TREATMENT REQUESTED

                                       5

<Page>

or (ii) for which the Joint Sales Company is required to allocate Profits,
Losses and other items of Joint Sales Company income, gain, loss or deduction
pursuant to Section 3 hereof.

     "AVAILABLE CASH" means on any date the amount of cash held by the Joint
Sales Company less all expenses of the Joint Sales Company less all other cash
requirements of the Joint Sales Company, as reasonably determined by the
unanimous decision of the Board of Directors.

     "BOARD OF DIRECTORS" has the meaning set forth in Section 5.1(a) hereof.

     "BUSINESS" means (i) the business of operating, managing, and/or developing
the manufacture, marketing and sale of PHA Material and PHA Formulations
worldwide, consistent with the terms of the Commercial Alliance Agreements, and
(ii) any other business that the Members may unanimously approve.

     "BUSINESS DAY" means a day of the year on which banks are not required or
authorized to close in New York, New York.

     "CAPITAL ACCOUNT" means, with respect to any Member, the Capital Account
maintained for such Member in accordance with the following provisions:

               (i) To each Member's Capital Account there shall be credited (A)
          such Member's Capital Contributions, (B) such Member's distributive
          share of Profits and any items in the nature of income or gain which
          are specially allocated pursuant to Section 3.3 or Section 3.4 hereof,
          and (C) the amount of any Joint Sales Company liabilities assumed by
          such Member or which are secured by any Property distributed to such
          Member. The principal amount of a promissory note which is not readily
          traded on an established securities market and which is contributed to
          the Joint Sales Company by the maker of the note (or a Member related
          to the maker of the note within the meaning of Regulations Section
          1.704-1(b)(2)(ii)(c)) shall not be included in the Capital Account of
          any Member until the Joint Sales Company makes a taxable disposition
          of the note or until (and to the extent) principal payments are made
          on the note, all in accordance with Regulations Section
          1.704-1(b)(2)(iv)(d)(2);

               (ii) To each Member's Capital Account there shall be debited (A)
          the amount of money and the Gross Asset Value of any Property
          distributed to such Member pursuant to any provision of this
          Agreement, (B) such Member's distributive share of Losses and any
          items in the nature of expenses or losses which are specially
          allocated pursuant to Section 3.3 or Section 3.4 hereof, and (C) the
          amount of any liabilities of such Member assumed by the Joint Sales
          Company or which are secured by any Property contributed by such
          Member to the Joint Sales Company;

*    CONFIDENTIAL TREATMENT REQUESTED

                                       6

<Page>

               (iii) In the event Units are Transferred in accordance with the
          terms of this Agreement, the transferee shall succeed to the Capital
          Account of the transferor to the extent it relates to the Transferred
          Units; and

               (iv) In determining the amount of any liability for purposes of
          subparagraphs (i) and (ii) above there shall be taken into account
          Code Section 752(c) and any other applicable provisions of the Code
          and Regulations.

     The foregoing provisions and the other provisions of this Agreement
relating to the maintenance of Capital Accounts are intended to comply with
Regulations Section 1.704-1(b), and shall be interpreted and applied in a manner
consistent with such Regulations. In the event the Board of Directors shall
determine that it is prudent to modify the manner in which the Capital Accounts,
or any debits or credits thereto (including, without limitation, debits or
credits relating to liabilities which are secured by contributed or distributed
property or which are assumed by the Joint Sales Company or any Members), are
computed in order to comply with such Regulations, the Board of Directors by a
unanimous decision may make such modification, provided that it is not likely to
have a material effect on the amounts distributed to any Person pursuant to
Section 12 hereof upon the dissolution of the Joint Sales Company. The Board of
Directors by a unanimous decision also shall (i) make any adjustments that are
necessary or appropriate to maintain equality between the Capital Accounts of
the Members and the amount of capital reflected on the Joint Sales Company's
balance sheet, as computed for book purposes, in accordance with Regulations
Section 1.704-1(b)(2)(iv)(q), and (ii) make any appropriate modifications in the
event unanticipated events might otherwise cause this Agreement not to comply
with Regulations Section 1.704-1(b).

     "CAPITAL CONTRIBUTIONS" means, with respect to any Member, the amount of
money and the initial Gross Asset Value of any Property (other than money)
contributed to the Joint Sales Company with respect to the Units in the Joint
Sales Company held or purchased by such Member, including Additional Capital
Contributions.

     "CERTIFICATE" means the certificate of formation filed with the Secretary
of State of the State of Delaware on the date hereof pursuant to the Act to form
the Company, as originally executed and amended, modified, supplemented or
restated from time to time, as the context requires.

     "CERTIFICATE OF CANCELLATION" means a certificate filed in accordance with
6 Del. C. section 18-203.

     "CHAIRMAN" means the Chairman of the Board of Directors of the Company.

     "CODE" means the United States Internal Revenue Code of 1986, as amended
from time to time.

     "COMMERCIAL ALLIANCE AGREEMENT" means the Commercial Alliance Agreement by
and between ADM Polymer Corporation, MBX and the Joint Sales Company, entered
into simultaneously herewith.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       7

<Page>

     "COMMERCIAL ALLIANCE AGREEMENTS" means this Agreement, the Commercial
Alliance Agreement, the ADM Polymer Corporation Manufacturing Agreement, the MBX
Formulation Agreement, the ADM Polymer Corporation Service Agreement, the MBX
Service Agreement and the Loan and Security Agreement.

     "COMPANY MINIMUM GAIN" has the same meaning as the term "Company Minimum
Gain" in Section 1.704-2(d) of the Regulations.

     "CONSTRUCT" shall have the meaning set forth in the Commercial Alliance
Agreement.

     "DAMAGES" shall have the meaning set forth in Section 11.1 hereof.

     "DEBT" means (i) any indebtedness for borrowed money or the deferred
purchase price of property as evidenced by a note, bonds, or other instruments,
(ii) obligations as lessee under capital leases, (iii) obligations secured by
any mortgage, pledge, security interest, encumbrance, lien or charge of any kind
existing on any asset owned or held by the Company whether or not the Company
has assumed or become liable for the obligations secured thereby, (iv) any
obligation under any interest rate swap agreement, (v) accounts payable and (vi)
obligations under direct or indirect guarantees of (including obligations
(contingent or otherwise) to assure a creditor against loss in respect of)
indebtedness or obligations of the kinds referred to in clauses (i), (ii),
(iii), (iv) and (v), above provided that Debt shall not include obligations in
respect of any accounts payable that are incurred in the ordinary course of the
Company's business and are not delinquent or are being contested in good faith
by appropriate proceedings.

     "DEFENDANT" shall have the meaning set forth in Section 12.11(b)(ii)
hereof.

     "DEPRECIATION" means, for each Allocation Year, an amount equal to the
depreciation, amortization, or other cost recovery deduction allowable for
federal income tax purposes with respect to an asset for such Allocation Year,
except that (x) with respect to any asset whose Gross Asset Value differs from
its adjusted tax basis for United States federal income tax purposes and which
difference is being eliminated by use of the "remedial method" defined by
section 1.704-3(d) of the Regulations, Depreciation for such Allocation Year
shall be the amount of book basis recovered for such Allocation Year under the
rules prescribed by section 1.704-3(d)(2) of the Regulations and (y) with
respect to any other asset whose Gross Asset Value differs from its adjusted
basis for federal income tax purposes at the beginning of such Allocation Year,
Depreciation shall be an amount which bears the same ratio to such beginning
Gross Asset Value as the federal income tax depreciation, amortization, or other
cost recovery deduction for such Allocation Year bears to such beginning
adjusted tax basis; PROVIDED, HOWEVER, that if the adjusted basis for federal
income tax purposes of an asset at the beginning of such Allocation Year is
zero, Depreciation shall be determined with reference to such beginning Gross
Asset Value using any reasonable method selected by the Board of Directors.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       8

<Page>

     "DIRECTOR" means any of the individuals elected by the Members to serve on
the Board of Directors and "DIRECTORS" means all of such individuals. Directors
shall be "managers" within the meaning of the Act.

     "DISSOLUTION EVENT" shall have the meaning set forth in Section 12.1
hereof.

     "EFFECTIVE DATE" means the date first set forth above as the effective date
hereof.

     "ELECTION NOTICE" shall have the meaning set forth in Section 11.2(a)
hereof.

     "ELECTION PERIOD" shall have the meaning set forth in Section 11.2(b)
hereof.

     "EQUALIZATION DATE" means the first Business Day after the First Commercial
Sale that the Ledger Account is reduced to zero.

     "EQUALIZATION DISTRIBUTION DATE" means a date not more than thirty (30)
days following the end of each Fiscal Quarter during the Equalization Period.

     "EQUALIZATION PAYMENT" means on any Equalization Distribution Date on which
both MBX and ADM Polymer Corporation (or a Wholly Owned Affiliate of MBX or ADM
Polymer Corporation) are Members of the Joint Sales Company, an amount equal to
the following (without duplication):

               (i)  with respect to MBX, the sum of (a) the amount, if any, by
                    which payments to ADM Polymer Corporation of ADM Polymer
                    Corporation Margin under the ADM Polymer Corporation
                    Manufacturing Agreement during the Equalization Period
                    exceed the sum of royalty payments to MBX under the
                    Commercial Alliance Agreement, payments to MBX pursuant to
                    Section 4.3.6 of the Commercial Alliance Agreement, and MBX
                    Margin under the MBX Formulation Agreement, plus (b) MBX
                    Equalization Payments relating to prior Equalization Periods
                    that were not paid on account of insufficient Available
                    Cash, if any; and

               (ii) with respect to ADM Polymer Corporation, the sum of (a) the
                    amount, if any, by which the sum of royalty payments to MBX
                    under the Commercial Alliance Agreement, payments to MBX
                    pursuant to Section 4.3.6 of the Commercial Alliance
                    Agreement, and MBX Margin under the MBX Formulation
                    Agreement exceed payments to ADM Polymer Corporation of ADM
                    Polymer Corporation Margin under the ADM Polymer Corporation
                    Manufacturing Agreement during the Equalization Period, plus
                    (b) ADM Polymer Corporation's Equalization Payments relating
                    to prior Equalization Periods that were not paid on account
                    of insufficient Available Cash, if any.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       9

<Page>

     Amounts payable as Equalization Payments shall be treated as guaranteed
payments within the meaning of Code Section 707(c), shall be considered an
expense of the Joint Sales Company for income tax purposes and an expense or
capital item for financial reporting purposes, as the case may be, and shall not
be considered a distribution of money that would reduce the Capital Account of
the Member to which such distribution is made. In the event Equalization
Payments are due and owing to MBX and ADM Polymer Corporation on any
Equalization Payment Date that there is insufficient Available Cash to pay all
then owing Equalization Payments, Equalization Payments shall be made to MBX and
ADM Polymer Corporation pro rata based on the amount each is owed, respectively,
as a percentage of the total amount owed to both of MBX and ADM Polymer
Corporation.

     "EQUALIZATION PERIOD" means in the case of (i) the first Equalization
Payment, the period from the Equalization Date to the Business Day immediately
preceding the first Equalization Distribution Date, or (ii) in the case of any
subsequent Equalization Payment, the period from the last Equalization
Distribution Date through the Business Day immediately preceding the pending
Equalization Distribution Date.

     "FIRM OFFER" shall have the meaning set forth in Section 10.4(a) hereof.

     "FIRST COMMERCIAL SALE" shall have the meaning set forth in the Commercial
Alliance Agreement.

     "FISCAL QUARTER" means (i) the period commencing on the Effective Date and
ending on September 30, 2006, (ii) any subsequent three-month period commencing
on each of July 1, October 1, January 1 and April 1 and ending on the last date
before the next such date and (iii) the period commencing on the immediately
preceding January 1, April 1, July 1, or October 1, as the case may be, and
ending on the date on which all Property is distributed to the Members pursuant
to Section 12 hereof.

     "FISCAL YEAR" means (i) the period commencing on the Effective Date and
ending on December 31, 2006, (ii) any subsequent twelve-month period commencing
on January 1st and ending on December 31st and (iii) the period commencing on
the immediately preceding January 1st and ending on the date on which all
Property is distributed to the Members pursuant to Section 12 hereof; provided,
however, that the Fiscal Year shall meet the requirements of Code Section 706.

     "GAAP" means generally accepted accounting principles in effect in the
United States of America from time to time.

     "GROSS ASSET VALUE" means with respect to any asset, the asset's adjusted
basis for federal income tax purposes, except as follows:

               (i) The initial Gross Asset Value of any asset contributed by a
          Member to the Company shall be the gross fair market value of such
          asset, as determined by the Board of Directors PROVIDED that the
          initial Gross Asset

*    CONFIDENTIAL TREATMENT REQUESTED

                                       10

<Page>

          Values of the assets contributed to the Company pursuant to Section
          2.1 hereof shall be as set forth in such section;

               (ii) The Gross Asset Values of all Company assets shall be
          adjusted to equal their respective gross fair market values (taking
          Code Section 7701(g) into account), as determined by the Board of
          Directors as of the following times: (A) the acquisition of an
          additional interest in the Company by any new or existing Member in
          exchange for more than a de minimis Capital Contribution; (B) the
          distribution by the Company to a Member of more than a de minimis
          amount of Company property as consideration for an interest in the
          Company; and (C) the liquidation of the Company within the meaning of
          Regulations Section 1.704-1(b)(2)(ii)(g), PROVIDED that an adjustment
          described in clauses (A) and (B) of this paragraph shall be made only
          if the Board of Directors reasonably determines that such adjustment
          is necessary to reflect the relative economic interests of the Members
          in the Company;

               (iii) The Gross Asset Value of any item of Company assets
          distributed to any Member shall be adjusted to equal the gross fair
          market value (taking Code Section 7701(g) into account) of such asset
          on the date of distribution as determined by the Board of Directors;
          and

               (iv) The Gross Asset Values of Company assets shall be increased
          (or decreased) to reflect any adjustments to the adjusted basis of
          such assets pursuant to Code Section 734(b) or Code Section 743(b),
          but only to the extent that such adjustments are taken into account in
          determining Capital Accounts pursuant to Regulations Section
          1.704-1(b)(2)(iv)(m) and subparagraph (vi) of the definition of
          "PROFITS" and "LOSSES" or Section 3.3(c) hereof; provided, however,
          that Gross Asset Values shall not be adjusted pursuant to this
          subparagraph (iv) to the extent that an adjustment pursuant to
          subparagraph (ii) is required in connection with a transaction that
          would otherwise result in an adjustment pursuant to this subparagraph
          (iv).

If the Gross Asset Value of an asset has been determined or adjusted pursuant to
subparagraph (ii) or (iv), such Gross Asset Value shall thereafter be adjusted
by the Depreciation taken into account with respect to such asset, for purposes
of computing Profits and Losses.

     "JOINT SALES COMPANY" means the limited liability company formed pursuant
to this Agreement and the Certificate and the limited liability company
continuing the business of this Joint Sales Company in the event of dissolution
of the Joint Sales Company as herein provided.

     "LEDGER ACCOUNT" means with respect to ADM Polymer Corporation, the Ledger
Account maintained for the purpose of determining certain rights and obligations
of ADM Polymer Corporation, MBX and the Joint Sales Company pursuant to this
Agreement and the other Commercial Alliance Agreements, all in accordance with
the following provisions:

*    CONFIDENTIAL TREATMENT REQUESTED

                                       11

<Page>

               (i) To ADM Polymer Corporation's Ledger Account there shall be
          credited (A) the cost incurred by ADM Polymer Corporation to Construct
          the ADM Polymer Corporation Manufacturing Facility, as approved by the
          Steering Committee pursuant to Section 4.2.5 of the Commercial
          Alliance Agreement, (B) other capital expenditures funded by ADM
          Polymer Corporation and approved for application as a credit against
          the Ledger Account by the Steering Committee, and (C) any negative Net
          Cash Flow funded by ADM Polymer Corporation;

               (ii) To ADM Polymer Corporation's Ledger Account there shall be
          debited (A) the cost incurred by MBX to Construct the MBX Formulation
          Facility, as approved by the Steering Committee pursuant to Section
          4.3.5 of the Commercial Alliance Agreement, (B) other capital
          expenditures funded by MBX and approved for application as a debit
          against the Ledger Account by the Steering Committee, and (C) Net Cash
          Flow distributed to ADM Polymer Corporation pursuant to Section 4.1.

     "LETTER OF INTENT" means a binding or non-binding letter of intent between
a Seller and a Third-Party Transferee regarding the sale of Offered Units
entered into after the Offer Period.

     "LICENSE FEE" has the meaning assigned to the term "License Fee" in the
Commercial Alliance Agreement.

     "LIQUIDATION PERIOD" has the meaning set forth in Section 12.7 hereof.

     "LIQUIDATOR" has the meaning set forth in Section 12.9(a) hereof.

     "LOAN AND SECURITY AGREEMENT" means the Loan and Security Agreement by and
between ADM Polymer Corporation and the Joint Sales Company entered into
simultaneously herewith.

     "LOSSES" has the meaning set forth in the definition of "PROFITS" and
"LOSSES."

     "MARKETING AND SALES MANAGER" means the Marketing and Sales Manager of the
Joint Sales Company.

     "MBX FORMULATION AGREEMENT" means the Formulation Agreement by and between
MBX and the Joint Sales Company entered into simultaneously herewith.

     "MBX FORMULATION FACILITY" means the facility constructed by MBX, pursuant
to the Commercial Alliance Agreement, to produce PHA Formulations pursuant to
the MBX Formulation Agreement

     "MBX MARGIN" has the meaning assigned to the term "Formulation Margin" in
the MBX Formulation Agreement.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       12

<Page>

     "MEMBER" means any Person (i) who is referred to as such on Exhibit A to
this Agreement, or who has become a substituted Member pursuant to the terms of
this Agreement and (ii) who has not ceased to be a Member. "Members" means all
such Persons.

     "MEMBER NONRECOURSE DEBT" has the same meaning as the term "Member
nonrecourse debt" in Section 1.704-2(b)(4) of the Regulations.

     "MEMBER NONRECOURSE DEBT MINIMUM GAIN" means an amount, with respect to
each Member Nonrecourse Debt, equal to the Company Minimum Gain that would
result if such Member Nonrecourse Debt were treated as a Nonrecourse Liability,
determined in accordance with Section 1.704-2(i)(3) of the Regulations.

     "MEMBER NONRECOURSE DEDUCTIONS" has the same meaning as the term "Member
nonrecourse deductions" in Sections 1.704-2(i)(1) and 1.704-2(i)(2) of the
Regulations.

     "MBX" means Metabolix, Inc.

     "MBX SERVICES AGREEMENT" means an agreement entitled MBX Services Agreement
between MBX and the Joint Sales Company entered into simultaneously herewith.

     "NET CASH FLOW" means the gross cash proceeds of the Joint Sales Company
less the portion thereof used to pay or establish reserves for all Joint Sales
Company expenses, debt payments, capital improvements, replacements, and
contingencies, all as determined by a unanimous vote of the Board of Directors.
"NET CASH FLOW" shall not be reduced by depreciation, amortization, cost
recovery deductions, or similar allowances, but shall be increased by any
reductions of reserves previously established pursuant to the first sentence of
this definition.

     "NONRECOURSE DEDUCTIONS" has the meaning set forth in Section 1.704-2(b)(1)
of the Regulations.

     "NONRECOURSE LIABILITY" has the meaning set forth in Section 1.704-2(b)(3)
of the Regulations.

     "OFFEREE" shall have the meaning set forth in Section 10.4 hereof.

     "OFFEROR" shall have the meaning set forth in Section 10.4(b) hereof.

     "OFFER NOTICE" shall have the meaning set forth in Section 10.4(a) hereof.

     "OFFER PERIOD" shall have the meaning set forth in Section 10.4(d) hereof.

     "OFFER PRICE" shall have the meaning set forth in Section 10.4(c) hereof.

     "OFFERED UNITS" shall have the meaning set forth in Section 10.4 hereof.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       13

<Page>

     "OFFICERS" means the Marketing and Sales Manager, the Assistant Marketing
and Sales Manager, the Treasurer and the Secretary together with such other
officers of the Joint Sales Company the Board of Directors may designate. An
"Officer" means one of the above.

     "PARENT" means with respect to a Member, any Person "controlling" such
Member and not "controlled" by any other Person, as such terms within quotation
marks are defined within the definition of Affiliate herein.

     "PERCENTAGE INTEREST" means, with respect to any Member as of any date, the
ratio (expressed as a percentage) of the number of Units held by such Member on
such date to the aggregate Units held by all Members on such date. The
Percentage Interest of each Member immediately after the Effective Date is set
forth in Section 2.1 hereof.

     "PERMITTED TRANSFER" has the meaning set forth in Section 10.2 hereof.

     "PERSON" means any individual, partnership (whether general or limited),
limited liability company, corporation, trust, estate, association, nominee or
other entity.

     "PHA FORMULATIONS" shall have the meaning set forth in the Commercial
Alliance Agreement.

     "PHA MATERIAL" shall have the meaning set forth in the Commercial Alliance
Agreement.

     "PRELIMINARY NEGOTIATIONS" shall mean all negotiations between a Seller and
a Third-Party Transferee occurring prior to the time that the Seller and
Third-Party Transferee have entered into a Letter of Intent.

     "PROFITS" and "LOSSES" mean, for each Allocation Year, an amount equal to
the Joint Sales Company's taxable income or loss, as the case may be, for such
Allocation Year, determined in accordance with Code Section 703(a) (for this
purpose, all items of income, gain, loss, or deduction required to be stated
separately pursuant to Code Section 703(a)(1) shall be included in taxable
income or loss), with the following adjustments (without duplication):

               (i) Any income of the Joint Sales Company that is exempt from
          federal income tax and not otherwise taken into account in computing
          Profits or Losses pursuant to this definition of "PROFITS" and
          "LOSSES" shall be added to such taxable income or loss;

               (ii) Any expenditures of the Joint Sales Company described in
          Code Section 705(a)(2)(B) or treated as Code Section 705(a)(2)(B)
          expenditures pursuant to Regulations Section 1.704-1(b)(2)(iv)(i), and
          not otherwise taken into account in computing Profits or Losses
          pursuant to this definition of "Profits" and "Losses" shall be
          subtracted from such taxable income or loss;

*    CONFIDENTIAL TREATMENT REQUESTED

                                       14

<Page>

               (iii) In the event the Gross Asset Value of any Joint Sales
          Company asset is adjusted pursuant to subparagraphs (ii) or (iii) of
          the definition of Gross Asset Value, the amount of such adjustment
          shall be treated as an item of gain (if the adjustment increases the
          Gross Asset Value of the asset) or an item of loss (if the adjustment
          decreases the Gross Asset Value of the asset) from the disposition of
          such asset and shall be taken into account for purposes of computing
          Profits or Losses;

               (iv) Gain or loss resulting from any disposition of Property with
          respect to which gain or loss is recognized for federal income tax
          purposes shall be computed by reference to the Gross Asset Value of
          the Property disposed of, notwithstanding that the adjusted tax basis
          of such Property differs from its Gross Asset Value;

               (v) In lieu of the depreciation, amortization, and other cost
          recovery deductions taken into account in computing such taxable
          income or loss, there shall be taken into account Depreciation for
          such Allocation Year, computed in accordance with the definition of
          Depreciation;

               (vi) To the extent an adjustment to the adjusted tax basis of any
          Joint Sales Company asset pursuant to Code Section 734(b) is required,
          pursuant to Regulations Section 1.704-1(b)(2)(iv)(m)(4), to be taken
          into account in determining Capital Accounts as a result of a
          distribution other than in liquidation of a Member's interest in the
          Joint Sales Company, the amount of such adjustment shall be treated as
          an item of gain (if the adjustment increases the basis of the asset)
          or loss (if the adjustment decreases such basis) from the disposition
          of such asset and shall be taken into account for purposes of
          computing Profits or Losses; and

               (vii) Notwithstanding any other provision of this definition, any
          items which are specially allocated pursuant to Section 3.3 or Section
          3.4 hereof shall not be taken into account in computing Profits or
          Losses.

     The amounts of the items of Joint Sales Company income, gain, loss or
deduction available to be specially allocated pursuant to Sections 3.3 and 3.4
hereof shall be determined by applying rules analogous to those set forth in
subparagraphs (i) through (vi) above.

     "PROMISSORY NOTE" means the Promissory Note made by the Joint Sales Company
to the order of ADM Polymer Corporation entered into simultaneously herewith.

     "PROPERTY" means all real and personal property acquired by the Joint Sales
Company, including cash, and any improvements thereto, and shall include both
tangible and intangible property.

     "PURCHASE OFFER" shall have the meaning set forth in Section 10.4(b)
hereof.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       15

<Page>

     "PURCHASER" shall have the meaning set forth in Section 10.4(a) hereof.

     "RECONSTITUTION PERIOD" has the meaning set forth in Section 12.1(b)
hereof.

     "REGULATIONS" means the Income Tax Regulations, including Temporary
Regulations, promulgated under the Code, as such regulations are amended from
time to time.

     "REGULATORY ALLOCATIONS" has the meaning set forth in Section 3.4 hereof.

     "SECRETARY" means the Secretary of the Joint Sales Company.

     "SELLER" shall have the meaning set forth in Section 10.4 hereof.

     "SECURITIES ACT" means the Securities Act of 1933, as amended.

     "STEERING COMMITTEE" shall have the meaning set forth in the Commercial
Alliance Agreement.

     "TAX MATTERS MEMBER" has the meaning set forth in Section 8.3(a) hereof.

     "TECHNOLOGY ALLIANCE AGREEMENT" means the Technology Alliance Agreement by
and between ADM Polymer Corporation and MBX entered into November 3, 2004.

     "TECHNOLOGY MANAGER" means the Technology Manager of the Joint Sales
Company.

     "THIRD-PARTY TRANSFEREE" shall have the meaning set forth in Section
10.4(i) hereof.

     "TRANSFER" means, as a noun, any voluntary or involuntary transfer, sale,
pledge or hypothecation or other disposition and, as a verb, voluntarily or
involuntarily to transfer, sell, pledge or hypothecate or otherwise dispose of.

     "TRANSFER OFFER" shall have the meaning set forth in Section 10.4(c)
hereof.

     "TREASURER" means the Treasurer of the Joint Sales Company.

     "UNITS" or "UNIT" means an ownership interest in the Joint Sales Company
represented by a certificate in the form of Exhibit B attached hereto and
bearing the legend required by Section 10.9 hereof, representing a Capital
Contribution of *, including the Voting Percentage noted on the certificate
therefor as well as any and all benefits to which the holder of such Units may
be entitled as provided in this Agreement, together with all obligations of such
Person to comply with the terms and provisions of this Agreement.

     "UNSOLICITED OFFER" shall have the meaning set forth in Section 10.4(b)
hereof.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       16

<Page>

     "VOTING PERCENTAGE" means the percentage set opposite each Member's name in
Section 2.1, and unless otherwise explicitly set forth herein to the contrary,
any matters requiring the Members to vote, approve, or take any other action
shall be determined by a majority in Voting Percentage of the Members.

     "WHOLLY OWNED AFFILIATE" of any Person means (i) an Affiliate of such
Person, one hundred percent (100%) of the voting stock or beneficial ownership
of which is owned by such Person, either directly or indirectly; (ii) an
Affiliate of such Person, and such Affiliate owns one hundred percent (100%) of
the voting stock or beneficial ownership of such Person, either directly or
indirectly; or (iii) an Affiliate of such Person, where a Person owns one
hundred percent (100%) of the voting stock or beneficial ownership of such
Affiliate and such Person, either directly or indirectly.

                    SECTION 2: MEMBERS' CAPITAL CONTRIBUTIONS

          2.1 ORIGINAL CAPITAL CONTRIBUTIONS.

     The name, address, original Capital Contribution, and initial Percentage
Interest of each of the Members is as follows:

                                Original Capital         Percentage     Voting
Names and Address                 Contribution            Interest    Percentage
-----------------------   ----------------------------   ----------   ----------
Metabolix Inc.            The property described             50%          50%
21 Erie Street            in Exhibit A attached hereto
Cambridge, MA 02139

ADM Polymer Corporation   The property described             50%          50%
4666 Faries Parkway       in Exhibit A attached hereto
Decatur, Illinois 62526

          2.2 CONTRIBUTIONS.

          Pursuant to Section 2.1 hereof, each Member agrees to contribute to
the Joint Sales Company on the date hereof, the amount of money or the property
set opposite such Member's name on the attached Exhibit A.

          2.3 ADDITIONAL CAPITAL CONTRIBUTIONS.

          A Member may make Additional Capital Contributions only with the
written consent of all Members, in which event the Joint Sales Company shall
issue to the contributing Member additional Units of an amount to be unanimously
agreed by the Members.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       17

<Page>

                             SECTION 3: ALLOCATIONS

          3.1 PROFITS.

          After giving effect to the special allocations set forth in Sections
3.3 and 3.4, Profits for any Allocation Year on or prior to the Equalization
Date shall be allocated to ADM Polymer Corporation, and Profits for any
Allocation Year after the Equalization Date shall be allocated to the Members in
proportion to their Percentage Interests.

          3.2 LOSSES.

          After giving effect to the special allocations set forth in Sections
3.3 and 3.4 and subject to Section 3.5, Losses for any Allocation Year on or
prior to the Equalization Date shall be allocated to ADM Polymer Corporation,
and Losses for any Allocation Year after the Equalization Date shall be
allocated to the Members in proportion to their Percentage Interests.

          3.3 SPECIAL ALLOCATIONS.

          The following special allocations shall be made in the following
order:

          (a) MINIMUM GAIN CHARGEBACK. Except as otherwise provided in Section
1.704-2(f) of the Regulations, notwithstanding any other provision of this
Section 3, if there is a net decrease in Company Minimum Gain during any
Allocation Year, each Member shall be specially allocated items of Joint Sales
Company income and gain for such Allocation Year (and, if necessary, subsequent
Allocation Years) in an amount equal to such Member's share of the net decrease
in Company Minimum Gain, determined in accordance with Regulations Section
1.704-2(g). Allocations pursuant to the previous sentence shall be made in
proportion to the respective amounts required to be allocated to each Member
pursuant thereto. The items to be so allocated shall be determined in accordance
with sections 1.704-2(f) (6) and 1.704-2(j) (2) of the Regulations. This Section
3.3(a) is intended to comply with the minimum gain chargeback requirement in
Section 1.704-2(f) of the Regulations and shall be interpreted consistently
therewith.

          (b) MEMBER MINIMUM GAIN CHARGEBACK. Except as otherwise provided in
Section 1.704-2(i) (4) of the Regulations, notwithstanding any other provision
of this Section 3, if there is a net decrease in Member Nonrecourse Debt Minimum
Gain attributable to a Member Nonrecourse Debt during any Allocation Year, each
Member who has a share of the Member Nonrecourse Debt Minimum Gain attributable
to such Member Nonrecourse Debt, determined in accordance with Section
1.704-2(i) (5) of the Regulations, shall be specially allocated items of Joint
Sales Company income and gain for such Allocation Year (and, if necessary,
subsequent Allocation Years) in an amount equal to such Member's share of the
net decrease in Member Nonrecourse Debt, determined in accordance with
Regulations Section 1.704-2(i) (4). Allocations pursuant to the previous
sentence shall be made in proportion to the respective amounts required to be
allocated to each Member pursuant thereto. The items to be so allocated shall be
determined in accordance with Sections 1.704-2(i) (4) and 1.704-2(j) (2) of the
Regulations. This Section 3.3(b) is intended to comply with the minimum gain

*    CONFIDENTIAL TREATMENT REQUESTED

                                       18

<Page>

chargeback requirement in Section 1.704-2(i) (4) of the Regulations and shall be
interpreted consistently therewith.

          (c) QUALIFIED INCOME OFFSET. In the event any Member unexpectedly
receives any adjustments, allocations, or distributions described in Sections
1.704-1(b)(2)(ii)(d)(4), 1.704-1(b)(2)(ii)(d)(5), or 1.704-1(b)(2)(ii)(d)(6) of
the Regulations, items of Joint Sales Company income and gain shall be specially
allocated to such Member in an amount and manner sufficient to eliminate, to the
extent required by the Regulations, the Adjusted Capital Account Deficit of the
Member as quickly as possible, provided that an allocation pursuant to this
Section 3.3(c) shall be made only if and to the extent that the Member would
have an Adjusted Capital Account Deficit after all other allocations provided
for in this Section 3 have been tentatively made as if this Section 3.3(c) were
not in the Agreement.

          (d) GROSS INCOME ALLOCATION. In the event any Member has a deficit
Capital Account at the end of any Allocation Year which is in excess of the sum
of (i) the amount such Member is obligated to restore pursuant to the
penultimate sentences of Regulations Sections 1.704-2(g)(1) and 1.704-2(i)(5),
each such Member shall be specially allocated items of Joint Sales Company
income and gain in the amount of such excess as quickly as possible, provided
that an allocation pursuant to this Section 3.3(d) shall be made only if and to
the extent that such Member would have a deficit Capital Account in excess of
such sum after all other allocations provided for in this Section 3 have been
made as if Section 3.3(c) and this Section 3.3(d) were not in the Agreement.

          (e) NONRECOURSE DEDUCTIONS. Nonrecourse Deductions for any Allocation
Year shall be specially allocated to the Members in proportion to their
respective Percentage Interests.

          (f) MEMBER NONRECOURSE DEDUCTIONS. Any Member Nonrecourse Deductions
for any Allocation Year shall be specially allocated to the Member who bears the
economic risk of loss with respect to the Member Nonrecourse Debt to which such
Member Nonrecourse Deductions are attributable in accordance with Regulations
Section 1.704-2(i)(1).

          (g) SECTION 754 ADJUSTMENTS. To the extent an adjustment to the
adjusted tax basis of any Joint Sales Company asset, pursuant to Code Section
734(b) or Code Section 743(b) is required, pursuant to Regulations Section
1.704-1(b)(2)(iv)(m)(2) or 1.704-1(b)(2)(iv)(m)(4), to be taken into account in
determining Capital Accounts as the result of a distribution to a Member in
complete liquidation of such Member's interest in the Joint Sales Company, the
amount of such adjustment to Capital Accounts shall be treated as an item of
gain (if the adjustment increases the basis of the asset) or loss (if the
adjustment decreases such basis) and such gain or loss shall be specially
allocated to the Members in accordance with their interests in the Joint Sales
Company in the event Regulations Section 1.704-1(b)(2)(iv)(m)(2) applies, or to
the Member to whom such distribution was made in the event Regulations Section
1.704-1(b)(2)(iv)(m)(4) applies.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       19

<Page>

          3.4 CURATIVE ALLOCATIONS.

          The allocations set forth in Sections 3.3(a), 3.3(b), 3.3(c), 3.3(d),
3.3(e), 3.3(f), 3.3(g) and 3.5 (the "REGULATORY ALLOCATIONS") are intended to
comply with certain requirements of the Regulations. It is the intent of the
Members that, to the extent possible, all Regulatory Allocations shall be offset
either with other Regulatory Allocations or with special allocations of other
items of Joint Sales Company income, gain, loss or deduction pursuant to this
Section 3.4. Therefore, notwithstanding any other provision of this Section 3
(other than the Regulatory Allocations), the Board of Directors may make with
the unanimous approval of the Board of Directors such offsetting special
allocations of Joint Sales Company income, gain, loss or deduction in whatever
manner it determines appropriate so that, after such offsetting allocations are
made, each Member's Capital Account balance is, to the extent possible, equal to
the Capital Account balance such Member would have had if the Regulatory
Allocations were not part of the Agreement and all Joint Sales Company items
were allocated pursuant to Sections 3.1 and 3.2.

          3.5 LOSS LIMITATION.

          Losses allocated pursuant to Section 3.2 hereof shall not exceed the
maximum amount of Losses that can be allocated without causing any Member to
have an Adjusted Capital Account Deficit at the end of any Allocation Year. In
the event some but not all of the Members would have Adjusted Capital Account
Deficits as a consequence of an allocation of Losses pursuant to Section 3.2
hereof, the limitation set forth in this Section 3.5 shall be applied on a
Member by Member basis and Losses not allocable to any Member as a result of
such limitation shall be allocated to the other Members in accordance with the
positive balances in such Member's Capital Accounts so as to allocate the
maximum permissible Losses to each Member under Section 1.704-1(b)(2)(ii)(d) of
the Regulations.

          3.6 OTHER ALLOCATION RULES.

          (a) For purposes of determining the Profits, Losses, or any other
items allocable to any period, Profits, Losses, and any such other items shall
be determined on a daily, monthly, or other basis, as determined by the Board of
Directors using any permissible method under Code Section 706 and the
Regulations thereunder.

          (b) The Members are aware of the income tax consequences of the
allocations made by this Section 3 and hereby agree to be bound by the
provisions of this Section 3 in reporting their shares of Joint Sales Company
income and loss for income tax purposes.

          (c) Solely for purposes of determining a Member's proportionate share
of the "excess nonrecourse liabilities" of the Joint Sales Company within the
meaning of Regulations Section 1.752-3(a) (3), the Members' interests in Joint
Sales Company profits are in proportion to their Percentage Interests.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       20

<Page>

          To the extent permitted by Section 1.704-2(h) (3) of the Regulations,
the Directors shall endeavor to treat distributions of Net Cash Flow as having
been made from the proceeds of a Nonrecourse Liability or a Member Nonrecourse
Debt only to the extent that such distributions would not cause or increase an
Adjusted Capital Account Deficit for any Member.

          3.7 TAX ALLOCATIONS: CODE SECTION 704(c).

          In accordance with Code Section 704(c) and the Regulations thereunder,
income, gain, loss, and deduction with respect to any Property contributed to
the capital of the Joint Sales Company shall, solely for tax purposes, be
allocated among the Members so as to take account of any variation between the
adjusted basis of such Property to the Joint Sales Company for federal income
tax purposes and its initial Gross Asset Value (computed in accordance with the
definition of Gross Asset Value) using the remedial method to the Regulations
under Code Section 704(c).

          In the event the Gross Asset Value of any Joint Sales Company asset is
adjusted pursuant to subparagraph (ii) of the definition of Gross Asset Value,
subsequent allocations of income, gain, loss, and deduction with respect to such
asset shall take account of any variation between the adjusted basis of such
asset for federal income tax purposes and its Gross Asset Value in the same
manner as under Code Section 704(c) and the Regulations thereunder.

          Any elections or other decisions relating to such allocations shall be
made by the Board of Directors in any manner that reasonably reflects the
purpose and intention of this Agreement. Allocations pursuant to this Section
3.6 are solely for purposes of federal, state, and local taxes and shall not
affect, or in any way be taken into account in computing, any Member's Capital
Account or share of Profits, Losses, other items, or distributions pursuant to
any provision of this Agreement.

                            SECTION 4: DISTRIBUTIONS

          4.1 NET CASH FLOW.

          Except as otherwise provided in Section 12 hereof, on or prior to the
Equalization Date, Net Cash Flow, if any, shall be distributed not later than
the thirtieth day after the end of each Fiscal Quarter to ADM Polymer
Corporation. Except as otherwise provided in Section 12 hereof or by the Board
of Directors, after the Equalization Date, Net Cash Flow, if any, shall be
distributed not later than the thirtieth day after the end of each Fiscal
Quarter to the Members following the Equalization Payments, if any, described in
Section 6.13 hereof, in proportion to their Percentage Interests.

          4.2 AMOUNTS WITHHELD.

          All amounts withheld pursuant to the Code or any provision of any
state, local or foreign tax law with respect to any payment, distribution or
allocation to the Joint Sales Company or the Members shall be treated as amounts
paid or distributed, as the case may be,

*    CONFIDENTIAL TREATMENT REQUESTED

                                       21

<Page>

to the Members with respect to which such amount was withheld pursuant to this
Section 4.2 for all purposes under this Agreement. The Joint Sales Company is
authorized to withhold from payments and distributions, or with respect to
allocations to the Members, and to pay over to any federal, state and local
government or any foreign government, any amounts required to be so withheld
pursuant to the Code or any provisions of any other federal, state or local law
or any foreign law, and shall allocate any such amounts to the Members with
respect to which such amount was withheld.

          4.3 [RESERVED]

          4.4 LIMITATIONS ON DISTRIBUTIONS.

          (a) The Joint Sales Company shall make no distributions to the Members
except (i) as provided in this Section 4 and Section 12 hereof, or (ii) as
agreed to by all of the Members.

          (b) A Member may not receive a distribution from the Joint Sales
Company to the extent that, such distribution would violate Sections 18-607 or
18-804 of the Act.

                              SECTION 5: MANAGEMENT

          5.1 DIRECTORS; BOARD OF DIRECTORS.

          (a) The management of the Joint Sales Company shall be vested in the
Board of Directors (the "BOARD OF DIRECTORS") designated by the Members as
provided in Section 5.1(c) hereof.

          (b) The number of Directors on the Board of Directors shall be four
(4). The initial Directors of the Joint Sales Company shall be as set forth on
Exhibit C hereto.

          (c) A Director shall remain in office until removed by the Member
designating such Director. MBX shall designate two (2) Directors, and ADM
Polymer Corporation shall designate two (2) Directors. Members shall designate
Directors with respect to any Director other than the initial Directors listed
on Exhibit C hereto, by delivering to the Joint Sales Company their written
statement designating their Director or Directors and setting forth such
Director's or Directors' business address and telephone number. The Members, by
signing this Agreement, hereby designate the Persons identified on Exhibit C
hereto as Directors of the Joint Sales Company until their successors are
designated, each such Director being deemed designated by the Member set forth
opposite such Director indicated on Exhibit C hereto.

          (d) A Director may be removed at any time, with or without cause, by
the written notice of the Member that designated such Director, delivered to the
Joint Sales Company, demanding such removal and designating the Person who shall
fill the position of the removed Director.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       22

<Page>

          (e) If any Director dies, resigns or is otherwise unable to serve as
such or is removed from office by the Member that designated such Director, the
appropriate Member shall promptly designate a successor to such Director. A
Director chosen to fill a vacancy shall be designated by the Member whose
previously designated Director shall have been removed or shall have resigned.

          (f) Each Director shall have one (1) vote. Except as otherwise
provided in this Agreement, the Board of Directors shall act by the affirmative
vote of a majority of a quorum.

          (g) Each Director shall perform his duties as a Director in good
faith, in a manner he reasonably believes to be in the best interests of the
Joint Sales Company, and with such care as an ordinarily prudent person in a
like position would use under similar circumstances. A person who so performs
his duties shall not have any liability by reason of being or having been a
Director of the Joint Sales Company.

          (h) The Board of Directors shall have the power to delegate authority
to such committees of Directors, Officers, employees, agents and representatives
of the Joint Sales Company as it may from time to time deem appropriate in
accordance with Section 5.7 below. Any delegation of authority to take any
action must be approved in the same manner as would be required for the Board of
Directors to approve such action directly.

          (i) A Director shall not be liable under a judgment, decree or order
of court, or in any other manner, for a debt, obligation or liability of the
Joint Sales Company.

          (j) The Chairman shall be a Director and shall hold office for a
period of one Fiscal Year. The Chairman shall be appointed on an alternating
basis, first as directed in writing by ADM Polymer Corporation, and then as
directed in writing by MBX. The Chairman may be removed at any time, with or
without cause, by the written notice of the Member that designated such
Chairman, delivered to the Joint Sales Company, demanding such removal and
designating the Person who shall fill the position of the removed Chairman. The
duties of the Chairman shall be to direct meetings of the Board of Directors.
The initial Chairman shall be as indicated on Exhibit C hereto.

     5.2 MEETINGS OF THE BOARD OF DIRECTORS.

          (a) The Board of Directors shall hold regular meetings no less
frequently than once every Fiscal Quarter and shall establish meeting times,
dates and places and requisite notice requirements (not shorter than those
provided in Section 5.2(b)) and adopt rules or procedures consistent with the
terms of this Agreement. Unless otherwise approved by the Board of Directors,
each regular meeting of the Board of Directors will be held at a location
specified on an alternating basis first, by those Directors designated by ADM
Polymer Corporation, next by those Directors designated by MBX, etc. for the
convenience of the Directors specifying the location. If the Directors
designated by a Member and having the right to specify the location do not so
specify, the meeting will be held at the Joint Sales

*    CONFIDENTIAL TREATMENT REQUESTED

                                       23

<Page>

Company's principal place of business. At such meetings the Board of Directors
shall transact such business as may properly be brought before the meeting,
whether or not notice of such meeting referenced the action taken at such
meeting. At all meetings of the Board of Directors, the participation of at
least one Director appointed by each of ADM Polymer Corporation and MBX shall
constitute a quorum. Each Director shall have one vote on all matters before the
Board of Directors; provided, however, that the Director appointed by each of
ADM Polymer Corporation and MBX present at any meeting shall have the authority
to cast the votes of any of such Party's appointed Directors who are absent from
the meeting. The act of a majority of the Directors present at any meeting at
which a quorum is present shall be the act of the Board of Directors, unless by
express provision of the Act, or of this Agreement, a different vote is
required, in which case such express provision shall govern and control. In the
absence of a quorum, a majority of the Directors present at any meeting may,
without notice other than announcement at the meeting, adjourn such meeting from
time to time until a quorum is present. A Director may appoint in writing an
alternate to act in such Director's absence at any meetings of the Board of
Directors.

          (b) Special meetings of the Board of Directors may be called by any
Director. Notice of each such meeting shall be given to each Director on the
Board of Directors by telephone, telecopy, telegram, or similar method, or sent
by first-class mail (in each case, notice shall be given at least three (3)
weeks before the time of the meeting, unless a longer notice period is
established by the Board of Directors). Each such notice shall state (i) the
time, date, place (which shall be at the principal office of a Member other than
the Member who designated the Director calling such meeting unless otherwise
agreed to by all Directors) or other means of conducting such meeting and (ii)
the purpose of the meeting to be so held. No actions other than those specified
in the notice may be considered at any special meeting unless unanimously
approved by the Directors. Any Director may waive notice of any meeting in
writing before, at, or after such meeting. The attendance of a Director at a
meeting shall constitute a waiver of notice of such meeting, except when a
Director attends a meeting for the express purpose of objecting, and does in
fact object, to the transaction of any business on grounds that the meeting was
not properly called.

          (c) Any action required to be taken at a meeting of the Board of
Directors, or any action that may be taken at a meeting of the Board of
Directors, may be taken at a meeting held by means of conference telephone or
other communications equipment by means of which all persons participating in
the meeting can hear each other. Participation in such a meeting shall
constitute presence in person at such meeting.

          (d) Notwithstanding anything to the contrary in this Section 5.2, the
Board of Directors may take without a meeting any action that may be taken by
the Board of Directors under this Agreement if such action is approved by the
unanimous written consent of the Directors.

     5.3 BOARD OF DIRECTORS POWERS.

          (a) Except as otherwise provided in this Agreement, all powers to
control and manage the Business and affairs of the Joint Sales Company shall be
exclusively vested in

*    CONFIDENTIAL TREATMENT REQUESTED

                                       24

<Page>

the Board of Directors and the Board of Directors may exercise all powers of the
Joint Sales Company and do all such lawful acts as are not by statute, the
Certificate or this Agreement directed or required to be exercised or done by
the Members and in so doing shall have the right and authority to take all
actions which the Board of Directors deems necessary, useful or appropriate for
the management and conduct of the Business, including exercising the following
specific rights and powers:

                    (i) Conduct its business, carry on its operations and have
          and exercise the powers granted by the Act in any state, territory,
          district or possession of the United States, or in any foreign country
          which may be necessary or convenient to effect any or all of the
          purposes for which it is organized;

                    (ii) Acquire by purchase, lease, or otherwise any real or
          personal property which may be necessary, convenient, or incidental to
          the accomplishment of the purposes of the Joint Sales Company;

                    (iii) Operate, maintain, finance, improve, construct, own,
          grant operations with respect to, sell, convey, assign, mortgage, and
          lease any real estate and any personal property necessary, convenient,
          or incidental to the accomplishment of the purposes of the Joint Sales
          Company;

                    (iv) Execute (but not to the exclusion of any Officer having
          such power) any and all agreements, contracts, documents,
          certifications, and instruments necessary or convenient in connection
          with the management, maintenance, and operation of the Business, or in
          connection with managing the affairs of the Joint Sales Company,
          including, executing amendments to this Agreement and the Certificate
          in accordance with the terms of this Agreement, both as Directors and,
          if required, as attorney-in-fact for the Members pursuant to any power
          of attorney granted by the Members to the Directors. Simultaneously
          with the execution of this Agreement, one or more of the Directors
          shall execute the Commercial Alliance Agreements on behalf of the
          Joint Sales Company;

                    (v) Borrow money and issue evidences of indebtedness
          necessary, convenient, or incidental to the accomplishment of the
          purposes of the Joint Sales Company, and secure the same by mortgage,
          pledge, or other lien on any Joint Sales Company assets;

                    (vi) Execute, in furtherance of any or all of the purposes
          of the Joint Sales Company, any deed, lease, mortgage, deed of trust,
          mortgage note, promissory note, bill of sale, contract, or other
          instrument purporting to convey or encumber any or all of the Joint
          Sales Company assets;

                    (vii) Prepay in whole or in part, refinance, recast,
          increase, modify, or extend any liabilities affecting the assets of
          the Joint Sales Company

*    CONFIDENTIAL TREATMENT REQUESTED

                                       25

<Page>

          and in connection therewith execute any extensions or renewals of
          encumbrances on any or all of such assets;

                    (viii) Manage and distribute funds to the Members by way of
          cash income, return of capital, or otherwise, all in accordance with
          the provisions of this Agreement, and perform all matters in
          furtherance of the objectives of the Joint Sales Company or this
          Agreement;

                    (ix) Contract on behalf of the Joint Sales Company for the
          employment and services or employees and/or independent contractors,
          such as lawyers and accountants, and delegate to such Persons the duty
          to manage or supervise any of the assets or operations of the Joint
          Sales Company;

                    (x) Engage in any kind of activity and perform and carry out
          contracts of any kind (including contracts of insurance covering risks
          to Joint Sales Company assets and Director liability) necessary or
          incidental to, or in connection with, the accomplishment of the
          purposes of the Joint Sales Company, as may be lawfully carried on or
          performed by a limited liability company under the laws of each state
          in which the Joint Sales Company is then formed or qualified;

                    (xi) Take, or refrain from taking, all actions, not
          expressly proscribed or limited by this Agreement, as may be necessary
          or appropriate to accomplish the purposes of the Joint Sales Company;

                    (xii) Institute, prosecute, defend, settle, compromise, and
          dismiss lawsuits or other judicial or administrative proceedings
          brought on or in behalf of, or against, the Joint Sales Company, the
          Members or any Director in connection with activities arising out of,
          connected with, or incidental to this Agreement, and to engage counsel
          or others in connection therewith;

                    (xiii) Purchase, take, receive, subscribe for or otherwise
          acquire, own, hold, vote, use, employ, sell, mortgage, lend, pledge,
          or otherwise dispose of, and otherwise use and deal in and with,
          shares or other interests in or obligations of domestic or foreign
          corporations, associations, general or limited partnerships, other
          limited liability companies, or individuals or direct or indirect
          obligations of the United States or of any government, state,
          territory, government district or municipality or of any
          instrumentality of any of them;

                    (xiv) Indemnify a Member or Director or former Member or
          Director, and to make any other indemnification that is authorized by
          this Agreement in accordance with the Act; provided the Board of
          Directors unanimously agrees on such indemnification.

          (b) The Board of Directors shall appoint and/or approve the Officers
in accordance with Section 5.7 and will establish policies and guidelines for
the hiring of

*    CONFIDENTIAL TREATMENT REQUESTED

                                       26

<Page>

employees to permit the Joint Sales Company to act as an operating company with
respect to its Business. The Board of Directors may adopt appropriate management
incentive plans and employee benefit plans. The Officers of the Joint Sales
Company shall be responsible for conducting, in the name of, and on behalf of,
the Joint Sales Company, the day-to-day business and affairs of the Joint Sales
Company.

     5.4 DUTIES AND OBLIGATIONS OF THE BOARD OF DIRECTORS.

          (a) The Board of Directors shall cause the Joint Sales Company to
conduct its business and operations separate and apart from that of any Member
or Director or any of its Affiliates, including, without limitation, (i)
segregating Joint Sales Company assets and not allowing funds or other assets of
the Joint Sales Company to be commingled with the funds or other assets of, held
by, or registered in the name of, any Member or Director or any of its
Affiliates, (ii) maintaining books and financial records of the Joint Sales
Company separate from the books and financial records of any Member or Director
and its Affiliates, and observing all Joint Sales Company procedures and
formalities, including, without limitation, maintaining minutes of Joint Sales
Company meetings and acting on behalf of the Joint Sales Company only pursuant
to due authorization of the Members, (iii) causing the Joint Sales Company to
pay its liabilities from assets of the Joint Sales Company, and (iv) causing the
Joint Sales Company to conduct its dealings with third parties in its own name
and as a separate and independent entity.

          (b) The Board of Directors shall take all actions which may be
necessary or appropriate (i) for the continuation of the Joint Sales Company's
valid existence as a limited liability company under the laws of the State of
Delaware and of each other jurisdiction in which such existence is necessary to
protect the limited liability of the Members or to enable the Joint Sales
Company to conduct the business in which it is engaged and (ii) for the
accomplishment of the Joint Sales Company's purposes, including the acquisition,
development, maintenance, preservation, and operation of Property in accordance
with the provisions of this Agreement and applicable laws and regulations.

          (c) It is expressly agreed by the Members that no Director shall be
liable to the Joint Sales Company or any Member for such Director's good faith
reliance on any provision of this Agreement.

     5.5 REIMBURSEMENTS.

          Except as otherwise provided in a Commercial Alliance Agreement, the
Members and Directors shall be reimbursed for certain expenditures as provided
herein. The Joint Sales Company shall reimburse the Members and Directors for
all expenses incurred and paid by any of them in the organization of the Joint
Sales Company and as authorized by the Joint Sales Company, in the conduct of
the Business, including, but not limited to, expenses of maintaining an office,
telephones, travel, office equipment and secretarial and other personnel as may
reasonably be attributable to the Joint Sales Company. Each Member that is party
to any contract or agreement with the Joint Sales Company (including but not
limited to the Commercial Alliance Agreements) shall be reimbursed amounts
specified or reimbursable

*    CONFIDENTIAL TREATMENT REQUESTED

                                       27

<Page>

thereunder pursuant to the terms thereof. Such expenses shall not include any
expenses incurred in connection with a Member's or Directors' exercise of its
rights as a Member or a Director apart from the authorized conduct of the
Business. The unanimous determination of the Board of Directors as to which
expenses are allocated to and reimbursed as a result of the Joint Sales
Company's activities or business and the amount of such expenses shall be
conclusive. Except as otherwise expressly provided herein, such reimbursement
shall be treated as expenses of the Joint Sales Company and shall not be deemed
to constitute distributions to any Member of profit, loss or capital of the
Joint Sales Company.

     5.6 INDEMNIFICATION OF THE DIRECTORS AND OFFICERS.

          (a) Unless otherwise provided in Section 5.6(d) hereof, the Joint
Sales Company, its receiver, or its trustee (in the case of its receiver or
trustee, to the extent of the Property) shall indemnify, save harmless, and pay
all judgments and claims against any Director or Officer relating to any
liability or damage incurred by reason *.

          (b) Unless otherwise provided in Section 5.6(d) hereof, in the event
of any *.

          (c) Unless otherwise provided in Section 5.6(d) hereof, the Joint
Sales Company shall *.

          (d) Notwithstanding the provisions of Sections 5.6(a), 5.6(b) and
5.6(c) above, such Sections shall be enforced only to the maximum extent
permitted by law and no Director or Officer shall be indemnified from any
liability for the fraud, intentional misconduct, gross negligence or a knowing
violation of the law which was material to the cause of action.

          (e) The obligations of the Joint Sales Company set forth in this
Section 5.6 are expressly intended to create third party beneficiary rights of
each of the Directors or Officers and any Member is authorized, on behalf of the
Joint Sales Company, to give written confirmation to any Director or Officer of
the existence and extent of the Joint Sales Company's obligations to such
Director or Officer hereunder.

     5.7 APPOINTMENT OF OFFICERS, AGENTS AND REPRESENTATIVES:

          (a) The Board of Directors shall appoint and remove persons from the
following offices, where indicated as directed by the appropriate Member:

                    (i) The Marketing and Sales Manager. The Marketing and Sales
          Manager shall be appointed as directed by MBX, subject to the approval
          of the Board of Directors. The Marketing and Sales Manager may be
          removed by the Board of Directors, only at the direction of MBX, and
          may be removed with or without cause. The duties of the Marketing and
          Sales Manager shall be to coordinate and manage the day to day
          Business of the Joint Sales Company as it relates to the marketing and
          sale of the Products. He shall consult

*    CONFIDENTIAL TREATMENT REQUESTED

                                       28

<Page>

          frequently and work closely with the Board of Directors to ensure that
          the Board of Directors is aware and approves of all significant
          actions taken by the Marketing and Sales Manager. The Marketing and
          Sales Manager shall not be a "manager" within the meaning of the Act;

                    (ii) The Assistant Marketing and Sales Manager. The
          Assistant Marketing and Sales Manager shall be appointed as directed
          by ADM Polymer Corporation, subject to the approval of the Board of
          Directors. The Assistant Marketing and Sales manager may be removed by
          the Board of Directors, only at the direction of ADM Polymer
          Corporation, and may be removed with or without cause. The duties of
          the Assistant Marketing and Sales manager shall be to assist the
          Marketing and Sales Manager in coordinating and managing the day to
          day Business of the Joint Sales Company as it relates to the marketing
          and sales of the Products. The Assistant Marketing and Sales Manager
          shall not be a "manager" within the meaning of the Act.

                    (iii) The Treasurer. The Treasurer shall be appointed as
          directed by ADM Polymer Corporation, subject to the approval of the
          Board of Directors. The Treasurer may be removed by the Board of
          Directors, only at the direction of ADM Polymer Corporation, and may
          be removed with or without cause. The Treasurer shall have custody of
          the Joint Sales Company's funds and shall keep full and accurate
          accounts of receipts and disbursements in books belonging to the Joint
          Sales Company and shall deposit or cause to be deposited moneys or
          other valuable effects in the name and to the credit of the Joint
          Sales Company in such depositories as may be designated by the Board
          of Directors. The Treasurer shall also maintain adequate records of
          all assets, liabilities, and transactions of the Joint Sales Company
          and shall see that adequate audits thereof are currently and regularly
          made. The Treasurer shall have such other powers and perform such
          other duties that generally are incident to the position of a
          treasurer of a corporation or as may from time to time be assigned to
          him or her by the Board of Directors.

                    (iv) The Secretary. The Secretary shall be appointed as
          directed first by ADM, subject to the approval of the Board of
          Directors, to serve commencing on the Effective Date and continuing to
          and including December 31 of the year of appointment. The Secretary
          shall thereafter be appointed to serve for a calendar year on an
          alternating basis as directed by MBX or ADM, commencing with MBX,
          subject to the approval of the Board of Directors. The Secretary may
          be removed by the Board of Directors, only at the direction of the
          Member making the appointment, and may be removed with or without
          cause. The Secretary shall attend meetings of the Board of Directors
          and meetings of the Members and record all votes and minutes of all
          such proceedings in a book kept for such purpose. He or she shall have
          all such further powers and duties as generally are incident to the
          position of a secretary

*    CONFIDENTIAL TREATMENT REQUESTED

                                       29

<Page>

          of a corporation or as may from time to time be assigned to him or her
          by the Board of Directors.

                    (v) Such other Officers as the Board of Directors deems
          necessary or desirable, upon such terms as the Board of Directors
          deems appropriate; provided, however, that such Officers may only be
          removed by the Board of Directors.

          (b) The Board of Directors or the Officers may appoint such agents and
representatives as they deem necessary or desirable, upon such terms as they
deem appropriate.

          (c) Except with respect to any matter as to which the Board of
Directors has authorized or directed an Officer, each Officer shall be under a
fiduciary duty to conduct the affairs of the Joint Sales Company in the best
interests of the Joint Sales Company, including the safekeeping and use of all
of the Property and the use thereof for the exclusive benefit of the Joint Sales
Company.

          (d) Except as otherwise provided in a Commercial Alliance Agreement,
the Joint Sales Company shall not enter into any contract without having the
written approval of both an Officer appointed by ADM Polymer Corporation and an
Officer appointed by MBX. Notwithstanding any other provision of this Agreement,
except as set forth in the Commercial Alliance Agreements, no action may be
taken by the Joint Sales Company (whether by the Officers, or otherwise) in
connection with any of the following matters without the unanimous approval of
the Board of Directors:

                    (i) Any grant or conveyance of any exclusive rights to any
          third party;

                    (ii) Any agreement to a voluntary restriction on the Joint
          Sales Company's Business;

                    (iii) Any contract to sell the Products or purchase
          materials for a term in excess of one (1) year;

                    (iv) Any activity that is inconsistent with a budget or
          business plan that has been adopted by the Board of Directors; or

                    (v) Any price incentives or rebates offered in connection
          with the sale of Products.

          (e) Each Member hereby agrees that the Joint Sales Company shall be
permitted to use any counsel regularly employed by any Member (including without
limitation the inside counsel of a Member) with respect to any issue arising
under any Transaction Document and the transactions contemplated hereby and
thereby; provided, however, that such issue does not involve any actual or
potential conflict of interest (i) between, the Members or their respective
Affiliates, a Member or its Affiliates and the Joint Sales Company, or any

*    CONFIDENTIAL TREATMENT REQUESTED

                                       30
<Page>

Member and an Affiliate of a Member, or (ii) for the proposed counsel. Such
counsel will certify in writing as to the absence of such conflict for such
proposed counsel if requested to do so by any Member; and provided, further that
this Section 5.7(e) shall not, without the written consent of a Member,
constitute a prospective waiver by such Member of its right to allege the
existence of an actual or potential ethical conflict of interest with respect to
such proposed counsel.

                           SECTION 6: ROLE OF MEMBERS

     6.1 RIGHTS OR POWERS.

          The Members shall not have any right or power directly to take part in
the management or control of the Joint Sales Company or its business and affairs
or to act for or bind the Joint Sales Company in any way. Notwithstanding the
foregoing, the Members have all the rights and powers specifically set forth in
this Agreement and, to the extent not inconsistent with this Agreement, in the
Act. The Members shall exercise such rights and powers through the Steering
Committee subject to the terms and conditions set forth in the Commercial
Alliance Agreements.

     6.2 VOTING RIGHTS.

          No Member has any voting right except with respect to those matters
specifically reserved for a Member vote which are set forth in this Agreement
and as required in the Act.

     6.3 REQUIRED MEMBER CONSENTS.

               Notwithstanding any other provision of this Agreement, except as
set forth in the Commercial Alliance Agreements, no action may be taken by the
Joint Sales Company (whether by the Board of Directors, the Officers or
otherwise) in connection with any of the following matters without the unanimous
consent of the Members, acting through the Steering Committee:

          (a) Any activity that is not consistent with the purposes of the Joint
Sales Company as set forth in Section 1.3 hereof;

          (b) Any act in contravention of this Agreement or any Commercial
Alliance Agreement to which the Joint Sales Company is a party;

          (c) Confession of a judgment against the Joint Sales Company in an
amount in excess of $200,000;

          (d) A material change in the Business;

*    CONFIDENTIAL TREATMENT REQUESTED

                                       31

<Page>

          (e) Any sale of assets by the Joint Sales Company, other than sales of
inventory in the ordinary course of business, involving total consideration in
excess of $200,000;

          (f) Any transaction by the Joint Sales Company involving the
incurrence, creation, assumption, guarantee or suffering by the Joint Sales
Company of any indebtedness in excess of $200,000 in principal amount, or the
issuance of any equity or any equity-based security by the Joint Sales Company;

          (g) Any expenditure, investment or acquisition involving total
consideration in excess of $200,000, other than the acquisition of raw materials
or products for sale in the ordinary course of business;

          (h) Any transaction between the Joint Sales Company and any Member,
Director or Affiliate of a Member;

          (i) Any transaction to liquidate or dissolve the Joint Sales Company;

          (j) Any transaction by the Joint Sales Company to merge or consolidate
with another entity;

          (k) Any transaction to sell or license any intellectual property owned
or licensed by the Joint Sales Company;

          (l) Adopting or implementing any business plan or budget intended to
represent a detailed statement of expected income, expenses and other
expenditures or receipts on behalf of the Joint Sales Company or any
Wholly-Owned Affiliate;

          (m) Any amendment and/or restatement of this Agreement or the
Certificate and/or any amendment and/or restatement of the governing documents
of any Wholly-Owned Affiliate of the Joint Sales Company;

          (n) The formation, dissolution, liquidation, merger or consolidation
of any Wholly-Owned Affiliate of the Joint Sales Company;

          (o) Issuing or committing to issue, or repurchasing or redeeming of or
committing to repurchase or redeem any Units or other equity interest that may
hereafter be created (collectively, "Equity Interests"), options to acquire
Equity Interests or any other rights relative to or in any way related to any
Equity Interests of the Joint Sales Company or any Wholly-Owned Affiliate of the
Joint Sales Company;

          (p) Causing the Joint Sales Company or any Wholly Owned Affiliate of
the Joint Sales Company to distribute any cash or property to any Member,
provided, however, that the distributions required by Sections 4.1 and 6.13
shall be made in accordance with such Sections;

*    CONFIDENTIAL TREATMENT REQUESTED

                                       32

<Page>

          (q) Any action requiring the unanimous consent of the Steering
Committee in the Commercial Alliance Agreements.

          The restrictions above shall not apply to actions or transactions
specifically contemplated by an agreement that is entered into on, as of or
prior to the Effective Date, by MBX or ADM Polymer Corporation, or their
respective Affiliates, with the Joint Sales Company, including but not limited
to the Commercial Alliance Agreements, or is entered into by both MBX and ADM
Polymer Corporation or their respective Affiliates at any time.

     6.4  [RESERVED]

     6.5  WITHDRAWAL/RESIGNATION.

          Except as otherwise provided in Sections 4 and 12 hereof, no Member
shall demand or receive a return on or of its Capital Contributions or withdraw
from the Joint Sales Company without the consent of all Members. Except as
otherwise provided in the Act or this Agreement, upon resignation, any resigning
Member is entitled to receive only the distribution to which it is entitled
under this Agreement, and if no specific provision of this Agreement calls for a
distribution or payment upon such resignation, then no payment or distribution
shall be due or owing. Under circumstances requiring a return of any Capital
Contributions, no Member has the right to receive Property other than cash
except as may be specifically provided herein.

     6.6  MEMBER COMPENSATION.

          No Member shall receive any interest, salary or drawing with respect
to its Capital Contributions or its Capital Account or for services rendered on
behalf of the Joint Sales Company, or otherwise, in its capacity as a Member,
except as otherwise provided in this Agreement.

     6.7  MEMBERS LIABILITY.

          No Member shall be liable under a judgment, decree or order of a
court, or in any other manner for the Debts or any other obligations or
liabilities of the Joint Sales Company. A Member shall be liable only to make
its Capital Contributions and shall not be required to restore a deficit balance
in its Capital Account or to lend any funds to the Joint Sales Company or, after
its Capital Contributions have been made, to make any additional contributions,
assessments or payments to the Joint Sales Company, provided that a Member may
be required to repay distributions made to it as provided in Section 18-607 of
the Act. The Directors shall not have any personal liability for the repayment
of any Capital Contributions of any Member.

     6.8  PARTITION.

          While the Joint Sales Company remains in existence or is continued,
each Member agrees and waives its rights to have any Property partitioned, or to
file a complaint or

*    CONFIDENTIAL TREATMENT REQUESTED

                                       33

<Page>

to institute any suit, action or proceeding at law or in equity to have any
Property partitioned, and each Member, on behalf of itself, its successors and
its assigns hereby waives any such right.

     6.9  CONFIDENTIALITY.

          Each Member covenants to comply with the terms and conditions of all
confidentiality agreements between and among ADM Polymer Corporation, MBX and
their respective Affiliates whether presently in existence or entered into after
the Effective Date and a breach of any such confidentiality agreement shall
constitute a breach of this Agreement.

     6.10 TRANSACTIONS BETWEEN A MEMBER AND THE JOINT SALES COMPANY.

          Except as otherwise provided by applicable law, any Member may, but
shall not be obligated to, lend money to the Joint Sales Company, act as surety
for the Joint Sales Company and transact other business with the Joint Sales
Company and has the same rights and obligations when transacting business with
the Joint Sales Company as a person or entity who is not a Member. A Member, any
Affiliate thereof or an employee, stockholder, agent, director or officer of a
Member or any Affiliate thereof, may also be an employee or be retained as an
agent of the Joint Sales Company. The existence of these relationships and
acting in such capacities will not result in the Member being deemed to be
participating in the control of the business of the Joint Sales Company or
otherwise affect the limited liability of the Member.

     6.11 OTHER INSTRUMENTS.

          Each Member hereby agrees to execute and deliver to the Joint Sales
Company within five (5) days after receipt of a written request therefor, such
other and further documents and instruments, statements of interest and
holdings, designations, powers of attorney and other instruments and to take
such other action as the Board of Directors deems necessary, useful or
appropriate to comply with any laws, rules or regulations as may be necessary to
enable the Joint Sales Company to fulfill its responsibilities under this
Agreement.

     6.12 NUMBER OF MEMBERS.

          Unless the Members shall unanimously agree to the contrary, there
shall at no time be more than two (2) Members of the Joint Sales Company.

     6.13 EQUALIZATION PAYMENTS.

          On each Equalization Distribution Date, the Joint Sales Company shall
pay to each Member, to the extent of all Available Cash, an amount equal to each
such Member's Equalization Payment, if any. Equalization Payments shall be
treated for income tax purposes as "guaranteed payments" within the meaning of
Code Section 707(c) and, whether or not paid, shall not affect any Member's
Capital Account balance.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       34

<Page>

                    SECTION 7: REPRESENTATIONS AND WARRANTIES

     7.1  IN GENERAL.

          As of the date hereof, each of the Members hereby makes each of the
representations and warranties applicable to such Member as set forth in Section
7.2 hereof, and such warranties and representations shall survive the execution
of this Agreement.

     7.2  REPRESENTATIONS AND WARRANTIES.

               Each Member hereby represents and warrants that:

          (a) Due Incorporation or Formation; Authorization of Agreement. Such
Member is a corporation duly organized or a partnership or limited liability
company duly formed, validly existing, and in good standing under the laws of
the jurisdiction of its incorporation or formation and has the corporate,
partnership, or company power and authority to own its property and carry on its
business as owned and carried on at the date hereof and as contemplated hereby.
Such Member is duly licensed or qualified to do business and in good standing in
each of the jurisdictions in which the failure to be so licensed or qualified
would have a material adverse effect on its financial condition or its ability
to perform its obligations hereunder. Such Member has the corporate, partnership
or company power and authority to execute and deliver this Agreement and to
perform its obligations hereunder and the execution, delivery, and performance
of this Agreement has been duly authorized by all necessary corporate,
partnership, or company action. This Agreement constitutes the legal, valid, and
binding obligation of such Member.

          (b) No Conflict with Restrictions; No Default. Neither the execution,
delivery, and performance of this Agreement nor the consummation by such Member
of the transactions contemplated hereby (i) will conflict with, violate, or
result in a breach of any of the terms, conditions, or provisions of any law,
regulation, order, writ, injunction, decree, determination, or award of any
court, any governmental department, board, agency, or instrumentality, domestic
or foreign, or any arbitrator, applicable to such Member, its Parent, or any of
its Affiliates, (ii) will conflict with, violate, result in a breach of, or
constitute a default under any of the terms, conditions, or provisions of the
articles of incorporation, bylaws, partnership agreement or operating agreement
of such Member, its Parent, or any of its Affiliates or of any material
agreement or instrument to which such Member, its Parent, or any of its
Affiliates is a party or by which such Member, its Parent, or any of its
Affiliates is or may be bound or to which any of its material properties or
assets is subject, (iii) will conflict with, violate, result in a breach of,
constitute a default under (whether with notice or lapse of time or both),
accelerate or permit the acceleration of the performance required by, give to
others any material interests or rights, or require any consent, authorization,
or approval under any indenture, mortgage, lease agreement, or instrument to
which such Member, its Parent, or any of its Affiliates is a party or by which
such Member, its Parent, or any of its Affiliates is or may be bound, or (iv)
will result in the creation or imposition of any lien upon any of the material
properties or assets of such Member, its Parent, or any of its Affiliates.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       35

<Page>

          (c) Governmental Authorizations. Any registration, declaration, or
filing with, or consent, approval, license, permit, or other authorization or
order by, any governmental or regulatory authority, domestic or foreign, that is
required in connection with the valid execution, delivery, acceptance and
performance by such Member under this Agreement or the consummation by such
Member of any transaction contemplated hereby has been completed, made, or
obtained on or before the Effective Date.

          (d) Litigation. There are no actions, suits, proceedings, or
investigations pending or, to the knowledge of such Member or any of its
Affiliates, threatened against or affecting such Member or any of its Affiliates
or any of their properties, assets, or businesses in any court or before or by
any governmental department, board, agency, or instrumentality, domestic or
foreign, or any arbitrator which could, if adversely determined (or, in the case
of an investigation could lead to any action, suit, or proceeding, which if
adversely determined could) reasonably be expected to materially impair such
Member's ability to perform its obligations under this Agreement or to have a
material adverse effect on the consolidated financial condition of such Member;
and such Member or any of its Affiliates has not received any currently
effective notice of any default, and such Member or any of its Affiliates is not
in default, under any applicable order, writ, injunction, decree, permit,
determination, or award of any court, any governmental department, board,
agency, or instrumentality, domestic or foreign, or any arbitrator which could
reasonably be expected to materially impair such Member's ability to perform its
obligations under this Agreement or to have a material adverse effect on the
consolidated financial condition of such Member.

          (e) Investment Company Act; Public Utility Holding Company Act.
Neither such Member nor any of its Affiliates is, nor will the Joint Sales
Company as a result of such Member holding an interest therein be, an
"investment company" as defined in, or subject to regulation under, the
Investment Company Act of 1940. Neither such Member nor any of its Affiliates
is, nor will the Joint Sales Company as a result of such Member holding an
Interest therein be, a "holding company," "an affiliate of a holding company,"
or a "subsidiary of a holding company" as defined in, or subject to regulation
under, the Public Utility Holding Company Act of 1935.

          (f) Investigation. Such Member is acquiring its Units based upon its
own investigation, and the exercise by such Member of its rights and the
performance of its obligations under this Agreement will be based upon its own
investigation, analysis, and expertise. Such Member's acquisition of its Units
is being made for its own account for investment, and not with a view to the
sale or distribution thereof. Such Member is a sophisticated investor possessing
an expertise in analyzing the benefits and risks associated with acquiring
investments that are similar to the acquisition of its Units.

                    SECTION 8: ACCOUNTING, BOOKS AND RECORDS

     8.1  ACCOUNTING, BOOKS AND RECORDS.

          (a) The Joint Sales Company shall keep on site at its principal place
of business each of the following:

*    CONFIDENTIAL TREATMENT REQUESTED

                                       36

<Page>

                    (i) Separate books of account for the Joint Sales Company
          which shall show a true and accurate record of all costs and expenses
          incurred, all charges made, all credits made and received, and all
          income derived in connection with the conduct of the Joint Sales
          Company and the operation of the Business in accordance with this
          Agreement;

                    (ii) current list of the full name and last known business,
          residence, or mailing address of each Member, Director, and Officer,
          both past and present;

                    (iii) copy of the Certificate and all amendments thereto,
          together with executed copies of any powers of attorney pursuant to
          which any amendment has been executed;

                    (iv) Copies of the Joint Sales Company's federal, state, and
          local income tax returns and reports, if any, for the three (3) most
          recent years;

                    (v) Copies of this Agreement;

                    (vi) Any written consents obtained from Members pursuant to
          Section 6.3(e) hereof regarding action taken by Members without a
          meeting; and

                    (vii) Any written consents obtained from the Directors
          pursuant to Section 5.2(d) hereof regarding action taken by the
          Directors without a meeting, and minutes of meetings of the Board of
          Directors.

          (b) The Joint Sales Company shall use the accrual method of accounting
in preparation of its financial reports and for tax purposes and shall keep its
books and records accordingly. Any Member or its designated representative has
the right to have reasonable access to and inspect and copy the contents of such
books or records and shall also have reasonable access during normal business
hours to such additional financial information, documents, books and records.
The rights granted to a Member pursuant to this Section 8.1 are expressly
subject to compliance by such Member with the safety, security and
confidentiality procedures and guidelines of the Joint Sales Company, as such
procedures and guidelines may be established from time to time.

     8.2  REPORTS.

          (a) IN GENERAL. The Treasurer shall be responsible for causing the
preparation of financial reports of the Joint Sales Company and the coordination
of financial matters of the Joint Sales Company with the Joint Sales Company's
accountants.

          (b) PERIODIC AND OTHER REPORTS. The Joint Sales Company shall cause to
be delivered to each Member the financial statements listed in clauses (i) and
(ii) below, prepared,

*    CONFIDENTIAL TREATMENT REQUESTED

                                       37

<Page>

in each case (other than with respect to Member's Capital Accounts, which shall
be prepared in accordance with this Agreement) in accordance with GAAP
consistently applied (and, if required by any Member or its Affiliates for
purposes of reporting under the Securities Exchange Act of 1934, Regulation
S-X), and such other reports as any Member may reasonably request from time to
time; PROVIDED that, if the Board of Directors so determines within thirty (30)
days thereof, such other reports shall be provided at such requesting Member's
sole cost and expense. The monthly and quarterly financial statements referred
to in clause (ii) below may be subject to normal year-end audit adjustments.

                    (i) As soon as practicable following the end of each Fiscal
          Year (and in any event not later than ninety (90) days after the end
          of such Fiscal Year) and at such time as distributions are made to the
          Members pursuant to Section 12 hereof following the occurrence of a
          Dissolution Event, a balance sheet of the Joint Sales Company as of
          the end of such Fiscal Year and the related statements of operations,
          Members' Capital Accounts and changes therein, and cash flows for such
          Fiscal Year, together with appropriate notes to such financial
          statements and supporting schedules, all of which shall be audited and
          certified by the Joint Sales Company's accountants, and in each case,
          to the extent the Joint Sales Company was in existence, setting forth
          in comparative form the corresponding figures for the immediately
          preceding Fiscal Year end (in the case of the balance sheet) and the
          two (2) immediately preceding Fiscal Years (in the case of the
          statements).

                    (ii) As soon as practicable following the end of each of the
          first three Fiscal Quarters of each Fiscal Year (and in any event not
          later than forty five (45) days after the end of each such Fiscal
          Quarter), a balance sheet of the Joint Sales Company as of the end of
          such Fiscal Quarter and the related statements of operations and cash
          flows for such Fiscal Quarter and for the Fiscal Year to date, in each
          case, to the extent the Joint Sales Company was in existence, setting
          forth in comparative form the corresponding figures for the prior
          Fiscal Year's Fiscal Quarter and the interim period corresponding to
          the Fiscal Quarter and the interim period just completed.

          The quarterly or monthly statements described in clause (ii) above
shall be accompanied by a written certification of the Treasurer of the Joint
Sales Company that such statements have been prepared in accordance with GAAP
consistently applied or this Agreement, as the case may be.

     8.3  TAX MATTERS.

          (a) TAX ELECTIONS. It is the intention of the parties hereto that the
relationships created by this Agreement will, for federal, state, and local
income tax purposes, be treated as a partnership and no Member nor the Tax
Matters Member shall take any action inconsistent with the Joint Sales Company's
status as a partnership for federal, state, or local income tax purposes without
the consent of all Members. The Board of Directors by a unanimous vote shall,
without any further consent of the Members being required (except as

*    CONFIDENTIAL TREATMENT REQUESTED

                                       38

<Page>

specifically required herein), make any and all elections for federal, state,
local, and foreign tax purposes including, without limitation, any election, if
permitted by applicable law: (i) to adjust the basis of Property pursuant to
Code Sections 754, 734(b) and 743(b), or comparable provisions of state, local
or foreign law, in connection with Transfers of Units and Joint Sales Company
distributions; (ii) with the consent of all of the Members, to extend the
statute of limitations for assessment of tax deficiencies against the Members
with respect to adjustments to the Joint Sales Company's federal, state, local
or foreign tax returns; and (iii) to the extent provided in Code Sections 6221
through 6231 and similar provisions of federal, state, local, or foreign law, to
represent the Joint Sales Company and the Members before taxing authorities or
courts of competent jurisdiction in tax matters affecting the Joint Sales
Company or the Members in their capacities as Members, and to file any tax
returns and execute any agreements or other documents relating to or affecting
such tax matters, including agreements or other documents that bind the Members
with respect to such tax matters or otherwise affect the rights of the Joint
Sales Company and the Members. ADM Polymer Corporation is specifically
authorized to act as the "TAX MATTERS MEMBER" under Section 6231 of the Code and
in any similar capacity under state or local law.

          (b) TAX INFORMATION. Necessary tax information shall be delivered to
each Member as soon as practicable after the end of each Fiscal Year of the
Joint Sales Company but not later than five (5) months after the end of each
Fiscal Year.

          (c) REIMBURSEMENTS. Notwithstanding anything to the contrary in this
Agreement, the Tax Matters Member shall be reimbursed for all reasonable
expenses incurred by it in connection with its service as Tax Matters Member.
Such reimbursements shall not affect the Capital Account of the Tax Matters
Member.

                              SECTION 9: AMENDMENTS

     9.1  AMENDMENTS.

          (a) Amendments to this Agreement may be proposed by any Director or
any Member. Following such proposal, the Board of Directors shall submit to the
Members a verbatim statement of any proposed amendment, providing that counsel
for the Joint Sales Company shall have approved of the same in writing as to
form, and the Board of Directors shall include in any such submission a
recommendation as to the proposed amendment. The Board of Directors shall seek
the written vote of the Members on the proposed amendment or shall call a
meeting to vote thereon and to transact any other business that it may deem
appropriate. A proposed amendment shall be adopted and be effective as an
amendment hereto if it receives the unanimous approval of the Members in
accordance with Section 6.4 hereof.

          (b) Notwithstanding Section 9.1(a) hereof, this Agreement shall not be
amended without the consent of each Member adversely affected if such amendment
would (i) modify the limited liability of a Member, or (ii) alter the interest
of such Member in Profits, Losses, other items, or any Joint Sales Company
distributions.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       39

<Page>

                              SECTION 10: TRANSFERS

     10.1 RESTRICTIONS ON TRANSFERS.

          Except as otherwise permitted by this Agreement, no Member shall (i)
Transfer directly or indirectly all or any portion of its Units, or (ii) pledge
or otherwise encumber all or any part of its Units as security for the payment
of a Debt.

     10.2 PERMITTED TRANSFERS.

          Subject to the conditions and restrictions set forth in Sections 10.3
and 10.6 hereof, a Member may at any time Transfer all (but not less than all)
of its Units to (a) the other Member or an Affiliate of the other Member, or (b)
the transferor's trustee to whom such Units are transferred involuntarily by
operation of law, (any such Transfer being referred to in this Agreement as a
"Permitted Transfer").

     10.3 CONDITIONS TO PERMITTED TRANSFERS.

               A Transfer shall not be treated as a Permitted Transfer under
Section 10.2 hereof unless and until the following conditions are satisfied:

          (a) Except in the case of a Transfer involuntarily by operation of
law, the transferor and transferee shall execute and deliver to the Joint Sales
Company such documents and instruments of conveyance as may be necessary or
appropriate in the opinion of counsel to the Joint Sales Company to effect such
Transfer. In the case of a Transfer of Units involuntarily by operation of law,
the Transfer shall be confirmed by presentation to the Joint Sales Company of
legal evidence of such Transfer, in form and substance satisfactory to counsel
to the Joint Sales Company. In all cases, the Joint Sales Company shall be
reimbursed by the transferor and/or transferee for all costs and expenses that
it reasonably incurs in connection with such Transfer.

          (b) The transferor and transferee shall furnish the Joint Sales
Company with the transferee's taxpayer identification number, sufficient
information to determine the transferee's initial tax basis in the Units
transferred, and any other information reasonably necessary to permit the Joint
Sales Company to file all required federal and state tax returns and other
legally required information statements or returns. Without limiting the
generality of the foregoing, the Joint Sales Company shall not be required to
make any distribution otherwise provided for in this Agreement with respect to
any transferred Units until it has received such information.

          (c) Except in the case of a Transfer of Units involuntarily by
operation of law, either (a) such Units shall be registered under the Securities
Act, and any applicable state securities laws, or (b) the transferor shall
provide to the Joint Sales Company and the other Member an opinion of counsel,
which opinion and counsel shall be reasonably satisfactory to the Board of
Directors, to the effect that such Transfer is exempt from all applicable

*    CONFIDENTIAL TREATMENT REQUESTED

                                       40

<Page>

registration requirements and that such Transfer will not violate any applicable
laws regulating the Transfer of securities.

          (d) Except in the case of a Transfer of Units involuntarily by
operation of law, the transferor shall provide to the Joint Sales Company and
the other Member an opinion of counsel, which opinion and counsel shall be
reasonably satisfactory to the Board of Directors, to the effect that such
Transfer will not cause the Joint Sales Company to be deemed to be an
"investment company" under the Investment Company Act of 1940.

     10.4 [RESERVED]

     10.5 PROHIBITED TRANSFERS.

          Any purported Transfer of Units that is not a Permitted Transfer shall
be null and void and of no force or effect whatever; provided that, if the Joint
Sales Company is required to recognize a Transfer that is not a Permitted
Transfer (or if the Members, in their sole discretion, unanimously agree to
recognize a Transfer that is not a Permitted Transfer), the Units Transferred
shall be strictly limited to the transferor's rights to allocations and
distributions as provided by this Agreement with respect to the transferred
Units, which allocations and distributions may be applied (without limiting any
other legal or equitable rights of the Joint Sales Company) to satisfy any
debts, obligations, or liabilities for damages that the transferor or transferee
of such Interest may have to the Joint Sales Company.

          In the case of a Transfer or attempted Transfer of Units that is not a
Permitted Transfer, the parties engaging or attempting to engage in such
Transfer shall be liable to indemnify and hold harmless the Joint Sales Company
and the other Members from all cost, liability, and damage that any of such
indemnified Members may incur (including, without limitation, incremental tax
liabilities, lawyers' fees and expenses) as a result of such Transfer or
attempted Transfer and efforts to enforce the indemnity granted hereby.

     10.6 TAX TERMINATION RESTRICTIONS.

          (a) Notwithstanding any other provision of this Section 10, except in
the case of a Transfer of Units involuntarily by operation of law and except as
otherwise provided in this Section 10.6, no Transfer of Units shall be permitted
if, in the opinion of the Joint Sales Company's tax counsel, (i) such Transfer
would more likely than not terminate the Joint Sales Company for federal income
tax purposes under Section 708(b)(1)(B) of the Code (a "Technical Termination")
and (ii) any Technical Termination caused by such Transfer would be
disadvantageous to the Joint Sales Company.

          (b) Prior to the effective date of any Transfer, the Joint Sales
Company may obtain and deliver to the transferor a written opinion from the
Joint Sales Company's tax counsel stating that the proposed Transfer would cause
a Technical Termination and explaining how such Technical Termination would be
disadvantageous to the Joint Sales Company (a

*    CONFIDENTIAL TREATMENT REQUESTED

                                       41

<Page>

"Termination Opinion"). If the Joint Sales Company fails to provide a
Termination Opinion prior to the effective date, the Transfer of such Offered
Units will not be prohibited by this Section 10.6, but shall remain subject to
any and all requirements of the remaining provisions of this Section 10.

          (c) If the Joint Sales Company provides a Termination Opinion to the
transferor prior to such effective date, the Board of Directors by a unanimous
decision shall have the right to restructure the proposed Transfer so that a
Technical Termination will not result therefrom. To restructure the Transfer,
the Board of Directors shall prior to the effective date of the transfer,
provide a written explanation to the transferor explaining any and all necessary
changes required by the Board of Directors so that a Technical Termination will
be avoided if the proposed Transfer is ultimately consummated. For the avoidance
of doubt, the Board of Directors shall only be entitled to make changes
necessary to avoid a Technical Termination, and shall not have the right to
restructure any proposed Transfer in any other way or for any other purpose.

     10.7 RIGHTS OF UNADMITTED ASSIGNEES.

          A Person who acquires Units but who is not admitted as a substituted
Member pursuant to Section 10.8 hereof shall be entitled only to allocations and
distributions with respect to such Units in accordance with this Agreement, and
shall have no right to any information or accounting of the affairs of the Joint
Sales Company, shall not be entitled to inspect the books or records of the
Joint Sales Company, shall not be entitled to designate any Directors and shall
not have any of the other rights of a Member under the Act or this Agreement.

     10.8 ADMISSION OF SUBSTITUTED MEMBERS.

          Subject to the other provisions of this Section 10, a transferee of
Units may be admitted to the Joint Sales Company as a substituted Member only
upon satisfaction of the conditions set forth in this Section 10.8:

          (a) The Units with respect to which the transferee is being admitted
were acquired by means of a Permitted Transfer;

          (b) The transferee of Units (other than, with respect to clauses (i)
and (ii) below, a transferee that was a Member prior to the Transfer) shall, by
written instrument in form and substance reasonably satisfactory to the Board of
Directors (and, in the case of clause (iii) below, the transferor Member), (i)
make representations and warranties to the nontransferring Member equivalent to
those set forth in Section 7, (ii) accept and adopt the terms and provisions of
this Agreement, including this Section 10, and (iii) assume the obligations of
the transferor Member under this Agreement with respect to the transferred
Units. The transferor Member shall be released from all such assumed obligations
except (x) those obligations or liabilities of the transferor Member arising out
of a breach of this Agreement, (y) in the case of a Transfer to any Person other
than a Member or any of its Affiliates, those obligations or liabilities of the
transferor Member based on events occurring,

*    CONFIDENTIAL TREATMENT REQUESTED

                                       42

<Page>

arising or maturing prior to the date of Transfer, and (z) in the case of a
Transfer to any of its Affiliates, any Capital Contribution of the transferor
Member under this Agreement;

          (c) The transferee pays or reimburses the Joint Sales Company for all
reasonable legal, filing, accounting and publication costs that the Joint Sales
Company incurs in connection with the admission of the transferee as a Member
with respect to the Transferred Units; and

          (d) Except in the case of a Transfer involuntarily by operation of
law, if required by the Board of Directors, the transferee (other than a
transferee that was a Member prior to the Transfer) shall deliver to the Joint
Sales Company evidence of the authority of such Person to become a Member and to
be bound by all of the terms and conditions of this Agreement, and the
transferee and transferor shall each execute and deliver such other instruments
as the Board of Directors reasonably deems necessary or appropriate to effect,
and as a condition to, such Transfer, including amendments to the Certificate or
any other instrument filed with the State of Delaware or any other state or
governmental authority.

     10.9 REPRESENTATIONS REGARDING TRANSFERS; LEGEND.

          (a) Each Member hereby covenants and agrees with the Joint Sales
Company for the benefit of the Joint Sales Company and all Members, that (i) it
is not currently making a market in Units and will not in the future make a
market in Units, (ii) it will not Transfer its Units on an established
securities market, a secondary market (or the substantial equivalent thereof)
within the meaning of Code Section 7704(b) (and any Regulations, proposed
Regulations, revenue rulings, or other official pronouncements of the Internal
Revenue Service or Treasury Department that may be promulgated or published
thereunder), and (iii) in the event such Regulations, revenue rulings, or other
pronouncements treat any or all arrangements which facilitate the selling of
Joint Sales Company interests and which are commonly referred to as "matching
services" as being a secondary market or substantial equivalent thereof, it will
not Transfer any Units through a matching service that is not approved in
advance by the Joint Sales Company. Each Member further agrees that it will not
Transfer any Units to any Person unless such Person agrees to be bound by this
Section 10.9(a) and to Transfer such Units only to Persons who agree to be
similarly bound.

          (b) Each Member hereby represents and warrants to the Joint Sales
Company and the Members that such Member's acquisition of Units hereunder is
made as principal for such Member's own account and not for resale or
distribution of such Units. Each Member further hereby agrees that the following
legend may be placed upon any counterpart of this Agreement, the Certificate, or
any other document or instrument evidencing ownership of Units:

                    The Company Units represented by this document have not been
               registered under any securities laws and the transferability of
               such Units is restricted. Such Units may not be sold, assigned,
               or transferred, nor will any assignee, vendee, transferee, or
               endorsee thereof be recognized as

*    CONFIDENTIAL TREATMENT REQUESTED

                                       43

<Page>

               having acquired any such Units by the issuer for any purposes,
               unless (1) a registration statement under the Securities Act of
               1933, as amended, with respect to such Units shall then be in
               effect and such transfer has been qualified under all applicable
               state securities laws, or (2) the availability of an exemption
               from such registration and qualification shall be established to
               the satisfaction of counsel to the Joint Sales Company.

                    The Units represented by this document are subject to
               further restriction as to their sale, transfer, hypothecation, or
               assignment as set forth in the Operating Agreement of the issuer
               and agreed to by each Member. Said restriction provides, among
               other things, that no Units may be transferred without first
               offering such Units to the other Member.

     10.10 DISTRIBUTIONS AND ALLOCATIONS IN RESPECT OF TRANSFERRED UNITS.

          If any Units are Transferred during any Allocation Year in compliance
with the provisions of this Section 10, Profits, Losses, each item thereof, and
all other items attributable to the Transferred Units for such Allocation Year
shall be divided and allocated between the transferor and the transferee by
taking into account their varying Percentage Interests during the Fiscal Year in
accordance with Code Section 706(d), using any conventions permitted by law and
selected by the Board of Directors. All distributions on or before the date of
such Transfer shall be made to the transferor, and all distributions thereafter
shall be made to the transferee. Solely for purposes of making such allocations
and distributions, the Joint Sales Company shall recognize such Transfer not
later than the end of the calendar month during which it is given notice of such
Transfer, provided that, if the Joint Sales Company is given notice of a
Transfer at least ten (10) Business Days prior to the Transfer, the Joint Sales
Company shall recognize such Transfer as of the date of such Transfer, and
provided further that if the Joint Sales Company does not receive a notice
stating the date such Units were transferred and such other information as the
Board of Directors may reasonably require within thirty (30) days after the end
of the Allocation Year during which the Transfer occurs, then all such items
shall be allocated, and all distributions shall be made to the Person who,
according to the books and records of the Joint Sales Company, was the owner of
the Units on the last day of such Allocation Year. Neither the Joint Sales
Company nor any Director shall incur any liability for making allocations and
distributions in accordance with the provisions of this Section 10.10, whether
or not any Director or the Joint Sales Company has knowledge of any Transfer of
ownership of any Units.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       44

<Page>

                             SECTION 11: ADVERSE ACT

     11.1 REMEDIES.

          (a) If an Adverse Act has occurred or is continuing with respect to
any Member, the non-Adverse Member may elect to cause the dissolution, winding
up and liquidation of the Joint Sales Company pursuant to Section 12.

          The foregoing remedy shall not be deemed to be exclusive, and, subject
to the requirements of this Section 11.1(a) regarding the timing of the election
of such remedies, selection or resort to any thereof shall not preclude
selection or resort to the others.

          The election of a remedy specified above may be exercised by notice
given to the Adverse Member (A) in case of an Adverse Act specified in clause
(i) of the definition of the term "Adverse Act" in Section 1.10, within ninety
(90) days after the occurrence of such Adverse Act or (B) in the case of any
other Adverse Act with respect to which such remedy is available, within ninety
(90) days after the Member making such election obtains actual knowledge of the
occurrence of such Adverse Act, including, if applicable, that any cure period
has expired.

          Except as provided in Section 11.1(b), the failure to elect the remedy
with respect to the subject Adverse Act within the time periods provided in the
preceding paragraph shall be conclusively presumed to be a waiver of the
remedies provided in this Section 11 with respect to the subject Adverse Act.

          The resort to any remedy pursuant to this Section 11.1(a) shall not
for any purpose be deemed to be a waiver of any remedy not described in this
Section 11.1(a) and otherwise available hereunder or under applicable law.

          (b) If the Joint Sales Company is dissolved pursuant to Section
12.1(a) at any time as a result of a Dissolution Event that occurs prior to a
remedy having been elected pursuant to Section 11.1(a) with respect to any
Adverse Member, the time periods for such election shall thereupon expire and
the Board of Directors shall deduct from any amounts to be paid to such Adverse
Member pursuant to Section 12.2 that amount which it unanimously estimates to be
reasonably sufficient to compensate the Joint Sales Company and the non-Adverse
Member for Damages incurred as a result of the Adverse Act (subject to the
limitations of Section 11.1(a)) and shall pay the same to the non-Adverse Member
on behalf of the Adverse Member.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       45

<Page>

                     SECTION 12: DISSOLUTION AND WINDING UP

     12.1 DISSOLUTION EVENTS.

          (a) DISSOLUTION. The Joint Sales Company shall dissolve and shall
commence winding up and liquidating upon the first to occur of any of the
following (each a "DISSOLUTION EVENT"):

                    (i) The unanimous vote of the Members to dissolve, wind up,
          and liquidate the Joint Sales Company;

                    (ii) A judicial determination that an event has occurred
          that makes it unlawful, impossible or impractical to carry on the
          Business;

                    (iii) The election of the non-Adverse Member pursuant to
          Section 11.1(a);

                    (iv) The termination or expiration of the Commercial
          Alliance Agreement;

                    (v) The election of a Member to dissolve the Joint Sales
          Company pursuant to Section 9.8.3 of the Commercial Alliance
          Agreement.

          The Members hereby agree that, notwithstanding any provision of the
Act, the Joint Sales Company shall not dissolve prior to the occurrence of a
Dissolution Event.

          (b) RECONSTITUTION. If it is determined, by a court of competent
jurisdiction, that the Joint Sales Company has dissolved prior to the occurrence
of a Dissolution Event, then within an additional ninety (90) days after such
determination (the "RECONSTITUTION PERIOD"), either Member may elect to
reconstitute the Joint Sales Company and continue its business on the same terms
and conditions set forth in this Agreement by forming a new limited liability
company on terms identical to those set forth in this Agreement. Unless such an
election is made within the Reconstitution Period, the Joint Sales Company shall
liquidate and wind up its affairs in accordance with Section 12.2 hereof. If
such an election is made within the Reconstitution Period, then:

                    (i) The reconstituted limited liability company shall
          continue until the occurrence of a Dissolution Event as provided in
          this Section 12.1(a);

                    (ii) Unless otherwise agreed to by a majority in Percentage
          Interests of the Members, the Certificate and this Agreement shall
          automatically constitute the Certificate and Agreement of such new
          Joint Sales Company. All of the assets and liabilities of the
          dissolved Joint Sales Company shall be deemed to have been
          automatically assigned, assumed, conveyed and transferred to the new
          Joint Sales Company. No bond, collateral, assumption or

*    CONFIDENTIAL TREATMENT REQUESTED

                                       46

<Page>

          release of any Member's or the Joint Sales Company's liabilities shall
          be required;

PROVIDED that the right of the Members to select successor Directors and to
reconstitute and continue the Business shall not exist and may not be exercised
unless the Joint Sales Company has received an opinion of counsel that the
exercise of the right would not result in the loss of limited liability of any
Member and neither the Joint Sales Company nor the reconstituted limited
liability company would cease to be treated as a partnership for federal income
tax purposes upon the exercise of such right to continue.

     12.2 WINDING UP.

          Upon the occurrence of (i) a Dissolution Event or (ii) the
determination by a court of competent jurisdiction that the Joint Sales Company
has dissolved prior to the occurrence of a Dissolution Event (unless the Joint
Sales Company is reconstituted pursuant to Section 12.1(b) hereof), the Joint
Sales Company shall continue solely for the purposes of winding up its affairs
in an orderly manner, liquidating its assets, and satisfying the claims of its
creditors and Members, and no Member shall take any action that is inconsistent
with, or not necessary to or appropriate for, the winding up of the Joint Sales
Company's business and affairs, PROVIDED that all covenants contained in this
Agreement and obligations provided for in this Agreement shall continue to be
fully binding upon the Members until such time as the Property has been
distributed pursuant to this Section 12.2 and the Certificate has been canceled
pursuant to the Act. The Liquidator shall be responsible for overseeing the
winding up and dissolution of the Joint Sales Company, which winding up and
dissolution shall be completed within ninety (90) days of the occurrence of the
Dissolution Event and within ninety (90) days after the last day on which the
Joint Sales Company may be reconstituted pursuant to Section 12.1(b) hereof, as
applicable. The Liquidator shall take full account of the Joint Sales Company's
liabilities and Property and shall cause the Property or the proceeds from the
sale thereof (as determined pursuant to Section 12.10 hereof), to the extent
sufficient therefor, to be applied and distributed, to the maximum extent
permitted by law, in the following order:

          (a) First, to creditors (including Members and Directors who are
creditors, to the extent otherwise permitted by law) in satisfaction of all of
the Joint Sales Company's Debts and other liabilities (whether by payment or the
making of reasonable provision for payment thereof), other than liabilities for
which reasonable provision for payment has been made and liabilities for
distribution to members under Section 18-601 or 18-604 of the Act;

          (b) Second, to ADM Polymer Corporation until the Ledger Account is
repaid;

          (c) Third, to the Members in amounts equal to any Equalization
Payments then due and owing to the Members;

          (d) Fourth, to the Members in accordance with the positive balance in
their Capital Accounts, after giving effect to all contributions, distributions
and allocations for all periods;

*    CONFIDENTIAL TREATMENT REQUESTED

                                       47

<Page>

          (e) The balance, if any, to the Members in accordance with their
respective Percentage Interests.

          No Member or Director shall receive additional compensation for any
services performed pursuant to this Section 12.

     12.3 COMPLIANCE WITH CERTAIN REQUIREMENTS OF REGULATIONS; DEFICIT CAPITAL
     ACCOUNTS.

          In the event the Joint Sales Company is "liquidated" within the
meaning of Regulations Section 1.704-1(b) (2) (ii) (g), distributions shall be
made pursuant to this Section 12 to the Members who have positive Capital
Accounts in compliance with Regulations Section 1.704-1(b) (2) (ii) (b) (2). If
any Member has a deficit balance in his Capital Account (after giving effect to
all contributions, distributions and allocations for all Allocation Years,
including the Allocation Year during which such liquidation occurs), such Member
shall have no obligation to make any contribution to the capital of the Joint
Sales Company with respect to such deficit, and such deficit shall not be
considered a debt owed to the Joint Sales Company or to any other Person for any
purpose whatsoever. In the discretion of the Liquidator, a pro rata portion of
the distributions that would otherwise be made to the Members pursuant to this
Section 12 may be:

          (a) Distributed to a trust established for the benefit of the Members
for the purposes of liquidating Joint Sales Company assets, collecting amounts
owed to the Joint Sales Company, and paying any contingent or unforeseen
liabilities or obligations of the Joint Sales Company. The assets of any such
trust shall be distributed to the Members from time to time, in the reasonable
discretion of the Liquidator, in the same proportions as the amount distributed
to such trust by the Joint Sales Company would otherwise have been distributed
to the Members pursuant to Section 12.2 hereof; or

          (b) Withheld to provide a reasonable reserve for Joint Sales Company
liabilities (contingent or otherwise) and to reflect the unrealized portion of
any installment obligations owed to the Joint Sales Company, provided that such
withheld amounts shall be distributed to the Members as soon as practicable.

     12.4 DEEMED DISTRIBUTION AND RECONTRIBUTION.

          Notwithstanding any other provision of this Section 12, in the event
the Joint Sales Company is liquidated within the meaning of Regulations Section
1.704-1(b)(2)(ii)(g) but no Dissolution Event has occurred, the Property shall
not be liquidated, the Joint Sales Company's Debts and other Liabilities shall
not be paid or discharged, and the Joint Sales Company's affairs shall not be
wound up. Instead, solely for federal income tax purposes, the Joint Sales
Company shall be deemed to have contributed all its Property and liabilities to
a new limited liability company in exchange for an interest in such new company
and, and immediately thereafter, the Joint Sales Company will be deemed to
liquidate by distributing interests in the new company to the Members.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       48

<Page>

     12.5 RIGHTS OF MEMBERS.

          Except as otherwise provided in this Agreement, each Member shall look
solely to the Joint Sales Company's Property for the return of its Capital
Contribution and has no right or power to demand or receive Property other than
cash from the Joint Sales Company. If the assets of the Joint Sales Company
remaining after payment or discharge of the debts or liabilities of the Joint
Sales Company are insufficient to return such Capital Contribution, the Members
shall have no recourse against the Joint Sales Company or any other Member or
Director.

     12.6 NOTICE OF DISSOLUTION/TERMINATION.

          (a) In the event a Dissolution Event occurs or an event occurs that
would, but for provisions of Section 12.1, result in a dissolution of the Joint
Sales Company, the Board of Directors shall, within thirty (30) days thereafter,
provide written notice thereof to each of the Members and to all other parties
with whom the Joint Sales Company regularly conducts business (as determined in
the discretion of the Board of Directors) and shall publish notice thereof in a
newspaper of general circulation in each place in which the Joint Sales Company
regularly conducts business (as determined in the discretion of the Board of
Directors).

          (b) Upon completion of the distribution of the Joint Sales Company's
Property as provided in this Section 12, the Joint Sales Company shall be
terminated, and the Liquidator shall cause the filing of the Certificate of
Cancellation pursuant to Section 18-203 of the Act and shall take all such other
actions as may be necessary to terminate the Joint Sales Company.

     12.7 ALLOCATIONS DURING PERIOD OF LIQUIDATION.

          During the period commencing on the first day of the Fiscal Year
during which a Dissolution Event occurs and ending on the date on which all of
the assets of the Joint Sales Company have been distributed to the Members
pursuant to Section 12.2 hereof (the "LIQUIDATION PERIOD"), the Members shall
continue to share Profits, Losses, gain, loss and other items of Joint Sales
Company income, gain, loss or deduction in the manner provided in Section 3
hereof, but no distributions shall be made pursuant to Section 4 hereof.

     12.8 CHARACTER OF LIQUIDATING DISTRIBUTIONS.

          All payments made in liquidation of the interest of a Member in the
Joint Sales Company shall be made in exchange for the interest of such Member in
Property pursuant to Section 736(b)(1) of the Code, including the interest of
such Member in Joint Sales Company goodwill.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       49

<Page>

     12.9 THE LIQUIDATOR.

          (a) DEFINITION. The "LIQUIDATOR" shall mean a Person appointed by the
unanimous decision of the Board of Directors to oversee the liquidation of the
Joint Sales Company.

          (b) FEES. The Joint Sales Company is authorized to pay a reasonable
fee to the Liquidator for its services performed pursuant to this Section 12 and
to reimburse the Liquidator for its reasonable costs and expenses incurred in
performing those services.

          (c) INDEMNIFICATION. The Joint Sales Company shall indemnify, save
harmless, and pay all judgments and claims against such Liquidator or any
officers, directors, agents or employees of the Liquidator relating to any
liability or damage incurred by reason of any act performed or omitted to be
performed by the Liquidator, or any officers, directors, agents or employees of
the Liquidator in connection with the liquidation of the Joint Sales Company,
including reasonable attorneys' fees incurred by the Liquidator, officer,
director, agent or employee in connection with the defense of any action based
on any such act or omission, which attorneys' fees may be paid as incurred,
except to the extent such liability or damage is caused by the fraud,
intentional misconduct of, or a knowing violation of the laws by the Liquidator
which was material to the cause of action.

     12.10 FORM OF LIQUIDATING DISTRIBUTIONS.

          For purposes of making distributions required by Section 12.2 hereof,
the Liquidator shall abide by any resolutions, plan or decision approved by the
unanimous vote of the Board of Directors as to whether to distribute all or any
portion of the Property in-kind or to sell all or any portion of the Property
and distribute the proceeds therefrom. In the absence of any such resolutions,
plan or decision, the Liquidator may determine in its reasonable discretion
whether to distribute all or any portion of the Property in-kind or to sell all
or any portion of the Property and distribute the proceeds therefrom.

                            SECTION 13: MISCELLANEOUS

     13.1 NOTICES.

          Any notice, payment, demand, or communication required or permitted to
be given by any provision of this Agreement shall be in writing and shall be
deemed to have been delivered, given, and received for all purposes (i) if
delivered personally to the Person or to an officer of the Person to whom the
same is directed, or (ii) when the same is actually received, if sent either by
registered or certified mail, postage and charges prepaid, or by facsimile, if
such facsimile is followed by a hard copy of the facsimile communication sent
promptly thereafter by registered or certified mail, postage and charges
prepaid, addressed as follows, or to such other address as such Person may from
time to time specify by notice to the Members and Directors:

*    CONFIDENTIAL TREATMENT REQUESTED

                                       50

<Page>

          (a) If to the Joint Sales Company:

              ADM / Metabolix Sales Company, LLC
              21 Erie Street
              Cambridge, MA 02139-4260

              With a copy to:

              ADM Polymer Corporation, at the address set forth below, and MBX,
              at the address set forth below

          (b) If to the Directors, to the address set forth in Exhibit C hereto
with respect to the initial Directors, and thereafter in the notices provided to
the Joint Sales Company by the Members designating substitute Directors;

          (c) If to ADM Polymer Corporation:

              Archer-Daniels-Midland Company
              4666 Faries Parkway
              Decatur, Illinois 62526
              Attn:  President
              Telephone: (217) 451-5200
              Facsimile: (217) 451-4181

              With a copy to:

              Archer-Daniels-Midland Company
              4666 Faries Parkway
              Decatur, Illinois 62526
              Attn:  General Counsel
              Telephone: (217) 424-6183
              Facsimile: (217) 424-6196

          (d) If to MBX:

              Metabolix Inc.
              21 Erie Street
              Cambridge, Massachusetts 02139-4260
              Attn:  President and CEO
              Telephone: (617) 492-0505
              Facsimile: (617) 4921996

              With a copy to:
              Goodwin Procter

*    CONFIDENTIAL TREATMENT REQUESTED

                                       51

<Page>

              Exchange Place
              53 State Street
              Boston, MA 02109
              Attn:  Christopher J. Denn, Esq

     13.2 BINDING EFFECT.

          Except as otherwise provided in this Agreement, every covenant, term,
and provision of this Agreement shall be binding upon and inure to the benefit
of the Members and their respective successors, transferees, and assigns.

     13.3 CONSTRUCTION.

          Every covenant, term, and provision of this Agreement shall be
construed simply according to its fair meaning and not strictly for or against
any Member.

     13.4 TIME.

          In computing any period of time pursuant to this Agreement, the day of
the act, event or default from which the designated period of time begins to run
shall not be included, but the time shall begin to run on the next succeeding
day. The last day of the period so computed shall be included, unless it is a
Saturday, Sunday or legal holiday, in which event the period shall run until the
end of the next day which is not a Saturday, Sunday or legal holiday.

     13.5 HEADINGS.

          Section and other headings contained in this Agreement are for
reference purposes only and are not intended to describe, interpret, define, or
limit the scope, extent, or intent of this Agreement or any provision hereof.

     13.6 SEVERABILITY.

          Except as otherwise provided in the succeeding sentence, every
provision of this Agreement is intended to be severable, and, if any term or
provision of this Agreement is illegal or invalid for any reason whatsoever,
such illegality or invalidity shall not affect the validity or legality of the
remainder of this Agreement. The preceding sentence of this Section 13.6 shall
be of no force or effect if the consequence of enforcing the remainder of this
Agreement without such illegal or invalid term or provision would be to cause
any Member to lose the material benefit of its economic bargain.

     13.7 INCORPORATION BY REFERENCE.

          Every exhibit, schedule, and other appendix attached to this Agreement
and referred to herein is not incorporated in this Agreement by reference unless
this Agreement expressly otherwise provides.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       52

<Page>

     13.8 VARIATION OF TERMS.

          All terms and any variations thereof shall be deemed to refer to
masculine, feminine, or neuter, singular or plural, as the identity of the
Person or Persons may require.

     13.9 GOVERNING LAW.

          The laws of the State of Delaware shall govern the validity of this
Agreement, the construction of its terms, and the interpretation of the rights
and duties arising hereunder.

     13.10 COUNTERPART EXECUTION.

          This Agreement may be executed in any number of counterparts with the
same effect as if all of the Members had signed the same document. All
counterparts shall be construed together and shall constitute one agreement.

                      [SIGNATURES FOLLOW ON SEPARATE PAGES]

*    CONFIDENTIAL TREATMENT REQUESTED

                                       53

<Page>

     IN WITNESS WHEREOF, the parties have executed and entered into this
Operating Agreement of the Joint Sales Company as of the day first above set
forth.

                                        METABOLIX INC.

                                        By: /s/ James J. Barber
                                            ----------------------------------
                                        Name: James J. Barber
                                        Title: President and CEO

                                        ADM POLYMER CORPORATION

                                        By: /s/ John D. Rice
                                            ----------------------------------
                                        Name: John D. Rice
                                        Title: President

*    CONFIDENTIAL TREATMENT REQUESTED

                                       54

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}]]